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Abstract 
 
Background– Mitochondria are able to change their morphology by undergoing 
either ‘fusion’ to form elongated interconnected networks or ‘fission’ to generate 
fragmented disconnected mitochondria. We investigated whether changes in 
mitochondrial morphology influence susceptibility of the heart to ischaemia-
reperfusion injury (IRI). We hypothesised that promoting mitochondrial fusion 
protects the heart against IRI by inhibiting mitochondrial permeability transition pore 
(mPTP) opening. Methods/Results– Mitochondrial fusion was induced in a HL-1 
cardiac cell line by: 1), over-expressing Mitofusin 1 or 2 (known mitochondrial 
fusion proteins) or Drp1K38A (a dominant negative mutant form of Drp1, a known 
mitochondrial fission protein), 2), using the drug mdivi-1 (a Drp1 small molecule 
inhibitor) and 3), over-expressing or pharmacologically activating Akt1 (a known 
pro-survival kinase involved in growth and proliferation). Promoting mitochondrial 
fusion decreased mitochondrial permeability transition pore (mPTP) sensitivity and 
reduced cell death following simulated IRI (SIRI). In contrast, inducing 
mitochondrial fragmentation by over-expressing hFis1 (a known mitochondrial 
fission protein), enhanced cell death following SIRI but had no effect on mPTP 
opening. Treatment with mdivi-1 decreased mPTP sensitivity and reduced cell death 
in both HL-1 cells and adult murine cardiomyocytes following SIRI, and reduced 
myocardial infarct size in the adult murine heart. Elongated adult cardiac 
mitochondria (4-6 µM) were observed using electron and confocal microscopy in 
adult murine hearts and these were increased with mdivi-1 treatment prior to 
ischaemia.  
Conclusions–For the first time we show that modulating mitochondrial morphology 
can influence the susceptibility of the heart to IRI. We show that inducing 
mitochondrial fusion protects the heart against IRI. These findings provide a novel 
pharmacological target for cardioprotection. 
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LIST OF ABBREVIATIONS 
 
The following is a list of abbreviations used in this thesis: 
 
%           percentage 
AAR        area-at-risk 
ADP         adenosine diphosphate 
AIF         apoptosis-inducing factor 
Akt         cellular Akt/protein kinase B 
AMI         acute myocardial infarction  
AMP        adenosine monophosphate 
AMPK       AMP-activated protein kinase 
ANF         atrial natriuretic factor 
ANOVA      analysis of variance 
ANT        andenince nucleotide translocase 
APAF-1       apoptosis protease-inducing factor 1 
APD         action potential duration 
ATP         adenosine triphosphate 
ATPase       ATP synthase 
Bad         Bcl-XL/Bcl-2-associated death promoter 
Bax         Bcl-associated X protein 
BDM        2, 3 – butanedione monoxime  
BSA         bovine serum albumin 
Ca2+           calcium ion 
caAkt        constitutively-activated Akt 
CaMK        calcium/calmodulin dependent protein kinase 
cAMP        cyclic adenosine monophosphate 
CARD       caspase-recruitment domain 
CAT         carboxyatractylate 
cBiMPS       Sp-5,6-Dichloro-cBIMPS 
Cdk1        cyclic dependent kinase 1 
Cl-          chloride  
CLSM        confocal laser scanning microscopy 
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CMV        cytomegalovirus 
CsA         ciclosporin A 
CypA        cyclophilin A 
CypD        cyclophilin D 
Cys         cysteine 
Da          Dalton 
DIABLO      direct IAP-binding protein with low pI 
DKO        double knock-outs 
DMSO       dimethyl sulphoxide 
DNA        deoxyribonucleic acid 
2-DOG       2-deoxyglucose 
Drp1        dynamin-related protein 1 
ECG         electrocardiogram 
EDTA        ethylenediaminetetraacetic acid 
eNOS        endothelial nitric oxide synthase 
EPO         erythropoietin 
ER          endoplasmic reticulum 
Erk         extracellular signal-regulated MAPK 
ETC         electron transport chain 
FAD         flavin adenine dinucleotide 
FMN        flavin mononucleotide 
Fzo         fuzzy onions 
GED        GTPase effector domain 
GFP         green fluorescent protein 
GLP         glucagon-like peptide 
GSK         glycogen synthase kinase 
GTP         guanosine triphosphate 
H+          hydrogen ion/proton 
HCO-3        hydrogen carbonate ion 
HEPES       4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hFis1        human fission protein 1 
HPO-4        hydrogen phosphate ion 
H2O         water 
iNOS        inducible nitric oxide synthase 
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IMM        inner mitochondrial membrane 
IPC         ischaemic preconditioning 
IPost        ischaemic postconditioning 
IP3R         inositol trisphosphate receptor 
IR          ischaemia reperfusion 
IRI          ischaemia reperfusion injury 
K+          potassium ion 
KATP         ATP-sensitive potassium channel 
kDa         kilodalton 
LAD        left anterior descending 
LV          left ventricular 
M          molar 
MABP       mean arterial blood pressure 
MAPK       mitogen activated protein kinase 
mdivi-1       mitochondrial division inhibitor 1 
MEF        mouse embryonic fibroblast 
Mfn1        mitofusin 1 
Mfn2        mitofusin 2 
Mg2+        magnesium ion 
Mgm1        mitochondrial genome maintenance 1 
MI          myocardial infarction  
min         minutes 
mitoKATP      mitochondrial KATP 
mM         milimolar 
µM         micromolar 
mPTP        mitochondrial permeability transition pore 
mRNA       messenger RNA 
mtPA-GFP     mitochondrial-targeted photo-activatable green fluorescent     
           protein 
mtRFP       mitochondrial-targeted red fluorescent protein 
Na+         sodium ion 
NADH       nicotinamide adenine dinucleotide 
NADPH       nicotinamide adenine dinucleotide phosphate 
NFAT        nuclear factor of activated T-cells 
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NGF         nerve growth factor 
nm          nanometres 
NO         nitric oxide 
NOS         nitric oxide synthase 
NRF1        nuclear respiratory factor 1 
OMM        outer mitochondrial membrane 
OPA1        optic atrophy 1 
PAO         phenylarsine oxide 
PARL        presenilin associated rhomboid-like protease (PARL) 
PB1         perfusion buffer 1 
PB2         perfusion buffer 2 
PCI         primary coronary intervention 
PDGF        platelet-derived growth factor 
PDK         3’-phosphoinositide-dependent protein kinase 
pEGFP       plasmid-enhanced green fluorescent protein 
PGC-1alpha    peroxisome proliferator-activated receptor-gamma coactivator 1  
           alpha 
PI          propidium iodide 
PI3K        phosphatidyl inositol 3’-OH kinase 
PKA         protein kinase A 
PKB         protein kinase B 
PKC         protein kinase C 
PPIase        peptidyl prolyl transisomerase 
P70S6K       70-kDa ribosomal protein S6 kinase 
RISK        reperfusion injury salvage kinase 
RNA        ribonucleic acid 
ROI         region of interest 
rpm         revolution per minute  
ROS         reactive oxygen species 
RyR         ryanodine receptor 
SEM        standard error of mean 
Ser          serine    
SfA         sanglifehrin A 
sIR         simulated ischaemia reperfusion 
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sIRI         simulated ischaemia reperfusion injury 
SMAC       second mitochondrial activator of caspases 
SO2-4        sulphate ion 
SR          sarcoplasmic reticulum 
TFAM       transcription factor A, mitochondrial 
Thr         threonine 
TMRM       tetramethyl rhodamine methyl ester 
TTC         triphenyltetrazolium chloride 
2-DOG       2-deoxyglucose 
UK         United Kingdom 
UV         ultraviolet 
VDAC       voltage-dependent anion channel 
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1.1 Epidemiology of Coronary Artery Disease 
 
 
Cardiovascular disease is the leading cause of death worldwide. It is 
responsible for over 200,000 deaths per year in the United Kingdom and was the 
cause of 17.5 million deaths in the year 2005, according to the World Health 
Organisation 1, 2. It has been estimated that the overall money spent on tackling 
cardiovascular disease in the UK amounts to 30.7 billion pounds per year with 47% 
of this for health care, followed by 27% for productivity losses due to mortality and 
morbidity, and the remaining 26% to informal care-related costs 3. Therefore, it is 
essential that cardiovascular research be carried out to explore every avenue for 
improving the treatment of cardiovascular disease.   
 
Cardiovascular disease in general, refers to the diseases of the heart and 
circulatory system, with the prevalent form of cardiovascular disease being coronary 
heart disease and cerebrovascular disease 4. Cardiovascular disease has a 
pathogenetic pathway that is complex in nature and is triggered by various 
environmental factors such as smoking, diet, sedentary lifestyle, alcohol, diabetes 
and obesity 5, 6. Modern scientific research has established that cardiomyocyte death 
caused by prolonged coronary artery occlusion is the major and most acute form of 
cardiovascular disease 5, 7. The occluded coronary artery is unable to provide 
sufficient oxygen and nutrient supply to the myocardium, causing the tissue to 
become ischaemic and infarct 7 (details in Section 1.2.1.1). Following an episode of 
ischaemia or restriction of blood supply, revascularisation of the infarcted tissue 
results in ischaemia-reperfusion injury (IRI) which leads to subsequent myocardial 
infarction, cardiac arrhythmias and contractile dysfunction 8, 9 (details in Section 
1.2.1.2). Cardiomyocytes are terminally differentiated and difficult to replace once 
dead, hence causing loss of function to the myocardium and finally a diseased heart 
5
. The death pathway involves either apoptosis, a highly regulated programmed cell 
death mechanism or necrosis, a highly detrimental, unregulated form of cell death 5, 
10
. Apoptosis can be differentiated from necrosis based on the amount or levels of 
adenosine triphosphate (ATP), a coenzyme responsible for transferring energy within 
cells, available. The occurrence of apoptosis relies on the presence of a high amount 
Sang Bing, Ong 
 32
of ATP whereas necrosis occurs when the ATP is scarce 11. These different forms of 
cell death will be discussed in greater detail in Section 1.2.3. 
 
The major cause of cardiovascular morbidity and mortality - acute 
myocardial IRI is discussed in the following section (see Section 1.2). 
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1.2 Myocardial Ischaemia-Reperfusion Injury 
 
 
Myocardial reperfusion injury is a term used to depict the injury to the heart 
culminating in cardiomyocyte death, caused by restoration of coronary blood flow 
after a prolonged blockage. Occlusion of the coronary artery will lead to progressive 
damage over time with changes in the contractility, metabolism and ultrastructural 
features of the myocardium 12-15. Ischaemia-reperfusion injury has been the subject 
of much debate, specifically as to whether the period of ischaemia is the main cause 
of cell death or whether the period of reperfusion exacerbates the injury inflicted 
during ischaemia and causes cell death 16. In laboratory animals, reperfusion 
generally has to be initiated within 20 minutes of the onset of ischaemia to prevent 
the occurrence of necrosis and permanent damage as prolonged ischaemia will lead 
to only modest or non-functional recovery 12. Nevertheless, recent studies have used 
a 30 minute ischaemia protocol with varying durations of reperfusion, depending on 
whether a Langendorff-perfused heart 17-19 or in vivo infarct model 20, 21 is used as the 
endpoint of interest. The concept of reperfusion injury was founded on the basis of 
experimental results showing a higher abundance of cell death following ischaemia-
reperfusion compared to ischaemia alone. In a study by Vanden Hoek et al using 
chick cardiomyocytes and propidium iodide staining for demarcation of cell death, 
they found that there was 17% of cell death in the group of sustained ischaemia 
versus 73% of cell death in the reperfused group when 4 hours ischaemia and 4 
hours of reperfusion were compared to 1 hour ischaemia and 3 hours reperfusion. 
Ischaemia alone causes cell death due to deprivation of oxygen 22. Apart from 
causing deleterious global injury, reperfusion also triggers a myriad of inflammatory 
effects which exacerbate the local insult 23-25. In the following section 1.2.1, we will 
explore the different metabolic and biochemical changes that occur during ischaemia 
and reperfusion. 
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1.2.1  Pathogenesis of Ischaemia-Reperfusion Injury  
 
1.2.1.1 Metabolic & Biochemical Consequences of Myocardial Ischaemia 
 
Complete occlusion of the coronary artery due to the formation of a thrombus at a 
site of atherosclerotic rupture deprives the cardiac tissue of oxygen. The deprivation 
of oxygen causes uncoupling of oxidative phosphorylation by impairing the electron 
flow through the respiratory chain leading to an accumulation of Nicotinamide 
adenine dinucleotide hydrogenase (NADH) and flavin adenine dinucleotide 
hydrogenase (FADH) and subsequent termination of ATP production 13, 14. The 
impaired electron flow causes the collapse of mitochondrial membrane potential as 
the electrochemical gradient across the inner mitochondrial membrane is no longer 
maintained 26. The remaining ATP is then hydrolysed by the F0F1-ATPase causing 
the accumulation of catalytic metabolites such as hypoxanthine which can be 
oxidised to release free radicals 27. The lack of ATP and oxygen causes the cells to 
utilise anaerobic glycolysis instead of aerobic respiration for ATP production 13, 14, 28. 
The process of glycolysis causes a build-up of lactic acid, hence accumulating H+ 
ions in the cytosol. The decrease in intracellular pH activates the Na+/H+ exchanger 
to remove the cytosolic protons but inadvertently causes accumulation of Na+ ions 13, 
14, 28
. The Na+/K+-ATPase which is responsible for removal of the Na+ ions is 
inactivated because of the lack of ATP and increasing intracellular phosphate (Pi) 13, 
14, 28
. The increasing levels of Na+ triggers the Na+/Ca+ exchanger to function in 
reverse, causing accumulation of intracellular Ca2+ while removing the Na+ 29. The 
high levels of cytosolic Ca2+ results in mitochondrial accumulation of Ca2+ via the 
mitochondrial Na+/Ca2+ exchanger and transfer of Ca2+ from endoplasmic reticulum 
(ER) 30. In summary, following a period of sustained myocardial ischaemia, there is 
a decrease in intracellular pH (< 7.0), elevated levels of intracellular Ca2+ and [Pi], 
and ATP depletion.  
 
1.2.1.2 Metabolic & Biochemical Consequences of Myocardial Reperfusion 
 
Following ischaemia, the restoration of blood flow re-oxygenates the ischaemic 
cardiac tissue. This reperfusion causes repolarisation of the mitochondrial membrane 
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potential and subsequent re-activation of the respiratory chain 30, triggering the 
production of reactive oxygen species (ROS) and oxidation of NADH/FADH 12, 16, 23, 
31, 32
. Reperfusion also leads to the wash-out of lactic acid, which restores the 
physiological pH. The levels of calcium drops initially but is then restored via the 
activation of the Ca2+-uniporter by recovery of the mitochondrial membrane 
potential 33, 34. The different factors and changes which takes place during ischaemia 
and the onset of reperfusion convenes to mediate cell death by triggering the opening 
of the mitochondrial permeability transition pore (mPTP) 23, 31, 35, a crucial mediator 
of cell death which will be discussed in greater details in Sections 1.2.2.4 and 1.7. 
 
1.2.2  Mediators of Lethal Myocardial Ischaemia-Reperfusion Injury 
 
In this section, we will explore in greater detail the individual changes happening 
during ischaemia and reperfusion that ultimately lead to lethal myocardial IRI.  
 
1.2.2.1 Re-oxygenation & production of reactive oxygen species (ROS) 
 
Re-oxygenation or re-vascularisation itself is a potent mediator of IRI. The 
respiratory chain in the mitochondria is re-initiated following oxygenation and thus 
leading to ROS generation by xanthine oxidase (O-form) which is derived from 
xanthine dehydrogenase (D-form) through a conformational change 36. ROS is a 
general term encompassing molecules including superoxide (O2−), peroxynitrite 
(ONOO−), singlet oxygen (O-), and hydroxyl (OH-) 37. The process of hypoxia and 
pathological conditions such as cardiovascular diseases triggers an elevated level of 
xanthine oxidase, particularly in the endothelial cells lining the blood vessels of the 
heart 38. During the conversion of hypoxanthine to xanthine and xanthine to uric 
acid, oxygen is used as an electron acceptor, producing O2•− and hydrogen peroxide 
(H2O2) as side products 36, 37.  
 
Another source of ROS is the NADPH oxidase originating from neutrophils 
or the superoxide produced from eNOS/iNOS 39. The non-phagocytic NADPH 
oxidases are termed as the NOX family, which comprises of seven isoforms: NOX1, 
NOX2 (formerly gp91phox), NOX3, NOX4, NOX5, and dual oxidases 1 and 2 
(DUOX1 and DUOX2) 37, 40. These isoforms are transmembrane proteins with 
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subunits located in both the cytosol and cellular membrane 40. Upon binding of the 
subunits to each other to form a functional isoform, the transmembrane complex is 
able to transport electrons across the membrane to reduce O2 to O2•− 37. The evidence 
supporting the role of NOX in tissue damage following myocardial infarction 
remains debatable but there are studies detecting an enhanced expression level of 
NOX in patients with myocardial infarction or coronary heart disease 41-43.  
 
eNOS is a homodimer comprising of two monomers which consist of both a 
reductase domain and an oxygenase domain 44, 45. The reductase domain is crucial 
for binding of NADPH, FAD, and flavin mononucleotide (FMN) while the 
oxygenase domain is responsible for carrying a prosthetic heme group for proper 
dimerisation of both monomers. The oxygenase domain binds (6R)-5,6,7,8-
tetrahydrobiopterin (BH4), molecular oxygen, and the substrate l-arginine to become 
a fully functional enzyme complex 44, 45. eNOS catalyses an electron transfer within 
the reductase domain from NADPH via the flavins FAD and FMN to the heme in the 
oxygenase domain 46. In patients with hypertension 47 or hypercholesterolemia-
associated endothelial dysfunction 48, there will be a reduction in tetrahydrobiopterin 
and L-arginine due to a perturbation in the electron flow within eNOS. Because of 
this reduction in the cofactor tetrahydrobiopterin and L-arginine as a substrate for 
eNOS/iNOS, production of superoxide (O2–) increases. The effects of NO can be 
controversial as NO is involved in cardioprotection but also mediates IR injury by 
reacting with the superoxide produced to form peroxynitrite (ONOO-) which will 
dissociate into cytotoxic NO2 and OH- 49, 50.   
 
The presence of ROS will lead to lipid peroxidation 32, induction of calcium 
overloading in the mitochondria 39, oxidative damage to the DNA 51 and opening of 
the mPTP 52. In addition to opening the mPTP, ROS also reduces the bioavailability 
of the intracellular signaling molecule, nitric oxide, which is known to confer 
cardioprotection effects by inhibition of neutrophil accumulation, inactivation of 
superoxide radicals, and improvement of coronary blood flow.  
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1.2.2.2 Calcium Overloading  
The calcium overload induced  by the Ca2+-induced Ca2+ release is a phenomenon 
that occurs in mitochondria due to the failure of the normal Ca2+ regulation system as 
a result of sarcolemmal-membrane damage, dysfunction of the sarcoplasmic 
reticulum (SR) and reversal of the Na+-Ca+ exchanger, all of which are caused by the 
increased levels of ROS 53. Calcium overloading will lead to cardiomyocyte cell 
death by opening of the mPTP triggered by the restoration of physiological pH 
following the wash out of lactic acid and hypercontracture, a term to describe the 
irreversible deformation of cytoskeletal elements in the cardiomyocyte 53. 
Experimental studies have shown that using pharmacological agents that inhibit the 
sarcolemmal Ca2+ ion channel, the mitochondrial Ca2+ uniporter, or the sodium–
hydrogen exchanger decreased myocardial infarct size by up to 50% 54, 55.   
Nevertheless, corresponding clinical studies have been found to be inconclusive 56, 57.  
 
1.2.2.3 pH Restoration  
The pH paradox is a phenomenon where the restoration of physiological pH occurs 
upon washout of lactic acid from glycolysis and subsequent activation of the 
sodium–hydrogen exchanger and the sodium–bicarbonate symporter and this has 
been identified as a cause of reperfusion injury 58. Reoxygenation with acidic buffer 
to maintain a low pH has been shown to protect the neonatal rat cardiomyocytes 59, 
although clinically, this has been yet to be successful 57, 60.  
 
1.2.2.4 Opening of the Mitochondrial PTP  
The mPTP is a nonselective channel in the inner mitochondrial membrane. Opening 
of the mPTP, which constitutes a cyclophilin D (CypD) component, causes the 
collapse of the mitochondrial membrane potential and uncoupling of oxidative 
phosphorylation which causes ATP depletion and cell death, hence placing the 
mPTP as a critical factor of lethal reperfusion injury 61.  It has been found that the 
mPTP remains closed during myocardial ischaemia and only opens at the onset of 
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reperfusion following the introduction of ROS, mitochondrial Ca2+ overload, pH 
increase and depletion of ATP 62, 63. Further details regarding the mPTP are available 
in Section 1.7.  
 
1.2.3   Damaging effects of Myocardial Ischaemia-Reperfusion Injury 
 
Lethal myocardial reperfusion injury causes cell death largely by necrosis which is 
proven by the fact that the central zone of the infarct is mainly made up of a necrotic 
band which depends on the duration of the ischaemia. Necrosis causes the loss of 
cellular integrity whereby the outflow of cytosolic contents triggers an inflammatory 
response 64. Apoptosis, located in the peri-infarcted area, is highly-regulated and 
energy dependent and is hampered by the lack of ATP production during ischaemia, 
but is re-activated during reperfusion 65 (see Figure 1.1).  
Death of cardiomyocytes in this setting is the main cause of an increase in infarct 
size of up to 50% and deaths following a myocardial infarction (MI). Extensive 
research in animal models have been conducted to reduce infarct size following an 
MI but these have yet been successfully transferred to clinical settings 66.  
The successful application of ischaemic postconditioning (IPost) in which 
reperfusion therapy is initiated by short-lived episodes of myocardial ischaemia has 
sparked interest in pursuing the reperfusion phase as a target for cardioprotection, 
especially following the elucidation of the Reperfusion Injury Salvage Kinase 
(RISK) pathway (see Section 1.6.2.3) and the mPTP (see Section 1.7) as an end-
point for conferring cardioprotection 67, 68. Formulation of new therapies based on 
these findings should improve clinical outcomes in acute myocardial infarction and 
reduce the risk of heart failure following MI.  
 
1.2.3.1 Apoptotic cell death 
 
Apoptosis is a well-organised, highly-regulated, energy-dependent suicidal 
process whereby a cell commits suicide without damaging the surrounding tissue and 
is a normal process which occurs during development, tissue turnover, and in the 
immune system 5. Apoptosis is characterised by the fact that it is controlled at the 
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genetic level, and is crucial for cells that are in certain stages of development or 
senescence 5, 69.  
 
There are two distinctive stages in mitochondrial-related apoptosis: first 
where the proapoptotic protein Bax translocates from the cytosol to the 
mitochondria; and second where the mitochondria release cytochrome c from the 
intermembrane space into the cytosol 70. The Bcl-2 gene, an oncogene that 
participates in the development of human B cell lymphomas is actively involved in 
the apoptosis process in mammalians 71. The Bcl-2 gene encodes for different 
proteins that are either pro-apoptotic (Bad, Bax, Bid) or anti-apoptotic (Bcl-2, Bcl-
xL). The balance of these proteins determines the cell fate. The mitochondria in 
eukaryotes are a target of the apoptotic Bcl-2 family proteins such as Bax and Bak. 
Death signals induce the translocation of the apoptotic protein from the cytosol to the 
outer membrane of the mitochondria, leading to the release of cytochrome c, 
apoptosis-inducing factor (AIF) and the Smac/Diablo proteins from the 
intermembrane space. Cytochrome c is nuclear-encoded and is translocated to the 
mitochondrial intermembrane space upon synthesis 72. A haem group is added to 
localise the cytochrome c in this space. Cytochrome c functions to shuttle the 
electrons from complexes III to IV in the mitochondrial electron transport chain 73. 
Only once released can the cytochrome c exerts its apoptotic effects 74. Apoptotic 
protease activating factor 1 (Apaf-1) can bind to cytochrome c upon initial binding 
of dATP/ATP and subsequent hydrolysis. Once Apaf-1 binds with cytochrome c, it 
undergoes oligomerisation and exposure of the caspase-recruitment domain 
(CARD). The existing CARD region on procaspase-9 induces binding to the CARD 
on Apaf-1, thus forming a complex known as apoptosome and subsequent activation 
of procaspase-9. Activated caspase-9 is then released to activate downstream 
caspases such as caspase 3, -6 and -7 through proteolytic cleavage to execute cell 
death action 75. Smac/Diablo functions to inhibit proteins that inhibit apoptosis 
(IAP). AIF in the cytosol translocates to the nucleus where it causes chromatin 
condensation and DNA fragmentation 73.  
 
Two causes underlie the release of proapoptotic proteins from the 
intermembranous space: the formation of non-specific channels in the outer 
membrane and the rupture of the outer membrane following swelling of the 
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mitochondrial matrix in the event of mPTP opening 76. Besides the release of 
cytochrome c from mitochondria, apoptosis is also initiated by the ligation of 
membrane-bound death receptors such as the tumour necrosis factor receptor (TNF) 
family 5, 77.  
 
Apoptosis is linked with two main variations in mitochondria: mPTP opening 
and mitochondrial fusion/fission, through cristae remodelling the proteins involved 
in the different processes such as the Bax protein which interacts with the mPTP 
components and certain fusion/fission proteins such as the Drp1 and Mfn2 11. 
Regulators of apoptosis include inhibitors of caspases e.g., cellular FADD-like 
inhibitory protein (cFLIP) and the inhibitor of apoptosis (IAP) family, Bcl-2 family 
of proteins and growth factors 5.  
 
Detection of apoptosis is usually conducted through two assays; Terminal 
deoxynucleotidyl-transferase-mediated dUTP nick end labelling (TUNEL) assay and 
in situ end labelling (ISEL) 5. The split DNA is fluorescently labelled in the TUNEL 
assay showing the occurrence of apoptosis and is used in conjunction with other 
techniques such as agarose gel electrophoresis for subsequent confirmation 5. 
Annexin V is a Ca2+ dependent phospholipid binding protein which can be used for 
measuring apoptosis. During the early stage of apoptosis, phosphatidylserine 
relocates from the inner plasma membrane to the outer plasma membrane which will 
then bind to Annexin V 78-80.   
 
Apoptosis can be differentiated from necrosis based on the amount or levels 
of ATP available. The occurrence of apoptosis relies on the presence of a high 
amount of ATP whereas necrosis occurs when the ATP is scarce 11. Another way of 
determining whether apoptosis or necrosis is predominant is to differentiate the 
occurence of inner membrane pore opening (iMPT) or outer membrane pore opening 
(oMPT) 11. iMPT decreases cellular ATP by blocking the synthesis of ATP while 
enhancing ATP hydrolysis. oMPT, on the other hand, promotes the release of 
cytochrome c and AIF to trigger the process of apoptosis 11.  Various studies have 
also used a combination of fluorescein isothiocyanite (FITC) – labelled Annexin V 
and propidium iodide (PI) to differentiate between apoptosis and necrosis: intact 
cells (FITC-/PI-), apoptotic (FITC+/PI-) and necrotic cells (FITC+/PI+) 79, 81-83.   
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1.2.3.2 Necrotic cell death 
 
 
Necrosis is characterised as the form of cell death that occurs following 
severe cellular damage 5. Characteristics of necrosis include uncontrolled disruption 
of organelles in the cell, severe enlargement of the organelles, membrane rupture, 
denaturation and coagulation of cytoplasmic proteins and depletion of ATP 69 (see 
Figure 1.1). Necrosis will induce inflammation in the tissue. In the case of 
ischaemia-reperfusion, severe or prolonged apoptosis will usually cause necrosis due 
to the failure of the heart to eliminate apoptotic myocytes 5. The process of necrosis 
is swift and irreversible and will usually occur if ischaemia is prolonged 5.  
 
Detection of necrosis is undertaken using propidium iodide (PI), an 
intercalating agent which is readily taken up by the necrotic cell which has lost its 
membrane integrity 84, 85. Upon entering the necrotic cell, PI binds to the DNA by 
intercalating between the bases with relatively no sequence preference and the 
fluorescence of the dye is enhanced 20 – 30 fold 84, 85.  
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Figure 1.1: Cell death fate as determined by extent of mPTP opening. The extent 
of injury or stress determines the level of mPTP opening and types of cell death. 
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1.3 The Mitochondria as Mediators of Cardioprotection 
 
 
    In order to protect the cardiac cells against ischaemia-reperfusion injury, 
various interventions have been formulated. Many of these interventions, including 
ours, have placed the mitochondria, a unique organelle in the cell as a central target 
of action. In the following sections, we will review the characteristics of the 
mitochondria before further exploring the cardioprotective interventions that target 
the mitochondria in the myocardium.  
 
 
1.3.1  The Structure of Mitochondria  
 
 
Mitochondrial research has a long history but its popularity soared in the 
1990’s when it was discovered that mitochondria intensify apoptosis by releasing 
cytochrome c and other intermembrane space proteins involved in activating effector 
caspases 86. Mitochondria play an important role in the life cycle of eukaryotic cells 
by governing the different types of cellular metabolic reactions, generating energy in 
the form of adenosine triphosphate (ATP) to carry out the processes and participating 
in calcium signalling, apoptosis and the aging process 11, 87, 88. In reference books, 
mitochondria are frequently portrayed as kidney bean-shaped organelles found in 
eukaryotic cells; however due to the advancements in imaging techniques, the 
mitochondria are found to come in the form of an extended network of tubular 
threads 89 (see Figure 1.2).  
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Figure 1.2: Mitochondria in a HL-1 cardiac cell with an overexpression of the 
mitochondrial-targeted red fluorescent protein (mtRFP) under the confocal 
microscope.  
 
 
Studies have shown that mitochondrial morphology is intricate and dynamic. 
In a typical animal cell, mitochondria come in a mixture of thread-like tubules and 
spherical globules 90. But, the shape and size of mitochondria change depending on 
the variety of cell type and cell’s needs 91. Changes are predominantly in the external 
shape with the internal structural organisation retaining a highly conserved form 92.   
 
The mitochondria are compartmentalised by two membranes; the inner and 
outer membrane, the intermembrane space and the matrix 93. The outer membrane, 
which encapsulates the whole organelle, acts as a permeability barrier to molecules 
larger than 1500 Da and separates the intermembrane space from the cell cytosol 94. 
The permeability barrier is constituted of integral proteins known as porins or 
channel formers. Larger proteins, however, can still enter the the matrix of the 
Sang Bing, Ong 
 45
mitochondrion provided they contain an N-terminal signalling sequence, which 
directs the large protein to a translocase of the outer mitochondrial membrane 
(OMM) to allow the movement of the protein into the mitochondria 93, 95. The OMM 
consists of a protein-to-phospholipid ratio of 1:1 by weight, which is very similar to 
the eukaryotic plasma membrane. The OMM has also been found to associate with 
the ER membrane via the mitochondria-associated ER-membrane (MAM) where 
calcium signalling and lipid transfer can take place 96.  When subjected to certain 
stresses or injury, the OMM will rupture and burst, hence releasing the proteins 
located in the intermembrane space into the cytosol 97. Nonetheless, the ionic 
composition of the intermembrane space is similar to the cytosol due to the fact that 
the outer membrane is permeable to small ions and solutes. A distinct group of 
intermembrane protein, the cytochrome c, will promote apoptosis or cell death once 
released into the cytosol.  
 
The inner membrane of the mitochondria (IMM), conversely, is different 
from the outer membrane in that it consists of regions parallel to the outer membrane 
as well as regions invaginating the matrix forming unique structures known as 
cristae, which enhance the ATP production capability by increasing the ratio of 
surface area to volume 94. The cristae are where the electron transport chain, 
transporter proteins and phosphorylation mechanisms can be found, constituting up 
to 1/5 of the total protein in a mitochondrion 94. The presence of the ETC creates a 
membrane potential across the IMM which is crucial to maintain oxidative 
phosphorylation. Contact sites that are involved in fusion of the inner and outer 
mitochondrial membranes, protein import and uptake of fatty acids of oxidative 
metabolism are also located at the cristae. The inner mitochondrial membrane, 
compared to the outer membrane has a higher protein-to-phospholipid ratio (3:1 by 
weight) and contains a special phospholipid known as cardiolipin, which confers 
impermeability to the IMM 98. Special membrane transporters are required to enable 
the entry of specific ions and molecules with proteins being transported via the 
translocase of the inner membrane (TIM) complex or via Oxa1 95.  
 
Mitochondrial DNA (mtDNA) which is responsible for encoding specific 
proteins for the electron transport chain can be found in the mitochondrial matrix. In 
addition to that, ribosomal RNA (rRNA) and transfer RNA (tRNA) for amino acid 
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synthesis as well as metabolic enzymes involved in the citric acid cycle, oxidation of 
pyruvate and fatty acids are also located in the mitochondrial matrix 94.    
 
 
1.3.2  Physical Distribution of the Mitochondria 
 
The distribution of mitochondria depends on various temporal and spatial 
needs, such as during different developmental stages and specific high-energy 
regions 99-101. In addition, the different pathological situations such as cancer and 
cardiomyopathy also affect mitochondrial morphology and distribution 92. 
Mitochondrial content can be reduced by chronic hypoxia, as in mouse diaphragm, 
with the underlying cause being postulated as increased mitophagy and reduced 
mitochondrial biogenesis 102. Mitochondrial subpopulations in skeletal and cardiac 
muscle (interfibrillar, subsarcolemmal and perinuclear) can also differ in terms of 
individual mitochondrial number following activity or stress 103, 104.   
 
Mitochondria can move to different parts of the cell depending on energy 
requirement and utilisation using the microtubule of the cytoskeleton as a migration 
track 105. However, fusion of mitochondria does not require the presence of the 
cytoskeleton. Mitochondria participate in regulation of cell death through several 
mechanisms such as mitochondrial fragmentation, cristae remodelling and the 
release of cytochrome c 106. 
 
1.3.3  Formation of the Mitochondria 
 
Production of mitochondria by mitosis is based on cellular energy need 
whereas degradation of mitochondria follows mitochondrial redundancy 107. The 
formation of mitochondria or mitochondriogenesis is divided into two distinctive 
stages with different genetic material involved. First, formation of the mitochondrial 
outer and inner membrane to facilitate compartmentalisation which is governed by 
the nuclear genes followed by mitochondrial diffentiation for oxidative 
phosphorylation which depends on both the mitochondrial and nuclear genes 108. 
Mitochondrial synthesis relies on the stimulation of the Peroxisome proliferator-
activated receptor- coactivator (PGC-1alpha) - Nuclear respiratory factor 1 (NRF1) - 
Transcription factor A, mitochondrial (TFAM) pathway with PGC-1alpha being the 
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first stimulator of mitochondriogenesis and oxidative stress sensor. Upon activation 
of PGC-1alpha, the downstream intermediate transcription factor NRF1 is produced, 
which then stimulates expression of TFAM, a duplicator of mitochondrial DNA 109, 
110
.   As mentioned in Section 1.3.2, chronic hypoxia impairs mitochondrial 
biogenesis. This phenomenon is analogous to performance of competitive sports and 
exhaustive exercises where mitochondrial content is affected by the presence of 
damaging levels of ROS. However, during normal daily aerobic training, non-
damaging levels of ROS may be required for activation of PGC-1alpha and 
subsequent muscle adaptation through mitochondriogenesis 107.     
 
 
 
1.3.4  Inheritance of the Mitochondria 
 
Mitochondria are unique organelles with their own genomes coupled to a 
transcription and translation system, which dictates their ability to perform 
specialized functions such as production of energy for different cellular processes 108, 
111
. Due to the fact that the mitochondrial membranes and mtDNA both serve as a 
crucial template for the proper growth and division of the mitochondria, the 
‘inheritance’ of mitochondria requires the proper transmission of mitochondria to 
daughter cells before every cell division 108. The division of mitochondria in 
eukaryotes is tightly regulated by both cell cycle and the energy needs of the cell. 
Mitochondrial inheritance in mammalian cells is generally maternal or uniparental-
derived. Biparental mitochondrial inheritance however, also exists in certain 
unicellular organisms such as the yeast 112. Cellular proliferation requires optimum 
regulation of DNA replication, organelle segregation and cytosolic contents 
maintenance through various signalling cascades 113. Mitochondrial segregation 
during mitosis is crucial as the mitochondria are also involved in regulation of a 
viable cell cycle 92, 113, 114. Using HeLa cells to study the dynamics of the 
mitochondria during cell cycle, the group of Taguchi found that mitochondria 
maintain the long tubular network during interphase but fragments in the early 
mitotic phase. Nevertheless, the filamentous network of mitochondria re-forms in the 
daughter cells 115. Fragmentation of the mitochondria during mitosis is regulated by 
the mitochondrial fragmentation-promoting protein, Dynamin-related protein 1 
(Drp1), specifically during the anaphase 115. In order to fragment the mitochondria 
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during mitosis, Drp1 has to be phosphorylated at position Ser-585 by the cell cycle-
specific kinase Cdk1/cyclin B1 115. A recently discovered SUMO protease, SenP5, 
was also found to be involved in regulation of Drp1 during mitosis 113, 116. At the 
G2/M transition prior to breakdown of the nuclear envelope, SenP5 is recruited from 
the cytosol and nucleolus to the mitochondria where it functions to deSUMOylate 
Drp1 to fragment the mitochondria and progress into the M phase of the cell cycle 
113
. Silencing of SenP5 has been detected to cause cell cycle arrest precisely at the 
time when the protease is translocated to the mitochondria 113 
 
 
 
1.3.5  Proteins & Compartmentalisation in the Mitochondria 
 
Another distinctive feature of mitochondria is the compartmentalisation of 
the different proteins and functions present in the matrix and intermembrane space 
91
. It has been a long time since mitochondria established themselves as key 
components affecting the life and death of eukaryotic cells through the presence of 
various proteins catalysing different biosynthetic (e.g. ATP production via the 
components of the respiratory chain) and degradative reactions (e.g. cell death via 
release of cytochrome c).  The mitochondrial structure, a result of the local synthesis 
of macromolecules within the mitochondria itself, as well as the import of proteins 
and lipids from outside the organelle, dictates the optimum performance of the 
mitochondrial functions with proper localisation of the enzymes in distinct 
membranes and aqueous compartments 92.   
  
The abundance of different protein molecules in the mitochondria derives 
from the protein targeting process. Protein targeting to mitochondria is basically 
defined as the shift of proteins translated from the nuclear genes and synthesised in 
the cell cytoplasm, into the mitochondria. Ironically, even though this process 
requires the complementation of different mitochondrial proteins, only a few protein 
molecules transferred originated from the mitochondrial DNA, synthesised on 
mitochondrial ribosomes and inserted into the inner membrane from the matrix 93.     
 
Studies have been conducted to shed new light on the mitochondrial protein 
import pathways and generally it was found that in mammalian cells, preproteins are 
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directed into the matrix of the mitochondria in a general pathway (via the translocase 
of the outer membrane) while a series of pathways directing mitochondrial precursor 
proteins to subsequent sites of functions were defined, with the presequence pathway 
for proteins to the matrix and inner membrane 117, the carrier protein pathway for 
the inner membrane 118-120, the redox-regulated import pathway into the 
intermembrane space 121, 122, and the β-barrel pathway into the outer membrane 93, 
123-125
.     
 
    A recent review by the group of Shirihai categorised the control of 
mitochondrial proteins to ‘local’ and ‘global’. The ‘local’ control functions include 
the micro-environmental changes in the organelle that affect the post-translational 
modification, oxidation or degradation of the encoded proteins which will affect 
processes such as energy production, apoptosis and division cycle. Control 
mechanisms stemming from the cell itself are regarded as ‘global’ controls. One 
example is the cell cyle where nuclear transcription factors such as PGC1α, PPARα, 
NRF1/2, and ERRα control the physical and physiological state of the mitochondria 
at different stages of the cell cycle 126-128  
 
    Compartmentalisation of the mitochondria is also affected by IMM 
remodeling which in turn plays a crucial role in regulating ATP production by 
governing the amount of ADP available to cross the OMM 129, 130. The cristae in the 
mitochondria are shown to be tubular and structurally distinct from the inner 
mitochondrial membrane using advanced tomographic imaging techniques 131, 132. In 
addition to that, the cristae were found to be attached to the inner boundary 
membrane via tubules termed cristae junction, which constitutes a general structural 
component in all mitochondria 131, 132. This interconnection between the cristae 
junction and the inner mitochondrial membrane changes with the respiratory state of 
the mitochondria 132-134. According to Hackenbrock and the group of Mannella, using 
isolated rat liver mitochondria under high-resolution electron microscopy, the 
number of cristae junction and cristae interconnections decreases during the high-
energy state of the mitochondria (state 4: low respiratory rate due to depletion of 
ADP) while the number increases during the low-energy state of the mitochondria 
(state 3: maximum respiratory rate in the presence of excess ADP and respiratory 
substrate) 132, 133. The increase in cristae junction has been speculated to aid in 
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reduction of ADP diffusion into the cristae across the IMM and hence ATP 
production while the low numbers of cristae junction during State 4 of the 
respiratory state helps ATP production by concentrating the ADP within a smaller 
intercristal volume 129, 130.  
      
    In the matrix, the enzymes of different metabolic pathways are grouped 
together in entities termed metabolons to facilitate diffusion of solutes from one 
enzyme to the next enzyme in a pathway. One of the typical metabolon is the 
pyruvate dehydrogenase complex (PDC).  
 
 
1.3.6  Role & Function of the Mitochondria 
 
The most prominent function of mitochondria is known to be the generation 
of ATP by oxidative phosphorylation and electron transport (see Figure 1.3), a 
process in which electrons from NADH are shifted along a series of complex carrier 
molecules, generating energy stored in the form of a proton gradient across the 
mitochondrial membrane which is subsequently utilised by ATP synthase on the 
inner membrane to produce ATP from ADP and phosphate.  
 
However, mitochondria also contribute to the biosynthesis of different 
compounds such as pyrimidines, nucleotides, amino acids, heme, and urea 108 as well 
as regulation of calcium and ROS-mediated processes in cells. The energy 
metabolism process is coupled to ion homeostasis through dynamic feedback 
mechanisms between the mitochondria and cell cytoplasm to maintain cell survival 
135
.  
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1.3.6.1 Energy conversion 
     The production of ATP is conducted via cellular respiration through 
oxidation of glucose, pyruvate and NADH in the presence of oxygen. Aerobic 
respiration will switch to glycolysis in the absence of oxygen  136.  
     The pyruvate molecule is transported across the IMM into the matrix where 
it undergoes oxidization and is combined with coenzyme A to form CO2, acetyl-CoA, 
and NADH. The acetyl-CoA then enters the citric acid cycle, also known as the 
tricarboxylic acid (TCA) cycle or Krebs cycle where it is oxidised to CO2 and 
releases reduced cofactors (three molecules of NADH and one molecule of FADH2) 
that are a source of electrons for the electron transport chain, and a molecule of GTP 
(that is readily converted to an ATP) 136 
     The NADH and FADH2 molecules are transported via the malate-aspartate 
shuttle system of antiporter proteins or feed into the electron transport chain using a 
glycerol phosphate shuttle. Components of the ETC include Complex I, II, III, IV 
and V. Complex I, III and IV perform the transfer of electrons along the ETC and 
H+ into the intermembrane space. The ETC transfer process is efficient, however, a 
small percentage of electrons may reduce the oxygen present thus forming ROS 
which is detrimental to the cell 137.  
     An electrochemical gradient is established across the IMM following the 
increase in proton concentration in the intermembrane space. The protons are then 
pumped back into the matrix through the ATP synthase (Complex V) and the 
potential energy is used to synthesise ATP from ADP and inorganic phosphate in a 
process termed chemiosmosis, first described by Peter Mitchell in 1967 136, 138-140.  
 
1.3.6.2 Heat production 
     The protons can also re-enter or diffuse into the mitochondrial matrix 
without leading to ATP synthesis in a process known as proton leak or mitochondrial 
uncoupling. This can however lead to heat production as a result of unutilised 
potential energy of the proton electrochemical gradient.  
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1.3.6.3 Storage of calcium ions 
     Free calcium exists in the cell for a myriad of reactions and signal 
transduction processes.  Mitochondria act as a cytosolic buffer by transiently taking 
in calcium from the cytosol or the ER. The ER is a crucial calcium store in the cell 
and is connected to the mitochondria for calcium uptake into the mitochondria via 
channels such as the inositol trisphosphate receptor (IP3R) or ryanodine receptor 
(RyR) 141-143. Mitochondrial calcium uptake occurs through a calcium uniporter on 
the IMM, which passes Ca2+ down the electrochemical gradient maintained across 
the mitochondrial membrane without direct coupling to ATP hydrolysis or transport 
of other ions 142, 144. Calcium in the mitochondria can also be released into the cell 
via a sodium-calcium exchanger or a "calcium-induced-calcium-release" pathway, 
which can be visualised as calcium spikes or waves that play a role in activation of 
second messenger systems for signal transduction or changes in mitochondrial 
membrane potential.   
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Figure 1.3: Mitochondrial oxidative phosphorylation. Mitochondrial oxidative 
phosphorylation and electron transport is actively carried out by a chain of 
multisubunit protein complexes present within the mitochondrial inner membrane. 
Reducing equivalents are provided within the mitochondrial matrix via metabolism 
of glucose via glycolysis and the citric acid cycle to complex I (NADH) and complex 
II (FADH2). Electrons are transferred to complex III via ubiquinol and subsequently 
to complex IV via cytochrome c, with the reduction of O2 to form H2O. The 
movement of electrons through the series of enzyme complexes promotes the 
pumping of protons (H+) across the inner membrane at complexes I, III, and IV, 
creating an electromotive differential across the inner membrane. Complex V (ATP 
synthase) utilises the potential energy created by this proton gradient to condense a 
molecule of ADP with Pi to form ATP. ATP is subsequently transported out of the 
mitochondrial matrix by the adenine nucleotide translocator (ANT), which is also 
responsible for moving cytoplasmic ADP into the mitochondrial matrix.  
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As in other cells, mitochondria act as a crucial regulator of the life and death 
cycle of cardiac myocytes. The key role these mitochondria have in the normal 
myocytes is in providing ATP through oxidative phosphorylation to meet the high 
energy requirements of the beating heart cells. The positioning of the mitochondria 
between the myofibrils and just below the sarcolemma of the myocyte enhances the 
efficiency of the localised ATP delivery system to support contraction, cell 
metabolism and ion homeostasis.  
 
Besides maintaining the life of the heart cells, mitochondria also regulate cell 
death by reacting in response to different stress signals such as damage of inheritable 
material, oxidative stress, hypoxia and loss of growth factors. Initiation of the death 
pathway occurs upon the opening of the mPTP in the inner mitochondrial membrane, 
which subsequently leads to collapse of the membrane potential, mitochondrial 
swelling, and rupture of the outer membrane followed by release of proapoptotic 
proteins to stimulate apoptosis or necrosis 145. The process of apoptosis requires the 
mitochondria to execute crucial functions such as the release of cytochrome c and 
certain cofactors to trigger the caspases 146. The particular role of mitochondria in 
promoting survival or performing apoptosis relies on the interplay between different 
pro- and anti-apoptotic members of the Bcl-2 protein family 146. Apoptosis and 
necrosis are different in the sense that a signaling cascade leading to cell death albeit 
without an inflammatory response is activated during apoptosis whereas necrosis 
causes cell swelling and rupture of the plasma membrane, further releasing the 
cellular content into the extracellular space which causes an inflammatory response 
which damages the neighboring cells 73. Both of these processes equally contribute 
to the loss of myocardial cells in pathologies such as ischaemia-reperfusion injury, 
cardiomyopathy and congestive heart failure 73. However, the contribution of 
apoptosis to cell death predominantly occurs in the reperfusion phase.  
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1.4 The Morphology of the Mitochondria 
 
 
The term mitochondria derived from the Greek word mitochondrion, a 
combination of mitos (thread) and chondros (grain) 147. In the early days, 
mitochondria were thought to be isolated cytosolic organelles independent of each 
other. Upon the advent of bright field microscopy in the 20th century, mitochondria 
were revealed to be dynamic in nature, and to vary in size and shape depending on 
the cell-type.   
 
The development of mitochondrial-targeted fluorescent dyes and proteins 
enabled the characterisation of mitochondrial dynamics involving movement of 
mitochondria along the cytoskeleton to changes in shapes, ranging from unicellular 
yeast to the multicellular mammalian cells 90, 148, 149. The first gene involved in 
mitochondrial fusion was discovered in Drosophila melanogaster in 1997, with 
subsequent fusion and fission genes being identified in yeast or Drosophila models 
and mammalian cells 92, 150. The key genes in regulation of mitochondrial fusion and 
fission have been identified but the mechanisms and effects on metabolism and other 
physiological effects have yet to be clarified.  
 
The mitochondria consist of two membranes differentiating the 
intermembrane space and the mitochondrial matrix 106. Mitochondria in cells come in 
a variety of shapes, depending on the different physiological stages the cell is in, e.g. 
the extent of a particular process such as cell cycle and division as well as 
positioning of cells in different parts of an organ 105. In addition, the shape and 
location of the mitochondria in the cell may regulate its respiration and metabolism 
106
. Mitochondria can be elongated and fused or fragmented into globules 106. The 
fusion and fission events of the mitochondria ensure that exchange of the contents 
(solutes, metabolites, enzyme, mtDNA) can occur.   
 
The mitochondrial arrangement in the adult cardiac cell differs from that in 
cardiac cell lines and neonatal cardiomyocytes. Mitochondria in the HL-1 cardiac 
cell line for example, exist as a mixture of elongated (spaghetti-like form) and 
fragmented form (see Figure 1.4). In the primary cardiomyocyte however, the 
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mitochondria are arranged in a very highly organised form, aligned alongside the 
sarcolemma with the myofibrils in-between, with very little space to move (see 
Figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Representative image of mitochondria in a HL-1 cardiac cell with an 
overexpression of the mitochondrial-targeted red fluorescent protein (mtRFP) 
under the confocal microscope.  
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Figure 1.5: Representative image of an adult cardiomyocyte with the 
mitochondria loaded with Tetramethyl Rhodamine Methyl Ester (TMRM) 
(bright orange) under the confocal microscope.  
 
 
Of note, mitochondria in neonatal cardiomyocytes are filamentous in nature 
showing that the typical longitudinal arrangement of mitochondria in adult 
cardiomyocytes only arises during cardiac development. The mitochondria in the 
primary adult cardiomyocytes are generally believed to be static, with very little 
probability of fusion or fission.  Nevertheless, studies carried out by different groups 
have successfully identified the presence of the mitochondrial-shaping proteins in the 
adult heart. Santel et al in 2003 detected the presence of both Mfn1 and Mfn2 in the 
heart using Northern and Western blots, and also in the rat and mouse hearts using 
RT-PCR through the studies of Rojo et al and Bach et al in 2002 and 2003 
respectively 151-154 while Optic Atrophy 1 (OPA1) was detected in adult mouse hearts 
in 2008 154, 155. The mRNA of the fission protein DLP1 was identified in the heart 
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using Northern Blot analysis in 1998 154, 156 while hFis1 was found in the isolated 
mitochondria from the heart in 2004 157. 
 
 
 
1.4.1  Mitochondrial Fusion 
 
Mitochondrial membrane fusion has been shown to be a distinct two-step 
process which occurs separately for the inner and outer membrane, but in chronology 
11
. Both the outer and inner membranes of the mitochondria must fuse properly in 
order for the matrix contents to mix properly 105.  
 
Specificity of membrane fusion is dictated by the generation of specific 
protein complexes in trans between the donor and acceptor membranes following 
which fusion is promoted by the formation of specific helical bundles 105.  
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1.4.2  Fusion Proteins 
 
 
1.4.2.1 Mitofusins 1 and 2 (Mfn 1 and Mfn2) 
 
    Two GTPases of the outer mitochondrial membrane involved in 
mitochondrial fusion of mammals, Mitofusin (Mfn) 1 and 2, were discovered by 
Santel & Fuller in 2001 158. Mitofusins constitute the mammalian homologues of 
Drosophila Fuzzy onions protein (Fzo1p), a transmembrane GTPase first discovered 
in 1997, which is responsible for the formation of a giant mitochondria during 
spermatogenesis 150. Mitofusins are conserved GTPases localised to the outer 
membrane of the mitochondria 105. Structural studies show that mitofusins (Mfn) 1 
and 2, are located in the mitochondrial outer membrane and span the membrane 
twice, exposing an N-terminal GTPase domain and two predicted coiled-coil regions 
to the cytosol 159 (see Figure 1.6). Both Mfn1 (743 residues) and Mfn2 (757 residues) 
are made up of a NH2-terminal region containing the GTP-binding domain, 2 heptad 
repeats (coiled-coil domain), a transmembrane domain and the COOH-terminal 152 
(see Figure 1.6). The GTPase activity is required for both Mfn1- and Mfn2-mediated 
mitochondrial fusion 158 (see Figure 1.7). The outer membrane of the mitochondria 
fuses in conditions of low levels of guanosine-5'-triphosphate (GTP) hydrolysis and 
the presence of a proton gradient across the inner membrane while inner membrane 
fusion relies on increased levels of GTP hydrolysis 160. Apart from the identity of 
fusion-promoting protein, Mfn2 has also been identified in muscle from obese 
Zucker rats as mitochondrial assembly regulatory factor (MARF) 153; and in vascular 
smooth muscle cells as hyperplasia suppressor gene (HSG) 161.  
 
Mfn1 and Mfn2 can substitute each other in terms of function. 
Overexpression of Mfn2 can replace the loss of function in cells without Mfn1 while 
overexpression of Mfn1 can replace the loss of function in cells without Mfn2 105. 
Nevertheless, it has been found that Mfn1 has higher GTPase activity and induces 
fusion more efficiently than Mfn2 146. A higher degree of mitochondrial 
fragmentation has also been observed in Mfn1 -/- mouse embryonic fibroblasts 
(MEFs) compared to the Mfn2 -/- MEFs indicating the roles of the Mfns do not 
completely overlap 162. Mfn1 has been found to be responsible for docking two 
adjacent mitochondria together for the fusion process while Mfn2 plays a crucial role 
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in stabilising the interaction between the two mitochondria 162, 163. In addition to 
promoting mitochondrial fusion in general, Mfn1 is also important for placental 
formation during embryonic development 162. Mfn2 has also pleiotropic effects 
where it participates in oxidative metabolism of the skeletal muscle and cell division 
capability of vascular smooth muscle cells 153, 161. Mfn2 has recently been shown to 
tether mitochondria to the ER for calcium exchange 164.  
 
Mitochondrial fusion is unaffected by Optic Atrophy 1 (OPA1) (see section 
4.1) expression in Mfn1 -/- but not Mfn2 -/- cells, and Mfn2 but not Mfn1 cells 
promote mitochondrial elongation in cells where OPA1 has been knocked down 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Domain structure of the Mitofusin proteins. Both Mfn1 and Mfn2 are 
similar in that they contain GTPase domains (pink), hydrophobic heptad repeat (HR) 
regions (light blue) and transmembrane (TM) segments (grey). The transmembrane 
segments are charged residues and are responsible for the configuration of the 
protein to face the cytosol by producing a U-turn in the mitochondrial outer 
membrane.  
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Figure 1.7: The fusion mechanism by fusion proteins. Mfn is a mitochondrial 
outer membrane protein with a cytosolic GTPase domain (pink) and two 
hydrophobic heptad repeat (HR) regions (light blue). The C-terminal HR region 
mediates oligomerisation between Mfn molecules on adjacent mitochodnira. GTP 
hydrolysis facilitates the fusion process.   
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4.1 Optic atrophy 1 (OPA1) 
 
 
     The discovery of the Optic Atrophy 1 (OPA1) gene was made from the 
identification of mutations in the OPA1 gene in 2000 as the cause for the human 
neurodegenerative condition, autosomal dominant optic atrophy 166.  It is the human 
homologue of the yeast mitochondrial shaping protein Mgm1, first discovered in 
yeast in 1992 167. OPA1 is a GTPase of the dynamin family, consisting of an N-
terminal mitochondrial import sequence (MIS), hydrophobic segments, coiled-coil 
domain, GTPase domain, a middle domain and a GTPase Effector Domain (GED) at 
the C-terminus (see Figure 1.8). The MIS is cleaved by the mitochondrial processing 
peptidase (MPP) upon fulfilling its duty of targeting the OPA1 protein to the 
mitochondria 168. The OPA1 is widely known to exert its function at the inner 
mitochondrial membrane (IMM), although it can also prevent apoptotic cell death 
with its role in cristae remodelling 169.  
 
     OPA1 is expressed throughout the body, but is present in largest quantities 
in the retina, brain, testis, liver, heart, skeletal muscle, and pancreas 170. The human 
OPA1 consists of 8 different isoforms (4 in mice). The function of each isoform is 
determined by the exon contained.  Promotion of mitochondrial fusion and 
maintenance of mitochondrial membrane potential is dependent on the OPA1 
isoform 1 (containing exon 4), whereas alternative isoforms containing exons 4b and 
5b may control cytochrome c release 170. OPA1 can also be cleaved by presenilin 
associated rhomboid-like protease (PARL), a protease into a small soluble form 
which localises at the intermembrane space and is responsible for preventing 
apoptosis by ‘locking’ the cytochrome c in the intermembrane space 169, 171. A recent 
study by Twig and co-workers has also implicated the OPA1 in ‘tagging’ of 
mitochondria for selective removal by autophagy 172.  
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Figure 1.8: Schematic representation of OPA1. The OPA1 protein consists of an 
N-terminal mitochondrial import sequence (MIS), hydrophobic segments, coiled-coil 
domain (CC), GTPase domain, a middle domain and a GTPase Effector Domain 
(GED) at the C-terminus.  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3  Mitochondrial Fission  
 
 
   Mitochondrial fission or fragmentation is signified by generation of small, 
discrete and globular mitochondria. The fragmentation process is driven by the 
presence of specific fragmentation-promoting proteins such as the Drp1 and hFis1. 
During the fission process, mitochondria undergo simultaneous ultrastructural 
changes involving opening of the narrow tubular cristae junction and fusion of 
individual cristae 160. The genome of the mitochondria is organised into distinct 
structures known as nucleoids and fission occurs to ensure every daughter 
mitochondria has at least one nucleoid 105.     
 
   Fission of mitochondria may be synchronised with other cellular processes. 
Fission of mitochondria occurs in normal cell during the cell division process, 
particularly in the late S and M phases, to ensure proper inheritance of the organelle 
and during apoptosis where the caspase-dependent cell death is initiated by the 
release of cytochrome c from the mitochondria by the fission protein hFis1 87, 105.  
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   Nevertheless, it should be noted that fission without cytochrome c release 
does not lead to cell death due to the fact that fission also occurs in normal cells 
where regulation of mitochondrial morphology takes place as mentioned above 173. 
In fact, in the case of Ca2+-mediated apoptosis, Drp1-induced mitochondrial fission 
protected the cell by dispersing the death signal instead of killing it 174.   
 
   A similar case would be double-KO cells without the Bcl-2 members Bax 
and Bak, and cells with a mutated hFis1. In the DKO cells, it was found that only 
mitochondrial fragmentation occurs in the presence of hFis1 but not apoptosis. 
Apoptosis or cell death only occurs upon rectification of the endoplasmic reticulum 
defect, thereby implying the dependency of the effects of hFis1 on the endoplasmic 
reticulum as well as the fact the hFis1 is also found on the endoplasmic reticulum. 
Generating a mutant in the intermembrane region of hFis1 caused fission only 
without progression into cell death 87.  
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1.4.4  Fission Proteins 
 
 
1.4.4.1 Dynamin-related protein 1 (Drp1) 
 
One of the proteins involved in mitochondrial fission is Drp1, a GTPase 
located in the cell cytosol which can translocate and form constrictive rings around 
the mitochondria for the purpose of fission 106.  Drp1 was first discovered in 1998 as 
a mammalian homologue to the yeast ortholog Dnm1p 175. Structurally, Drp1 is 
made up of a GTPase, the central domain, and the GED or GTPase effector domain 
176
  (see Figure 1.11). 
 
The translocation of Drp1 involves the generation of a translocation 
activation signal followed by a vector to transfer the fission protein to the 
mitochondria in the cell due to the lack of an outer mitochondrial membrane 
targeting sequence in Drp1  70, 160. The GED domain is required for regulation of 
GTPase activity and for mitochondrial targeting 177. Drp1 has been proposed to bind 
to hFis1 which serves as a docking site for Drp1 or it may actually induces 
mitochondrial fission independently of hFis1 178. Alternatively, the presence of 
adaptor proteins such as Mdv1p and Caf4p (in the yeast system) may mediate the 
binding of Drp1 to Fis1, such as in the case for Dnm1p, the yeast ortholog for Drp1, 
although the mammalian homologous proteins have yet to be identified 179, 180 
 
A small fraction of the Drp1 from the cytosol will be utilised to form 
punctuate spots on mitochondrial tubules which indicates potential fission locations 
177
. Drp1 inhibition by generating a dominant-negative mutant or by RNA 
interference enhances the length and interconnectivity of the mitochondrial tubules 
70, 105, 177
.   The GTP-binding defective mutant of Drp1 (Drp1K38A) functions as a 
dominant negative by sequestering endogenous Drp1, thus inhibiting mitochondrial 
localisation of Drp1 181.  
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Figure 1.11: Drp1 protein. The Drp1 protein has domains typical of dynamin 
family GTPases, including a GTPase domain, a central domain and a GTPase 
effector domain (GED).  
 
 
     Drp1 can be regulated by phosphorylation 182, 183, SUMOylation 113, 116, 184 
or ubiquitination 185-188. Phosphorylation of Drp1 at different sites of different 
isoforms of the Drp1 produces different effects. The serine residues phosphorylated 
consist of either Ser616 or Ser637 182, 189, 190. Ser616 on human Drp1 splice variant 1 
(Ser585 on rat Drp1) is phosphorylated by cyclic dependent kinase 1 (Cdk1/cyclin 
B) during mitosis in HeLa cells, thereby promoting transient fission of the 
mitochondria and allowing proper distribution of the mitochondria into daughter 
cells 115. Mitochondrial fission induced by nitric oxide has also been demonstrated to 
involve phosphorylation of the Drp1 at the Ser616 site 191. 
 
     In 2008 however, the group of Chang and co-workers showed that Protein 
Kinase A (PKA) phosphorylates Ser637 on human Drp1 splice variant 1 (Ser656 on 
rat Drp1 splice variant 1) 182, 190. The phosphorylation at Ser637 inhibits the fission 
activity of Drp1 by decreasing the intramolecular interactions that normally drive 
GTP hydrolysis, albeit this was not observed in phosphorylation of Ser656 182, 190. 
Dephosphorylation by the calcium-sensitive phosphatase, calcineurin, acts in reverse 
by promoting Drp1 translocation to the mitochondria and causing fission 189, 190.  
 
     Phosphorylation at Ser600 of Drp1 isoform 3 (Ser637 on human Drp1 
splice variant 1) by the Ca2+/calmodulin dependent protein kinase Iα (CaMKIα) 
promotes mitochondrial fission 183. Therefore, it appears that the same serine residue 
(Ser637 on human Drp1 splice variant 1 and Ser600 on Drp1 isoform 3) resulted in 
mitochondrial fission if phosphorylated by CaMKIα, but mitochondrial fusion if 
phosphorylated by PKA.  
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1.4.4.2 Fis1  
 
 
Mammalian Fis1 was first identified in 2001 by its homology with Fis1p, the 
yeast ortholog 178, 192. Fis1 is a fission protein of 17 kDa and 152 amino acids 
containing a tetratricopeptide repeat (TPR) motif domain that is located evenly on 
the outer membrane of the mitochondria via the single C-terminal transmembrane 
domain (TM) with most of the protein facing the cytosol 105, 193, 194 (see Figure 1.12).  
The TPR motif is constituted of five α-helices with the first α-helix of rat Fis1 
critical for oligomerisation and for its fission activity 195. The next four α-helices are 
involved in protein-protein interactions required for fission but are not required for 
Fis1 oligomerisation 195.      
 
Apoptosis caused by hFis1 relies on the proper interplay between the 
intracellular calcium concentration, state of the mPTP and endoplasmic reticulum 87. 
Inhibition of hFis1protects against apoptotic cell death 70.   
 
Mitochondrial fission caused by overexpression of hFis1 relies on the 
presence of Drp1 105 (see Figure 1.13). However, it should also be noted that hFis1 
can promote cell death without the influence of Drp1 and can also fragments 
mitochondria without leading to cell death 87.  
 
 
 
 
 
 
 
 
 
Figure 1.12: hFis1 protein. Fis1 is a small mitochondrial outer membrane protein 
with the N-terminal facing the cytosol and the cytosolic domain (green and white) 
forming a six-helix bundle with two central tetratricopeptide repeats (TPR) (white).  
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Figure 1.13: The fission mechanism. Fis1 is localised to the mitochondrial outer 
membrane with most of the protein facing the cytosol while Drp1 is localised to the 
cytosol and on mitochondria at the punctuate spots. Drp1 will polymerise around the 
mitochondria to facilitate constriction which in the end will lead to mitochondrial 
fission.  
GTP hydrolysis 
    hFis1 Drp1 
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 The two fission proteins hFis1 and Drp1 execute their functions at different 
steps in the process of apoptosis. Absence of hFis1 (hFis RNAi) in cells inhibits 
translocation of Bax from cytosol to mitochondria whereas absence of Drp1 inhibits 
the release of cytochrome c, albeit Bax successfully translocates from the cytosol to 
the mitochondria 70. It has been found that in the absence of Drp1 (which results in 
inhibition of cytochrome c release), apoptosis still occurs. Absence of hFis1 or the 
presence of Bcl-2 prevents apoptosis to a larger extent 70. Indirectly, this shows that 
Bax translocation may be more potent in inducing apoptosis than cytochrome c 
release 192. Therefore, it can be concluded that hFis1 and Drp1 exert their effects at 
different steps of the apoptotic pathway; hFis1 upstream of Bax translocation and 
Drp1 upstream of cytochrome c release 196. Bax translocation precedes cytochrome c 
release in close time proximity to the extent that cells basically are Bax translocation 
negative and cytochrome c release negative or Bax translocation positive and 
cytochrome c release positive 70.  
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1.4.5  Other regulators of mitochondrial morphology 
 
 
     Different effectors of mitochondrial morphology have also been identified, 
such as mitochondrial protein 18kDa (Mtp18) 197, Rab32 198, Endophilin B1 199, and 
the Mitofusin-binding protein (Mib) 200.  A brief summary of the current known 
mitochondrial shaping proteins is depicted in Table 1.   
 
Table 1 
List of some of the known mitochondrial-shaping proteins 
 
Yeast Drosophila Human Location Function Notes 
Mgm1 OPA1 OPA1 IMM IMM fusion Pleiotropic 
effects 
include 
cristae 
remodelling 
Fzo1p Fzo Mfn1 OMM OMM 
fusion 
 
Fzo1p Fzo Mfn2 OMM OMM 
fusion 
Pleiotropic 
effects on 
metabolism, 
apoptosis, 
proliferation, 
ER tethering 
Ugo1 ? ? OMM OMM 
fusion 
 
Dnm1p Drp1 Drp1 or 
DNM1L 
Cytosol & 
OMM 
OMM 
fission 
 
Fis1p Fis1 Fis1 OMM OMM 
fission 
 
? ? Mtp18 IMM IMM 
fission 
Thought to 
be 
the IMM 
equivalent of 
OPA1 
Mdv1p and 
Caf4p 
? ? OMM OMM 
fission 
Adaptor 
proteins 
which aid 
Drp1 
docking 
to hFis1 
Mdm33 ? ? IMM IMM 
fission 
 
 
Sang Bing, Ong 
 71
1.4.6.  Functions & effects of changes in mitochondrial morphology 
 
 
    Changes in shapes of mitochondria may play a role in reducing the distance 
between neighbouring organelles, such as the mitochondria and ER, where material 
exchange is facilitated (e.g. Ca2+) 143, 164, 201, or initiation of certain mechanisms can 
be performed such as cell death initiation between ER and mitochondria through the 
unfolded protein response (UPR) pathway 202, 203. In addition to that, mitochondrial 
fission is crucial in ensuring proper cellular distribution of the mitochondria to areas 
of high-energy need such as the neuromuscular junction 204. With regards to cell 
death susceptibility there has been intense debate over the role of mitochondrial 
fragmentation with certain groups showing the influence of mitochondrial 
fragmentation in apoptosis 192, 205, 206 while others have showed a deviation from the 
implication of mitochondrial fragmentation in cell death 207, 208. A study by Yu and 
co-workers demonstrated that mitochondrial fission was enhanced in the diabetic 
model while also mediating high glucose-induced cell death through elevated 
production of reactive oxygen species 209. Conversely, mitochondrial fusion has yet 
to be implicated in any major pathological conditions. Elongation of mitochondria 
was found to protect senescent cells against oxidative stress by reduction of Drp1 
and hFis1 210. Loss of fusion proteins, particularly OPA1 were found to be 
detrimental in the settings of heart failure and suggest that OPA1 is needed for 
maintenance of normal mitochondrial function 211.   A mutation close to the GTPase 
region of the Mfn2 will lead to Charcot-Marie-Tooth neuropathy type 2A 212. Studies 
conducted in cardiomyocytes, skeletal muscle and kidney cells have shown that 
elongated mitochondria are present in these cells and fusion is needed to maintain 
integrity of both the mitochondria and the host cell 210, 213-215. Fragmentation of 
mitochondria conversely, may imply susceptibility of the cells to the death pathway 
or subsequent removal by mitophagy 216, 217. Nevertheless, fragmented mitochondria 
may also be needed for proper embryonic development, synapse formation and cell 
division 218.  
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1.5   Cardioprotection via Ischaemic Preconditioning /         
     Postconditioning 
 
 
     Following a detailed review of the unique functions and characteristics of 
mitochondria in the previous sections, we now move to explore some of the 
cardioprotective interventions that target the mitochondria to exert the beneficial 
effects. In order to prevent IRI, the myocardium has its own endogenous 
cardioprotective agents, such as production of a cardioprotective nucleoside by the 
name of adenosine 219, 220, opening of the ATP-sensitive potassium channels (KATP) 
to shorten the action potential duration (APD) 221-223 and release of nitric oxide (NO) 
224-227
 or the activation of the RISK pathway (see Section 1.6.2.3), a cascade of pro-
survival kinases. All of these mechanisms confer protection to the myocardium via 
inhibition of the mitochondrial permeability transition pore (mPTP), a non-specific 
channel in the inner membrane of the mitochondria 228, 229 (see Section 1.7). Two 
particularly well-known cardioprotective strategies based on the endogenous system 
of cardioprotection have been described over the years; ischaemic preconditioning 
(IPC) (see Section 1.5.1) and ischaemic postconditioning (IPost) (see Section 1.5.2). 
IPC of myocardium refers to the cardioprotection elicited from periods of brief 
exposure to ischaemia-reperfusion before the sustained ischaemic event, whereas 
IPost refers to that elicited by brief episodes of ischaemia-reperfusion at the 
immediate onset of reperfusion 9. Recently conducted studies have found that the 
beneficial effects of both IPC and IPost converge on the mitochondria, particularly 
inhibition of the mitochondrial permeability transition pore (mPTP) 17, 230. 
 
     Different research groups have tried to manipulate or confer 
cardioprotection by targeting individual mediators of lethal reperfusion injury. 
Nevertheless there is constant discrepancy in the results generated and transfer to the 
clinical settings has also proved to be problematic 66. There have been directives to 
target more than one mediator at a time, e.g. ischaemic preconditioning and 
postconditioning where components of the RISK pathway and the mPTP are targeted 
61, 67, 229, 231, 232
. A recent ‘proof-of-concept’ study by Argenta et al in 2010 also 
proposed using mechanical tissue resuscitation (MTR) to remove soluble 
inflammatory mediators such as TNF-alpha which may assist in enhancing cellular 
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viability and reduction of tissue oedema 233. However, it may be more practical and 
useful if a sole critical factor is identified and targeted for cardioprotection. This 
statement raises equivocal opinions in which some groups prefer targeting a few 
different factors in a multifaceted cascade. We believe and postulate that 
manipulations of the mitochondrial dynamics and function by genetic interventions 
or drug treatments may serve to prevent IRI. Modulation of mitochondrial 
morphology may serve as a potential mediator of inhibition of the mPTP and thus 
can be regarded as a new target for preventing lethal reperfusion injury.   
 
1.5.1  Ischaemic Preconditioning  
     Ischaemic preconditioning is the term used to describe the intermittent 
episodes of ischaemia and reperfusion before the prolonged period of ischaemia. The 
efficacy of IPC was first shown by the group of Murry in 1986 where they 
significantly reduced the infarct sizes in dog hearts by 75% following 40 minutes of 
coronary artery occlusion, when the occlusion was preceded by four episodes of 5 
minutes ischaemia and 5 minutes of reperfusion 234. In human subjects, the duration 
and number of episodes of ischaemia and reperfusion vary between 3 to 5 minutes. 
Compared to naïve hearts, hearts that have undergone IPC have higher levels of 
Protein Kinase C (PKC) activation due to activation of the adenosine, bradykinin and 
opioid receptors. PKC activation can subsequently lead to downstream beneficial 
effects such as activation of the PI3K kinases, Akt and ERK which are responsible 
for inhibition of the mPTP 235, 236, and opening of the ATP-sensitive KATP channel 
thereby shortening action potential duration and decreasing Ca2+ influx into 
myocytes as well as inhibiting the opening of the mPTP 237, 238. These results suggest 
that the mitochondrion is the converging point of the mechanisms evoked by IPC yet 
the underlying common factor in the mitochondria remains to be elucidated.   
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1.5.2  Ischaemic Postconditioning  
    The group of Zhao et al demonstrated in 2003 that three intermittent 30-
second cycles of myocardial repefusion and ischaemia at the onset of reperfusion 
following 45 minutes of sustained myocardial ischaemia showed an infarct size 
reduction from 47% to 11% in a canine model 67. The term ‘ischaemic 
postconditioning’ was thus coined, emphasizing the myocardial reperfusion phase as 
a target of cardioprotection.  
The use of IPost in the clinical settings has been employed on patients with 
acute myocardial infarction (AMI) who are undergoing primary coronary 
intervention (PCI) and the results show that  myocardial infarct size was reduced by 
36% 68  and endothelial and left ventricular (LV) function were improved 239. In a 
recent study, the group of Thibault demonstrated a reduction in infarct size at 6 
months and preservation of LV function of up to a year following a postconditioning 
protocol of three to six cycles of inflation and deflation of the angioplasty balloon 
within the infarct-related coronary artery 240. The beneficial effects of IPost appear to 
be related to several important mediators of lethal reperfusion injury such as 
activation of the RISK pathway 241,  reduction of oxidative stress 242, decreasing 
intracellular Ca2+ overload 242, improving endothelial function 67, attenuating 
apoptotic cardiomyocyte death, reducing neutrophil accumulation 243, delaying the 
restoration of neutral pH 244, 245 and ultimately inhibition of the mPTP 230, 246. 
Postconditioning has been shown to preserve mitochondrial integrity in terms of 
cristae shapes and mitochondrial membrane structure in isolated rat hearts 247 but 
there has not been documented evidence of the effects of both preconditioning and 
postconditioning on mitochondrial morphology.   
Another alternative to ischaemia postconditioning is remote ischaemic 
postconditioning where the same protocol for postconditioning (intermittent 
ischaemic episodes at the onset of reperfusion) is applied to an organ or tissue but 
not the heart itself (e.g. the arm or leg) 248-251. This alternative, while still being 
subjected to scrutiny in trials involving upper-limb ischaemia in patients with acute 
MI undergoing PCI, is relatively less invasive compared to direct postconditioning 
on the heart by manipulating the angioplasty balloon 231, 252, 253.  
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1.5.3  Targeting the RISK Pathway  
    The RISK pathway comprises of different pro-survival kinases (explained in 
Section 1.6) that are activated via pharmacological manipulations such as glucagon-
like peptide 1 254, erythropoietin 255, atorvastatin256 and atrial natriuretic peptide 257 or 
mechanical interventions 258 during myocardial reperfusion and are crucial mediators 
of cardioprotection in the settings of ischaemia-reperfusion. Studies have shown that 
activation of this RISK pathway can successfully reduce the infarct size by up to 
50% and this reduction has been attributed to inhibition of mPTP opening 259, 
improved uptake of Ca2+ in the sarcoplasmic reticulum 260 and the recruitment of 
anti-apoptotic pathways 228. A recent clinical study has shown that high-dose 
atorvastatin given to patients with a non–ST-elevation myocardial infarction at the 
time of urgent PCI reduces myocardial injury during PCI 261 
 
1.5.4   Targeting the Mitochondrial PTP  
    The mPTP is a pore formed in the inner membrane of the mitochondria. 
Constitutents of the mPTP include CypD and possibly the phosphate carrier 262. The 
implication of mPTP in cardioprotection was initiated based on animal studies where 
pharmacological inhibition of mPTP at the onset of reperfusion by CsA or SfA 
reduces infarct sizes by up to 50% 232, 232. Similar results were also obtained in 
studies involving human atrial trabeculae subjected to sIRI 263. In addition to that, 
smaller infarct sizes were also detected in mice lacking CypD (a component of the 
mPTP) 264.  Inhibition of the mPTP can be categorised into direct or indirect 
inhibition. Studies are ongoing to determine the feasibility and practicality of the 
usage of CsA in inhibition of mPTP in the clinical settings, particularly before PCI 
during an acute MI. Further details are available in Section 1.7.  
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1.6  Pro-Survival Kinases in Cardioprotection 
 
    As mentioned in Section 1.5.3 where kinases play a crucial role in the RISK 
pathway which is core to both IPC and IPost, we attempt to detail the three kinases 
which will be used in this study to confer cardioprotection in the following sections.   
 
 
1.6.1  Protein Kinase A (PKA)  
 
 
Protein Kinase A (PKA), also known as cyclic AMP-dependent protein 
kinase, has been investigated since the 1970s when different groups found that PKA 
phosphorylates troponin, a mediator of contractility in the heart 265 and mediates 
calcium uptake in the sarcoplasmic reticulum 266. Since then studies have placed 
PKA phosphorylation as a crucial mediator of metabolism, contractile activity 267, 
ion fluxes 268 and gene transcription where pathological conditions ensue in the case 
of aberration of PKA signalling 269. PKA is a ubiquitous cellular kinase that 
phosphorylates serine and threonine residues following activation by cAMP 270. 
Structurally, PKA consists of two regulatory subunits, RI and RII, which will release 
two catalytic subunits, Cα and Cβ upon activation by cAMP 271, 272 (see Figure 1.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. Structure of PKA. PKA consists of cAMP binding sites, two     
regulatory subunits (R) and two catalytic subunits (C). 
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The expression levels and subcellular localisation of PKA depend on the 
isoforms of PKA expressed 271. There are four isoforms of the regulatory subunit 
(RIα, RIβ, RIIα, RIIβ) and three types of catalytic subunits (Cα, Cβ, Cγ) 271, 273. PKA 
activates complex I of the respiratory chain in the inner membrane and the matrix of 
the mitochondria 76.  Temperature preconditioning has been found to activate PKA 
prior to PKCε activation as a form of cardioprotection. The activation of PKA in this 
setting by moderate ROS production and β-adrenergic stimulation causes β-
adrenergic desensitisation 274 and attenuation of calpain-mediated degradation 
pathways 275.  Nevertheless, there have also been claims that PKA confers 
cardioprotection independent of PKC signalling, in the form of Rho-kinase inhibition 
which leads to formation of the actin cytoskeleton, chemotactic migration, activation 
of platelet, and cytokinesis 274, 276-279. PKA signalling has also been implicated in 
attenuation of ROS-induced senescence by GLP-1 280 and reduction of calcium 
overloading by opening of the mitochondrial Ca2+-activated K+ channels in cardiac 
myocytes 281 Paradoxically, increased PKA phosphorylation of the ryanodine 
receptor (RyR) has been detected in human heart failure 282. There has been a study 
investigating the role of PKA in protection against cerebral ischaemia by suppression 
of ROS production 283. Suppression of PKA however, has also been detected to 
confer cardioprotection by downregulation of the Ca2+/calmodulin-dependent protein 
kinase II (CaMKII) 284. PKA has also been demonstrated to phosphorylate and 
inhibit Drp1, the fission protein at Ser637 182 (see Figure 1.15).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Sang Bing, Ong 
 78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Mechanisms of action of PKA in the cell. Activation of PKA 
(denoted by red arrows) will lead to effects such as (A) inhibition of mitochondrial 
fission, (B) reduction of calcium overloading by opening of the mitochondrial Ca2+-
activated K+ channels, and (C) expression of growth factors.  
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1.6.2   Protein Kinase B (PKB)  
 
 
The PKB/Akt protein consists of three isoforms; PKBα/Akt1, PKBβ/Akt2 
and PKBγ/Akt3 with all three comprising of a pleckstrin homology (PH) domain at 
its amino-terminal end (amino acids 1-106), which makes up the major part of the 
amino-terminal regulatory domain (residues 1-147), a serine/threonine kinase 
domain from amino acid 148 to 411, and the carboxy-terminal tail region (amino 
acids 412 – 480) accounting for the remainder of the protein  285 (see Figure 1.17).  
 
PKB/Akt is involved in phosphorylation of the mitochondrial ATP synthase 
β subunit and glycogen synthase kinase 3β (Gsk3β), which in turn, inhibits the 
activity of pyruvate dehydrogenase 76. Knockouts of the different types of PKB/Akt 
cause different effects. Akt1 knockout causes retardation of growth 286-288, Akt2 
knockout in mice causes insulin resistance and slight retardation of growth 
depending on the genetic background 286, 289, 290 whereas knockout of Akt3 decreases 
the neural cell size and cell number hence reducing brain size 286, 291, 292.  
 
Research conducted on transgenic mice has proven that the overexpression of 
wild-type Akt1 in the nucleus of cardiac myocytes confers cardioprotection from 
ischaemia-reperfusion 293. The subcellular distribution affects the respective growth 
and cardioprotective effects of Akt as detected from the absence of cardiac growth 
following chronic Akt1 activation 294.  However, overexpression of Akt1 has also 
been found to exhibit adverse effects. In the case of Akt1 overexpression in 
endothelial cells, cells undergo apoptosis right from the embryonic stage due to 
irregular alteration of the vascular tissue up to the adult stage where blood vessel 
formation deviates from normal physiological state to the pathological state 286, 295, 
296
.   
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Figure 1.17: The four isoforms of PKB/Akt. PKB and PKB isoforms derived from 
the same gene but alternatively spliced with different total number of amino acid 
residues. Phosphorylation sites by insulin-induced kinases are shown. PH: pleckstrin 
homology domain. 
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1.6.2.1  Mechanism of action for Akt 
 
 
Insulin or insulin growth factor-1 (IGF-1) interacts with its respective receptor,  
phosphatidylinositol 3-kinase (PI3K) 
 
 
 PI3K phosphorylates membrane inositol lipids 
 
 
The membrane inositol lipids bind to the pleckstrin domain of Akt, inducing its 
translocation to the plasma membrane. 
 
 
Akt becomes the substrate of 3β-phosphoinositide-dependent kinase-1 (PDK-1),  
which activates it through phosphorylation of residue Thr308. 
 
 
Phosphorylation of Akt results in full activation of Akt kinase activity and the 
subsequent regulation of multiple cellular processes, including the transmission of 
growth factor-dependent survival signal 
 
 
Our study places emphasis on PKB/Akt in view of the documented effects of 
Akt on cell survival and protection from apoptosis 258, 285, 293, 297-309. Akt is a member 
of a kinase family in mammalian cells, but Akt homologs can be found in 
Drosophila melanogaster, Caenorhabditis elegans and Dictyostelium discoideum 310. 
Akt is characterised as a serine/threonine kinase which is regulated by growth factors 
and consists of a plekstrin homology domain at the amino terminal end, kinase 
domain as well as the carboxy terminal tail 285. Akt was identified independently in 
1991 by three different groups due to the similarity to both PKA and PKC and as a 
product of the oncogene v-akt of the acutely transforming retrovirus AKT8 in the 
rodent T-cell lymphoma 285, 311-313.  
. 
In general, the activation of the serine-threonine protein kinase Akt in cells 
exposed to different growth factors such as platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), insulin, thrombin and nerve growth factor (NGF) 
involves sequential steps starting from activation of the PI3K by 
autophosphorylation of receptor tyrosine kinases and generation of the second 
messenger PtdIns(3,4,5)P3 from PtdIns(4,5)P2 by the PI3K. Following that, Akt is 
recruited and translocated by PIP3 through the PH domain to the plasma membrane 
Sang Bing, Ong 
 82
followed by its phosphorylation by upstream kinases (PDK1 and PDK2) in a PI3K-
dependent signalling system 285, 310, 314-316 (see Figure 1.18). The PH domain is 
extremely important in the sense that the lipids produced by PIP3 and PI(3,4)P2 need 
to bind to the PH domain of Akt with high affinity and specificity in order to activate 
the Akt and mediates its translocation from the cytosol to the plasma membrane to 
present to the upstream activating kinases 285. Phosphorylation of Akt occurs at two 
sites; Thr308 in the activation loop of the kinase domain and Ser473 in the 
hydrophobic-motif of the carboxy-terminal tail 317 (see Figure 1.18).  
Phosphorylation of the two residues occurs independently and is probably mediated 
by two different kinases, PDK1 for Thr308 and PDK2 for Ser473 317, 318. A study by 
Yang et al in 2002 demonstrated that activation of Akt relies on the phosphorylation 
of Ser473 as it stabilises its active conformation 319. The activity of PDK1 is 
stimulated by PIP3 and PI(3,4)P2, hence suggesting another role for PIP3 and 
PI(3,4)P2, the products of PI3-K besides binding to the PH domain of Akt 285.  
Nevertheless, the exact identity of PDK2 has yet to be elucidated, with speculations 
as to the different cellular and physiological context being the main determinants of 
the exact identity of the PDK2. PDK2 candidates include a myriad of kinases such as 
PKB itself 320, PDK1 321, integrin-linked kinase 1 (ILK1) 322, mitogen activated 
protein kinase activated protein kinase 2 (MAPKAPK2) 317, protein kinase C _II 
(PKC_II) 323, and the members of the atypical PI 3-kinase related protein kinase 
(PIKK) family: DNA-dependent protein kinase (DNA-PK) 324, ataxia telangiectasia 
mutant (ATM) 325 and, more recently, the rapamycin-insensitive mTOR complex 
TORC2 326 (see Figure 1.18). 
 
Upon activation at the plasma membrane, phosphorylated Akt then 
translocates to either the nucleus or cytosol to exert its effects 327. The downstream 
substrates of Akt include GSK3, p70 S6K, GLUT4 and the metabolic regulatory 
enzyme PFK2 285, 328. GSK3 is involved in regulation of several intracellular 
signalling pathways such as the control of certain transcription factors, tumour 
suppressor gene product APC, and wingless developmental pathway in flies and 
dorsoventral patterning in frogs 328. P70 S6K is involved in alteration of the protein 
synthesis pattern following mitogenic stimulation of cells. GLUT4 translocation 
from the intracellular environment to the plasma membrane following insulin uptake 
also relies on the Akt.    
Sang Bing, Ong 
 83
In terms of cardiac myocytes, documented effects of Akt include control of 
metabolism, which is dependent on cytoplasmic phosphorylation, sequestration and 
consequential inhibition of the FOXO 3 transcription factor, which in turn controls 
the expression of multiple atrophy-related genes (“atrogenes”), including the 
ubiquitin ligase atrogin-1 (MAFbx), an enzyme enhancing muscle protein catabolism 
329
, activation of different mitochondrial proteins which are involved in the inhibition 
of apoptosis 69, intracellular acidification, mitochondrial hyperpolarisation, and the 
decline in oxidative phosphorylation that precedes cytochrome c release and 
increases coupling of glucose metabolism to oxidative phosphorylation and regulates 
mPTP opening via the promotion of hexokinase-VDAC interaction at the outer 
mitochondrial membrane 5. 
 
The ability of activated Akt, which is dependent on glucose as an interlink 
between glycolysis and oxidative phosphorylation 330 to prevent apoptosis is 
mediated by its ability to phosphorylate BAD 310, induce the antiapoptotic protein 
members of the Bcl-2 family, inhibit the release of cytochrome c by maintaining the 
mitochondrial integrity, activate the mitoKATP channels, phosphorylate and inactivate 
the caspase family, as well as inactivate the AMP-activated protein kinase (AMPK) 
in the heart 69. 
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Figure 1.18: The PI3K-Akt signalling pathway. Upon stimulation by insulin or 
growth factors, PI3K, a heterodimer of p85 regulatory subunit and p110 catalytic 
subunit is activated, either through Ras molecules or adaptor molecules. The 
activated PI3K will phosphorylate PIP2 to become PIP3 and PI(3,4)P2. These 
phosphoinositides recruit the PDK1 and PKB/Akt to the plasma membrane via the 
N-terminal plekstrin homology (PH) domain. PDK1 subsequently phosphorylates 
and activates Akt at the Thr308 residue on the kinase domain whereas PDK2 
phosphorylates Ser473 on the tail. Activated PKB/Akt translocates to different sites 
in the cell and phosphorylates other downstream substrates, resulting in a variety of 
physiological effects such as protein synthesis, cell cycle and survival (Adapted from 
Downward, 1998; Franke, 1999; Luo et al., 2003; Shiojima & Walsh, 2006).  
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1.6.2.2  Acute vs. Chronic Akt Activation 
 
 
In human models of advanced-stage heart disease, Akt phosphorylation has 
been found to be enhanced 331-333. This implies two possibilities: first is activation of 
Akt alone is not cardioprotective for long term and second is that chronic or long-
term Akt activation may be harmful 334.    
Although Akt is known to be a pro-survival protein, chronic Akt activation 
has been documented to cause several adverse effects. The duration of Akt activation 
influences cardiac hypertrophy in which activating Akt for a short time induces  
normal physiological hypertrophy with a reasonable increase in heart size (~80%) 
while activation for a prolonged period causes ‘pathological’ hypertrophy with an 
extreme increase in heart size (2.7-fold) 335.  
 
As an example, chronic Akt activation decreases the GLUT4 expression in 
insulin-responsive compartments 336. Besides that, through negative feedback 
inhibition of IRS-1/PI3K signalling activity,  chronic Akt activation has also been 
found to inhibit cardiac function recovery as well as increasing cardiac injury in an 
ex vivo model of IRI 334. The negative feedback inhibition relies on proteasome-
dependent degradation of insulin receptor substrate–1 (IRS-1) and inhibition of 
transcription of both IRS-1 and IRS-2 334, 337.  Chronic Akt activation in the heart 
also causes an increase in the level of basal glucose uptake and glycogen deposition 
albeit decreases the sensitivity to insulin 336. The toxicity of Akt is due to the 
variance of expression based on the α-myosin heavy chain promoter 338.  
 
    Akt can be constitutively activated by artificially targeting Akt to the plasma 
membrane by attaching a myristoylated/palmitoylated sequence motif fused to the N-
terminus of Akt.  The Akt gene construct (myr-Akt) has been modified to localise to 
the sarcolemma in order to be constitutively active 338. The phosphorylation and 
activation of Akt can be inhibited by using the PI3K inhibitors such as wortman and 
LY294002.  
 
    Akt/PKB can also be negatively regulated by either the tumor suppressor 
phosphatase and tensin homology deleted on chromosome ten (PTEN) 302 or the 
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SH2-domain-containing inositol polyphosphate 5-phosphatase (SHIP) 339, which 
convert PtdIns(3,4,5)P3 to PtdIns(4,5)P2 and PtdIns(3,4)P2. Protein phosphatase 2A 
(PP2A) and PH domain leucine-rich repeat protein phosphatase (PHLPP) do so 
directly by dephosphorylating Ser473 and/or Thr308 on PKB 340, 341.    
 
1.6.2.3  Reperfusion Injury Salvage Kinase (RISK)  
 
Apoptotic cell death following IRI and the ability of the serine/threonine 
kinase (Akt) and 42- and 44-kDa extracellular signal-regulated kinases (Erk1/2) 
mitogen-activated protein kinase to promote cell survival through activation of 
different antiapoptotic mechanisms triggered off the initial investigation of the role 
of these kinases and cardioprotection 228, 229, 342, 343, leading to the term of RISK 
pathway being coined by Yellon & colleagues 320.This is the reference that first used 
the term RISK pathway -  The term RISK pathway refers to the group of protein 
kinases specifically activated during myocardial reperfusion, such as the PI3K-Akt 
pathway and (Erk1/2) mitogen-activated protein kinase (MAPK) which is 
responsible for conferring cardioprotection and preventing lethal reperfusion injury 
228, 231
. Activation of the RISK pathway can be induced in the presence of growth 
factors and cytokines, insulin, urocortin and other agents such as atorvastatin and 
bradykinin 256, 344, 345.  
  
The cardioprotective function of the RISK components has been 
demonstrated in 2000 by Fujio et al and Miao et al where gene constructs encoding 
for constitutively active Akt transfected in mural or rat hearts protect against IRI 304, 
346
. In the presence of IPC stimulus using the isolated perfused rat heart, the 
protection effects can be traced as far as the reperfusion period where the opening of 
the mPTP is inhibited following phosphorylation of Akt as well as ERK 1 and ERK 
2 (referred to as ERK 1/2) 17, 235, 307. Tong et al in 2000 demonstrated the 
phosphorylation of both Akt and its downstream target, GSK3β by a standard IPC 
stimulus on the same model. The phosphorylation of ERK and its potential signalling 
role is debatable, with some studies showing phosphorylation of ERK by a standard 
IPC stimulus 347 and some studies reporting no changes in phosphorylation status of 
ERK 348. However, the study by Hausenloy et al in 2005 demonstrated that the IPC 
stimulus actually phosphorylates both the Akt and ERK at the time of reperfusion, 
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thereby showing two phases of phosphorylation, one before the index ischaemia and 
one at the onset of reperfusion 235. These findings were verified by the use of the 
PI3K inhibitor, wortmannin, where application of wortmannin at the onset of 
reperfusion completely abrogates the IPC-induced protection 235, 349. IPost, 
comprising six 10-seconds episodes of alternating myocardial ischaemia and 
reperfusion, applied onto the isolated perfused rat heart also showed simultaneous 
activation of the RISK pathway through phosphorylation of Akt and ERK1/2 at 
reperfusion occurring in line with mPTP inhibition 241. Pharmacologically inhibiting 
the phosphorylation of Akt and ERK again blocks the protective effect of IPost 241, 
350, 351
. In a nutshell, irrespective of Akt or ERK, IPC and IPost converge on a 
common signaling pathway – the RISK pathway to mediate cardioprotection at the 
onset of reperfusion 235, 308, 352 (see Figure 1.19). The activation mechanism of the 
RISK pathway by IPC or IPost remains unclear but has received various 
speculations. In the settings of IPC, the biphasic phosphorylation response may serve 
to activate the Akt and ERK before ischaemia so as to potentiate full 
phosphorylation at the onset of reperfusion 258. An alternative hypothesis is IPC 
induces the release or activation of an intermediary factor, such as adenosine, ROS 
or PKC to activate the RISK pathway at reperfusion 258. The activation of the RISK 
pathway by IPost is much more defined by the results of studies by Kin et al., and 
Philipp et al., where G-protein-coupled receptor (GPCR) activation by adenosine 
receptors occupancy as a result of PKC activation from IPost has been proposed to 
activate the RISK pathway 353, 354. Downstream effectors of the upregulation of the 
RISK pathway include inhibition of mitochondrial PTP opening 259, improved uptake 
of Ca2+ in the sarcoplasmic reticulum 260 and the recruitment of antiapoptotic 
pathways 231.  
 
The mPTP is believed to be the central target of the RISK pathway because 
both IPC and IPost have been shown to confer cardioprotection by inhibiting the 
mPTP opening as an endpoint 258. Downstream effects of the RISK pathway itself 
involves closing the mPTP as shown by the phosphorylation of various downstream 
effectors such as the p70S6K 305, activation of endothelial NO synthase (eNOS) to 
inhibit mPTP opening through its release of NO 256, 344, 355, inactivation of Bcl-2-
associated death promoter (BAD) which exerts its apoptotic actions via the opening 
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of the mPTP 305 and activation of GSK3β which has been demonstrated to mediate 
inhibition of mPTP opening 356, 357. These effectors are the main players in inhibiting 
the opening of the mPTP during the onset of reperfusion in response to 
mitochondrial calcium overload, oxidative stress, and ATP depletion 61.  The 
interplay between cardioprotection of IPC and IPost, activation of RISK pathway 
and inhibition of mPTP opening was further proven by pharmacologically inhibiting 
the IPC- or IPost-induced phosphorylation of these kinases, leading to the failure in 
limitation of infarct size 241, 258   
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Figure 1.19: Scheme demonstrating the role of IPC and IPost in conferring 
cardioprotection through activation of the RISK pathway and subsequent 
inhibition of the mPTP opening (Adapted from Hausenloy et al., 2005).  
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1.6.3   Protein Kinase C (PKC)  
 
 
PKC in the mitochondria exist in a variety of different isoforms with different 
function. PKCε confers cardioprotection by phosphorylating the VDAC component 
of the mPTP and hence prevents its opening 10, 76. The combination of both PKCε 
and PKCδ plays a crucial role in regulating mitochondrial KATP channel during the 
ischaemic preconditioning phase 7, 76, 358. PKC has also been found to phosphorylate 
the BH3-only protein Bad which increases the availability of Bcl-2 for antioxidant 
and anti-apoptotic functions 359, 360. The activation of PKCε by PKA during 
temperature preconditioning underlies the cardioprotection elicited through 
mechanisms such as myocardial glycogen breakdown prior to ischaemia which will 
reduce the amount of calcium overloading during ischaemia, reduction of ROS and 
inhibition of mPTP opening 361, 362.  
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1.7   The Mitochondrial Permeability Transition Pore (mPTP) 
 
 
    In the previous sections, we have reviewed the myocardial IRI (Section 1.2), 
the mitochondria as a crucial organelle for cardioprotection (Sections 1.3 & 1.4), the 
cardioprotective interventions that targets the mitochondria (Section 1.5) and the 
survival kinases that play a role in the cardioprotective interventions (Section 1.6). In 
this section, we will be reviewing the discovery, characteristics and components of 
the mPTP in the mitochondria, which is a central mediator of cell death following 
ischaemia-reperfusion and an important target for successful cardioprotective 
interventions.  
 
 
1.7.1   Origins of the mPTP 
 
    The mPTP was first recognised in the 1960s when studies discovered that 
mitochondria swell upon exposure to high levels of calcium and this swelling 
decreases light scattering in the spectrophotometer 363, 364. Using calcium chelators, 
the light scattering effect returned to normal 363, 364. This effect was originally 
attributed to the non-specific permeabilisation of the IMM by the build up of fatty 
acids and lysophospholipids from the activation of Ca2+-sensitive phospholipases 142. 
It was not until the late 1970s that two different groups: Haworth and Hunter 365, 366 
and the group of Crompton 367 identified the opening of a non-specific channel in the 
IMM as the cause of the increase in permeability.  
 
 
 
1.7.2   Characterisation of the mPTP 
 
Intra- or extracellular stress causes cellular malfunctioning which usually 
congregates on mitochondria, triggering an increase in the permeability of the inner 
mitochondrial membrane, a phenomenon known as mitochondrial permeability 
transition 135. This mitochondrial permeability transition is actually caused by the 
opening of permeability transition pore (PTP) in the inner mitochondrial membrane 
with ensuing loss of ionic homeostasis, matrix swelling as well as outer membrane 
rupture 135. The mPTP was traditionally thought to be made up of a complex of inner 
[adenine nucleotide translocase (ANT)] and outer [voltage-dependent anion channel 
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(VDAC) or porin] membrane proteins as well as the ciclosporin A (CsA)-binding 
protein, cyclophilin D (CypD) in the matrix 76, 368 (see Figure 1.20). However, 
following subsequent studies by Baines and colleagues in 2005, Nakagawa and 
colleagues in 2005, found that only the CypD remains as a regulatory component of 
the mPTP, while the mitochondrial permeability transition was still detected in cells 
lacking ANT or VDAC 369-371. Recent studies have also implicated the mitochondrial 
phosphate carrier as a key component of the mPTP 262, 370, 372 (see Figure 1.21). 
Cardiac cell death by apoptosis or necrosis during ischaemia-reperfusion is 
associated with mPTP opening of the mitochondria, of which opening is induced by 
certain conditions in the heart, particularly post-ischaemia and during reperfusion, 
such as the generation of reactive oxygen species (ROS), calcium overload, low 
levels of adenine nucleotides and a normalised intracellular pH (pHi) 31, 373, 374. Once 
opened, external solutes <1500Da enter the mitochondria causing swelling of 
mitochondria, rupture of the mitochondrial outer membrane and the subsequent 
release of pro-apoptotic proteins such as cytochrome c and second mitochondria-
derived activator of caspases/direct IAP-binding protein with a low isoelectric point 
(Smac/DIABLO) in line with depolarisation of the inner membrane potential and 
inhibition of ATP synthesis 10. Failure to inhibit pore opening will therefore causes 
apoptosis and ensuing necrosis if prolonged. 
 
 
 
1.7.2.1  ANT 
 
    The ANT was implicated as a component for the mPTP based on findings that 
ATP and ADP both inhibit mPTP. However, complexes formed with other 
compounds such as Mg, AMP, GDP or GRP failed to inhibit the mPTP 365. The 
notion was further solidified when studies found that inhibition of the binding of 
ATP and ADP to the ANT by depletion of adenine nucleotides or modification of 
thiol groups on the ANT leads to mPTP opening 375. CypD when bound to ANT with 
the ‘c’ conformation under high levels of Ca2+ will undergo a conformational change 
to facilitate pore formation 375-377. The role of ANT as a core component of the 
mPTP remained widely accepted until the group of Kokoszka in 2004 showed that 
genetic ablation of ANT1 and ANT2 did not prevent mPTP activation in mouse liver 
mitochondria 371. Nevertheless, the Ca2+ threshold needed to induce mPTP opening 
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in these mitochondria was increased compared to wild-type mitochondria while 
efficiency of the ANT ligands such as ADP and CAT was decreased 371. The 
availability of the isoform ANT4 however, is probably the factor that determines the 
normal functions of the liver 378, 379. The ANT therefore, will possibly play a 
regulatory role in the opening of the mPTP 380.  
 
 
1.7.2.2 VDAC 
 
     VDAC was originally proposed to be a constituent of the mPTP based on 
the fact that it was found to co-purify with the ANT in a complex under certain 
conditions. Re-constitution of this complex can lead to formation of a calcium-
activated pore that can be inhibited by CsA 381. Nevertheless, it was later 
demonstrated that mitochondria lacking all three isoforms of VDAC can still have 
normal mPTP opening hence eradicating the role of VDAC as an essential 
constituent of the mPTP 369.  
 
 
 
 
1.7.2.3 CypD 
 
     CypD was initially identified as a component of the mPTP based on the fact 
that the opening of the mPTP is inhibited by CsA 382. The mechanism for this 
inhibition lies in the inhibition of a matrix peptidyl-prolyl cis–trans isomerase 
(PPIase) which was subsequently purified and identified as CypD 376, 383, 384. CyPD is 
a matrix protein of about 18 kDa and is encoded by the nuclear gene PPIF 385. CypD 
is different from the cytosolic cyclophilin A (CypA) where a combination of CypA 
and CsA will lead to immunosuppressive reactions and inhibition of calcineurin, a 
calcium-sensitive phosphatase 386. The role of CypD in mPTP was confirmed by 
studies using mitochondria from livers of CypD knockout mice in which calcium-
induced mPTP opening was not significantly detected, in line with studies using 
mitochondria from wild-type mice treated with CsA 264, 387, 388. Nevertheless, it is 
noteworthy to point out that loss of CypD does not signify loss of mPTP opening. 
The loss of CypD only raises the threshold levels of calcium needed for mPTP 
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opening as the main role of CypD is to provide conformational changes to the 
membrane protein through its PPIase activity 388, 389.  
 
1.7.2.4  Mitochondrial phosphate carrier (PiC) 
 
     The studies carried out in the laboratory of Halestrap demonstrated that the 
PiC may be involved as a component of the mPTP 262. According to the study carried 
out, ANT binding to the phenylarsine oxide (PAO) affinity column was prevented by 
carboxyatractylate (CAT). Yet induction of mPTP opening by PAO was not 
prevented by CAT 262. Based on this data, an additional activating site apart from the 
ANT was speculated and the PiC was identified from the component IMM proteins 
isolated from CAT-treated beef heart mitochondria 262. Inhibitors of the mPTP can 
prevent both the binding of the PiC and the activation of the mPTP by PAO in 
isolated mitochondria, in line with the mode of action on PiC 262. PiC binding with 
CypD has also been shown in the same study where co-immunoprecipitation and 
GST-CyP-D pull-down experiments were carried out 262.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20: Original proposed structure of mPTP: a complex of voltage-
dependent anion channel (VDAC) on the outer membrane, adenine nucleotide 
translocase (ANT) on the inner membrane and cyclophilin D (CypD) from the 
matrix.  
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Figure 1.21: Current structure of mPTP. The mPTP complex is currently thought 
to be composed of the CypD component with the phosphate carrier (PiC) bound to it.  
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1.7.3   Triggers of mPTP opening 
 
mPTP opening is induced by calcium overloading in the mitochondria, 
increased ROS, changes in membrane potential, matrix pH, divalent cation 
concentrations, reduced/oxidised thiol balance and reduced pyridine nucleotide 
pools, all of which occurs during myocardial ischaemia and reperfusion 11, 35, 368, 390-
393
 (see Figure 1.22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22: mPTP formation. The current core components of the mPTP consist 
of only Cyclophilin D (purple) with the phosphate carrier (PiC) (red) as a regulator. 
Under normal aerobic conditions, the mitochondrial membrane is impermeable to 
most solutes hence providing an optimum environment for oxidative 
phosphorylation and ATP synthesis. In the presence of external stress such as 
ischaemia-reperfusion with the increase of reactive oxygen species (ROS), 
mitochondrial calcium overload and ATP depletion, the permeability of the 
membrane changes leading to mPTP formation. Mitochondria will depolarise due to 
influx of water and ions from the cytosol and cytochrome c will be released by 
rupture of the outer membrane. 
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During ischaemia-reperfusion, ROS originates from two sources: xanthine 
oxidase and the mitochondrial respiratory chain 394. Xanthine oxidase, an enzyme 
formed from xanthine dehydrogenase by the oxidation of enzyme thiols and Ca2+ 
activated proteases during ischaemia and reperfusion, oxidises xanthine into oxygen 
free radicals. Xanthine itself is produced from adenosine monophosphate (AMP) 
which originates from the ATP hydrolysis during ischaemia 373.  The second source 
is the mitochondrial electron transport chain where ubiquinone, a component of the 
Complex III, is partially reduced to ubisemiquinone during the lack of oxygen in 
ischaemia, which then reacts with oxygen during reperfusion to produce oxygen free 
radicals 373. Oxidative stress produced by chemicals sensitises the mPTP to Ca2+ by 
thiol modification as can be seen in the usage of PAO and diamide where ADP 
binding to the ANT is impaired by the cross-linking of Cys160 to Cys257 on two 
matrix-facing loops of the ANT 395-397. This particular effect will causes the mPTP to 
open even at negative MMP potential as the adenine nucleotides can no longer bind 
to the ANT 398, 399.   
 
The positioning of mitochondria itself near calcium-release sites in the 
endoplasmic reticulum (ER) can promote uptake of calcium released from the ER 73. 
Mitochondrial calcium overload occurs when the mitochondria becomes unable to 
cope with the increasing calcium influx. The calcium concentration in the matrix is 
controlled by a calcium uniporter channel for influx and a Na+/Ca2+ exchanger 
(NCX) for efflux 141. When the calcium concentration in the matrix increases beyond 
a certain threshold, the NCX becomes saturated whereas the uniporter which acts as 
a channel is unaffected 141. Therefore, calcium overload occurs, hence promoting 
mPTP opening by binding to the cyclophilin D component. In the case of ischaemia, 
there is a drop in both ATP and intracellular pH levels, caused by a build-up of lactic 
acid produced from the glycolysis used to synthesis ATP in the absence of oxygen. 
In order to increase the pHi, the cell utilises the sodium-hydrogen exchanger 1 
(NHE-1) to extrude the H+ while pumping in Na+. Due to the lack of ATP levels, the 
Na+ cannot be pumped out by the NCX. Similarly, malfunctioning of the NCX will 
promote loading of Ca2+ which it normally extrudes. Either situation will lead to 
increased Ca2+ in the cytoplasm and subsequent increase in the mitochondria 135.  
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     A low pH particularly during ischaemia will also inhibit the opening of the 
mPTP. This may be due to the presence of high levels of protons that will inhibit 
binding of Ca2+ at its trigger site 366, 400, 401. Conversely, during reperfusion the pH 
levels return to normal and the pore will open as there are fewer protons available to 
compete with Ca2+.  
 
     A hyperpolarised (more negative) mitochondrial membrane potential will 
also inhibit the opening of the mPTP 402, 403. The impairment of the respiratory chain 
by the presence of ROS at the onset of reperfusion will lead to uncoupling of the 
mitochondria, MMP depolarisation and subsequent mPTP opening.  
 
     There are a few explanations for the role of phosphates in triggering the 
mPTP. Enhancement of calcium uptake in the mitochondria is the primary role of 
phosphate in inducing the mPTP 363, 396. In addition to that, there are also other roles 
of phosphate such as the chelation of free Mg2+ cations which are responsible for the 
inhibition of mPTP and prevention of matrix acidification 402, 404. The phosphate 
carrier (PiC) also serves as an additional binding site for PAO in the activation of the 
mPTP 262.  
 
     Free adenine nucleotides have been known to inhibit the mPTP by inducing 
the ‘m’ conformation of the ANT 405. Bongkrekic acid (BKA) desensitises the mPTP 
to Ca2+ while CAT sensitises the pore to Ca2+ 365, 405. The mode of action of both of 
these chemicals converges on the ANT. The sensitivity of the mPTP is reduced in 
the presence of both ATP and ADP but not by the complexes of ATP with cations 
such as Mg2+ or by other nucleotides that are not transported by the ANT such as 
AMP, GDP or GTP 365, 376, 405 
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1.7.4   Types of pore opening 
 
Membrane pore opening can be divided into inner membrane pore opening 
and outer membrane pore opening. Inner membrane pore opening can cause 
membrane depolarisation, release of low molecular weight compounds, cristae 
reorganisation and swelling of the mitochondrial matrix. A number of factors can 
cause iMPT, including increasing intracellular calcium concentration, reactive 
oxygen species, and the process of ischaemia-reperfusion 11. In the absence of inner 
membrane cristae remodelling, outer membrane pore opening is responsible for the 
partial release of apoptotic proteins while the presence of cristae remodelling will 
allow the complete release of apoptotic proteins 11.   
 
The function of the mitochondrial pore complex is based on two operating 
modes; a high conductance mode and a low conductance mode. The high 
conductance mode renders permeability to solutes with the MW of less than 1500 Da 
which then causes iMPT leading to loss of membrane potential that will inhibit 
mitochondrial fusion, release of Ca2+ and interruption of oxidative phosphorylation. 
The low conductance mode allows solutes with MW of less than 343 Da responsible 
for signal transduction to enter the mitochondria 11.   
 
The number of mitochondria involved in iMPT dictates the different cellular 
response pathways occurring. In the case of few mitochondria with iMPT, the 
organelles become encapsulated in autophagosomes for subsequent lysosomal 
digestion which removes the damaged and probably lethal mitochondria. If MPT 
becomes more prevalent and ATP depletion occurs, then the glycine-sensitive 
organic anion channel will be opened leading to the initiation of a metastable state 
with subsequent rupture of the plasma membrane and necrosis 11. 
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1.8 Summary and Main Objectives of the Thesis 
 
We hypothesise that one potential way to keep the mPTP closed is to 
promote mitochondrial fusion. Mammalian mitochondria exist in a typical network 
of branched reticular tubules originating from the nucleus 146, 406. Nonetheless, 
mitochondrial shape is not constant, with interchanges between the fused state and 
the fragmented state 87, 91. Different proteins (e.g. Mfn1, Mfn2, Drp1 and hFis1) 
which govern the morphology of the mitochondria have been subsequently identified 
in the yeast and the mammalian system 151, 158, 176, 407.  
 
The myriad of functions performed by the mitochondria is complemented by 
its dynamics, which appear to be linked to cellular development, cell cycle and death 
77, 84, 99, 114, 128, 149, 150, 297, 368, 408, 408, 409
. Recent studies conducted have seen an 
advance in the understanding of the molecular basis of mitochondrial dynamics 
where the morphology, allocation and activity of mitochondria are regulated by the 
fusion and fission cycles 106, 126, 196, 215, 410-415. The balance between fusion and fission 
is vital for several important cellular processes and the changes in the shape rely on 
the extracellular signals received and intracellular requirements, the particular cell 
type and organism 87, 159, 416.  
 
On the basis that changes in mitochondrial morphology appear to impact on 
many factors known to be relevant to the cellular response to ischaemia-reperfusion 
injury; we were keen to examine this phenomenon in the context of cardioprotection. 
It has been demonstrated that mitochondrial fragmentation precedes cellular 
apoptosis and fragmentation is caused by an increase in oxidative stress from 
reactive oxygen species (ROS) with the endpoint to this fragmentation being the 
opening of the mPTP 409, 417. Therefore, we hypothesised that promoting 
mitochondrial fusion or inhibiting mitochondrial fragmentation in the HL-1 cardiac 
cell line, endothelial cells and adult cardiomyocytes protects against simulated 
ischaemia-reperfusion injury by inhibiting mPTP opening. In addition, we also 
proposed that the application of drugs modulating mitochondrial morphology in vitro 
such as the mitochondrial division inhibitor-1 (mdivi-1) and the cAMP-dependent 
protein kinase (PKA) activator, Sp-5,6-dichloro-1-f-D-ribofuranosylbenzimidazole-
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3',5' monophosphorothioate (Sp-5,6-DCl-cBiMPS) may actually enhance myocardial 
protection in the face of ischaemia-reperfusion injury by inhibiting the opening of 
the mPTP. Mdivi-1 was chosen because it was shown by Cassidy-Stone and 
colleagues in 2008 to be a specific small molecule inhibitor of Drp1 in various 
different cell types 418. Similarly, PKA activation was used in our study due to the 
findings of Chang and Blackstone in 2007 where they found that PKA can 
phosphorylate the fission protein, Drp1 at Ser637 and inhibit its mitochondrial 
fragmentation capability by inhibiting its GTPase activity 182. cBiMPS was chosen 
because it has been tested to be a potent and specific PKA activator 419. We are also 
interested to determine whether erythropoietin (EPO), a known cardioprotective 
agent can actually protect cardiomyocytes by promoting mitochondrial fusion and 
inhibiting mPTP opening. It has been shown that EPO protects the heart by 
activating the PI3K pathway and subsequently protein kinase B (Akt) which inhibits 
the mPTP opening 420-422. However, we were keen to investigate whether EPO can 
actually promote mitochondrial fusion through the activation of Akt and hence 
inhibit the mPTP opening.  
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Chapter Two: HYPOTHESES 
 
2.1     HYPOTHESIS ONE 
 
Modulating mitochondrial morphology protects cardiac cells against ischaemia-
reperfusion injury by inhibiting mPTP opening. 
 
 
This first major hypothesis was divided into 3 parts: 
 
2.1.1   Mitochondrial morphology in cardiac cells can be manipulated using either  
     genetic or pharmacological manipulations 
 
2.1.2   Modulating mitochondrial morphology by genetic or pharmacological    
     manipulations protects the cardiac cells against ischaemia-reperfusion     
     injury 
 
2.1.3   Modulating mitochondrial morphology by genetic or pharmacological    
     manipulations inhibits  the opening of the mPTP in cardiac cells 
 
In the introduction, the unique role of mitochondrial morphology in pathological 
conditions was described. We hypothesised that modulation of mitochondrial 
morphology by increasing fusion may protect heart cells against ischaemia 
reperfusion by inhibition of mPTP opening. The first objective of the study (2.1.1) 
was to demonstrate that mitochondrial fusion can be promoted via genetic or 
pharmacological means. The next objective (2.1.2) was to determine whether 
increasing the presence of elongated mitochodnria in cardiac cells protect aginst IR. 
We also attempted to inhibit mPTP opening in cardiac cells by promoting 
mitochondrial fusion in the last objective of hypothesis one (2.1.3) 
 
 
 
 
Sang Bing, Ong 
 103
2.2     HYPOTHESIS TWO 
 
The known cardioprotective effect of kinases such as Protein Kinase A and B is 
mediated via mitochondrial morphology 
 
Pro-survival kinases inhibits mPTP opening in cardiac cells via modulating 
mitochondrial fusion 
  
In the introduction, the cardioprotective roles of the kinases were described. We 
attempted to investigate whether these kinases may modulate mitochondrial 
morphology and hence confer cardioprotection via inhibition of mPTP opening.   
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3.1  List of chemicals 
3.1.1   Pre-coating flasks for HL-1 cell culture 
 
 
 
Name             Fibronectin, 0.1% solution from    
                         bovine plasma 
Company         Sigma® 
Catalogue No. F1141-5mg 
 
 
 
 
Name               Gelatin from bovine skin, Type B  
Company         Sigma® 
Catalogue No. G9391-100g 
 
 
 
 
 
 
3.1.2   Components for HL-1 cell culture 
 
 
 
Name               Claycomb w/o Glutamine 
Company         SAFC BiosciencesTM                                                 
Catalogue No. 51800C 
 
 
 
 
Name               Foetal Bovine Serum 
Company         SAFC Biosciences™ 
Catalogue No. 12103C-500ml 
 
 
 
 
 
Name               L-Glutamine 
Company         Sigma® 
Catalogue No. G7513 
[Stock]            200 mM 
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Name               Norepinephrine 
Company         Sigma® 
Catalogue No. A0937-1g    
 
 
 
 
 
Name           Penicillin-streptomycin 
                   (5000 U penicillin with 5 mg  
                        streptomycin/ml) 
Company        Sigma®  
Catalogue No. P4458-100ml 
 
 
 
 
3.1.3   Components for endothelial cell culture 
 
 
Name              Endothelial Basal Medium without L- 
                        glutamine 
Company         PAA Laboratories GmbH 
Catalogue No. U15-011 
 
 
 
 
Name              Endothelial Medium without L- 
                        glutamine 
Company         PAA Laboratories GmbH 
Catalogue No. U15-002 
 
 
 
 
 
3.1.4   Components adult cardiomyocytes culture 
 
 
Name              Earle’s Medium 199 (1x) without L-    
                        glutamine – 500 ml 
Company         PAA Laboratories GmbH 
Catalogue No. E15-033 
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Name               Albumin fraction V – 100 g 
Company         Merck 
Catalogue No. 1.12018.0100 
 
 
 
 
 
Name               Creatine hydrate min 99% - 100 g  
Company         Sigma 
Catalogue No  C-3630 
 
 
 
 
 
Name               Taurine – 1 kg  
Company         Sigma 
Catalogue No. T8691 
 
 
 
 
 
Name               (±) – Carnitine – hydrochloride  
Company         Sigma 
Catalogue No.  C9500 – 25 g  
 
 
 
 
 
Name            Penicillin-streptomycin 
                    (5000 U penicillin with 5 mg     
                        streptomycin/ml) 
Company         Sigma®  
Catalogue No. P4458-100ml 
 
 
 
 
3.1.5   Chemicals for experimental use 
 
 
Name               (+)-Sodium L-ascorbate (Ascorbic  
                        acid) 
Company         Sigma® 
Catalogue No. A7631 – 25g 
Purpose: Component of norepinephrine 
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Name               Dimethyl sulfoxide (DMSO) 
Company         Sigma® 
Catalogue No. D8418 – 50 ml 
Purpose: Solvent and component for cell culture  
 
 
 
 
 
 
Name               25% Trypsin – EDTA 1× 
Company         Gibco 
Catalogue No. 25200 
Purpose: For cell passaging (HL-1 and endothelial) 
 
 
 
 
 
Name               FuGENE® 6 Transfection Reagent 
Company         Roche 
Catalogue No. 11814443001-1 ml 
Purpose: For transfection (HL-1 and endothelials) 
 
 
 
 
Name               MEM 1x (+Earle’s, + L-Glutamine)  
Company         Gibco 
Catalogue No. 31095-500ml 
Purpose: Serum starvation for endothelials 
 
 
 
 
Name            Propidium iodide (minimum 95%  
                        HPLC) 
Company        Sigma® 
Catalogue No. P4170-100mg 
Purpose: Cell death marker 
 
 
 
Name           Ciclosporin A Tolypocladium inflatum 
Company       Calbiochem® 
Catalogue No. 239835-100mg 
[Stock]         0.2 M 
[Working]      0.2 µM 
Purpose: Positive control for mPTP inhibition  
 
Name Tetramethylrhodamine methyl ester 
perchlorate, minimum 98% (TMRM) 
Company        Sigma-Aldrich®  
Catalogue No. T5428 – 25 mg 
Purpose: ROS source for mPTP assay 
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3.1.6   Drugs for modulating mitochondrial morphology 
 
 
 
Name mdivi-1 
Company         Key Organics Ltd. UK 
Catalogue No.  
 
Function: Inhibitor of Drp1 
 
 
 
Name Sp-5,6-Dichloro-cBIMPS 
Company Biomol International  
Catalogue No.  BML-CN120-0001 
 
Function: Inhibitor of Drp1 
 
 
 
 
Name Erythropoietin beta (EPO) 
Company Roche   
Catalogue No.   
 
Function: Red blood cell producer 
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3.2    Molecular formulas and structures of drugs and indicator  
      dyes used 
 
 
Ciclosporin A 
 
Molecular Formula: C62H111N11O12  
Molecular Weight: 1202.6  
Molecular structure: 
 
* Molecular structure obtained from the website of Merck Chemicals UK 423.  
 
 
Propidium iodide (PI) 
 
 
Molecular Formula:  C27H34I2N4  
Molecular Weight:  668.40 
Molecular structure: 
 
 
 
* Molecular structure obtained from the website of Sigma-Aldrich UK 424. 
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Tetramethylrhodamine methyl ester (TMRM) 
 
Molecular Formula:  C25H25ClN2O7  
Molecular Weight:  500.93 
Molecular structure:  
 
 
* Molecular structure obtained from the website of Sigma-Aldrich UK 425 
 
 
Sp-5,6-Dichloro-cBIMPS 
 
Molecular Formula: C12H10N2O2SCl2 . Na 
Molecular Weight:  419.2 
Molecular structure: 
 
 
 
 
*Molecular structure obtained from the website of Enzo Life Sciences UK 426   
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mdivi-1 
 
Molecular Formula: C15H10Cl2N2O2S 
Molecular Weight: 353.2  
Molecular structure: 
 
 
 
 
 
* Molecular structure obtained from the website of Sigma-Aldrich UK 427 
 
 
 
Erythropoietin (EPO) 
 
Molecular Formula: C134H226N38O41  
Molecular Weight: 3025.49 
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Vector:  
 
RcCMV 
 
 
 
* There is an ATG upstream of the XbaI site. The vector map was obtained from the 
website of Invitrogen 428.  
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3.3     Cell Culture 
 
3.3.1     HL-1 cardiac cell line 
 
Cardiovascular studies carried out in most laboratories utilise isolated 
embryonic as well as neonatal rat primary cardiomyocytes as the standard cellular 
models. However, the use of these cells is limited because of the lack of many 
typical adult cardiomyocytes characteristics such as the expression of certain genes 
and receptors, presence of sarcomeres for contraction as well as the ability of 
depolarisation and generation of action potentials 429. Additionally, overgrowth of 
nonmyocytes in culture, termination of cell division after the neonatal stage and 
difficulty in genetic manipulation further increases the challenges of using these cells 
429-431
.  
 
At present, HL-1 is the only cardiac cell line available that is able to divide 
continuously in culture and contract while maintaining a differentiated cardiac 
phenotype 429. HL-1 cells are derived from the AT-1 mouse atrial cardiomyocytes 
tumour lineage which was originally muscle cells from the atria of transgenic mice 
which exhibits unilateral right atrial tumorigenesis by having the atrial natriuretic 
factor (ANF) promoter to control the expression of the SV40 large T antigen 432, 433. 
Useful characteristics of HL-1 cells include the ability to be passaged indefinitely in 
culture while retaining a differentiated cardiomyocyte phenotype as well as the 
ability to be thawed and recovered from frozen stock 432. The morphology of HL-1 is 
irregular with most of them containing a nucleus surrounded by contracting 
myofibrils 432.   
 
Furthermore, the structural characteristics of HL-1 such as cytoplasmic 
organisation and myofibrillogenesis (myofibril formation) have been found to be 
similar to that of the mitotic cardiomycytes of the developing heart, whereas 
ultrastructural studies reveal them to be similar to primary cultures of adult atrial 
cardiac myocytes and AT-1 cells 432-434.  This explains why HL-1 in general 
represent a hybrid between an embryonic and an adult myocyte. Ongoing cellular 
division underlies the reason why they are less differentiated and less organised 
compared to the adult myocyte while the existence of atrial granules do not classify 
them as a mitotic embryonic myocyte 432.  
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In order to ensure that HL-1 cells maintain the contractile cardiac phenotype 
during the passages, a fibronectin: 0.02% gelatin substrate (1:200) and a specially 
formulated growth medium – Claycomb medium (SAFC Biosciences), are needed 
429, 432
. The medium should be changed approximately every 24 hours. HL-1 cells are 
grown at 37°C in an atmosphere with 5% CO2 and 95% oxygen at a relative 
humidity of approximately 95%. Upon reaching adequate confluency, which is 
judged from the proportion of cells reaching contractile state, the cells can be split 1 
to 3 and this can be designated a passage 432. The confluency and frequency of 
passaging should be taken into account when performing the experiments. In order to 
maintain reproducibility, the same density of HL-1 cells cultured for every 
experiment has to be achieved 429.  
 
HL-1 cells can be serially passaged in culture indefinitely. However, the 
natural phenotype and characteristics have to be examined with caution. Under 
selective culture conditions, HL-1 cells are able to maintain contractility through at 
least 240 passages 432.   
 
3.3.1.1   Thawing frozen stocks of HL-1 
 
Frozen glycerol stocks of HL-1 were thawed in a water bath at 37°C and the 
contents transferred to a sterile 15-ml Falcon tube using a sterile Pasteur pipette 
(VWR International). 5 ml of Claycomb medium (SAFC Biosciences) was slowly 
added to equilibrate the DMSO (Sigma) from the cells. The tube containing the cells 
was then centrifuged at 1000 rpm for 3 minutes and the supernatant was discarded 
directly. The remaining pellet was dispersed and 7 ml of Claycomb medium was 
added in slowly. The cell suspension was then pipetted out slowly into a fibronectin 
pre-coated culture flask. 
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3.3.1.2   Culturing and passaging of HL-1 
 
    Once the HL-1 cells reach confluency, clusters of cells will start ‘beating’ in 
culture. The presence of huge ‘beating’ clusters signifies adequate confluency to 
perform cell passaging. New culture flasks or plates were coated with fibronectin 
two to three hours prior to passaging,. The flask with confluent cells was washed and 
coated with 2 ml pre-warmed Trypsin-EDTA (PAA Laboratories) and returned to the 
37°C incubator for 10 minutes. After 10 minutes, the flask was then ‘tapped’ at the 
side to dislodge the cells. Pre-warmed Claycomb medium (8 ml) was then added and 
the solution transferred to a sterile 15-ml Falcon tube. Fifteen microlitres of this cell 
suspension was then used for cell-number determination on a haemacytometer and 
the required volume pipetted into the flasks and plates.  
 
 
 
3.3.1.3    Preparation of frozen stocks of HL-1  
 
   To prepare frozen stocks of HL-1 cells, the remaining cell suspension in the 15-
ml Falcon tube was centrifuged at 1000 rpm for 3 minutes. The supernatant was 
discarded and the flask was tapped to dislodge the pellet. A pre-mixed concoction of 
1.8 ml FBS and 200 µl DMSO was then slowly added to the tube and the solution 
pipetted out using a sterile Pasteur pipette into sterile tubes for storage at -80°C. 
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3.3.2   Rat coronary endothelial cells 
 
     Rat coronary endothelial cells were isolated by Dr. Sean Davidson, Senior 
Research Fellow in our laboratory. Cell culture dishes were coated with 50 µl 
laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane (Sigma 
UK) in the centre and left to dry. The isolation rig was also warmed up with 
circulating water at 37°C.  
 
 
 
 
Figure 3.1: Isolation rig for endothelial cells and murine cardiomyocytes. 
 
 
The specific chambers on an isolation rig (see Figure 3.1) were filled up with 
calcium-free perfusion buffer (PB1) containing (in mM): NaHCO3 25.0, NaCl 116.0, 
KCl 5.4, MgSO4.7H2O 0.4, KH2PO4 1.2, glucose 10.0, taurine 20.0, Na pyruvate 5.0 
and digestion buffer, which is CaCl2 (44.0 µM) and collagenase (1 mg/ml) dissolved 
in 50 ml of PB1, respectively and oxygenated. Tubings were pre-filled with PB1 and 
the bubble-trap was also filled half-full with PB1. The flow rate of the isolation rig 
Digestion 
buffer 
PB1 
Attachment 
site for 
cannulae 
Perfusate 
collection 
chamber 
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was set at 3 ml/min. the heart of the mouse was excised and placed in cold PB1 in a 
weighing boat and immediately perfused with PB1 for 4 minutes and subsequently 
changed to digestion buffer until the 14th minute. At the 13th minute, a weighing boat 
was placed under the heart to collect the drops of digestion buffer. The heart was 
removed from the rig at the 14th minute and the tissue was gently teased apart with 
forceps in the weighing boat containing the drops of digestion buffer. The tissue 
suspension was then placed in a 50 ml tube and transferred to a 37°C shaking 
incubator at 177 rpm with flow of 100% oxygen for 10 minutes. The solution was 
discarded leaving tissue in the tube. Before discarding, the solution should be 
checked under the microscope where there should be mainly red cells and debris, but 
also some live myocytes. Fresh digestion buffer (15 ml) was added to the tissue and 
transferred to a 37°C shaking incubator at 177 rpm with flow of 100% oxygen for 20 
minutes. After allowing the cell debris to settle, the supernatant is re-centrifuged at 
1000 rpm for 5 minutes. The resulting pellet was then resuspended endothelial 
growth medium (Lonza).  Cells were stained with LDL-Alexa488 to confirm their 
identity as endothelial cells (the endothelial cells take up the labelled LDL thus 
emitting fluorescence).  
 
 
 
3.3.3  Adult Mouse Cardiomyocytes 
 
     Isolation of adult mouse cardiomyocytes was performed with the assistance 
of Dr. Shiang Yong Lim (Postdoctoral Research Fellow from our laboratory). Cell 
culture dishes were coated with 50 µl laminin from Engelbreth-Holm-Swarm murine 
sarcoma basement membrane (Sigma UK) in the centre of the coverslips and left to 
dry. The isolation rig was also warmed up with circulating water at 37°C. The 
chambers were filled with calcium-free perfusion buffer (PB1) containing (in mM): 
NaCl 113.0, KCl 4.7, KH2PO4 0.6, Na2HPO4, MgSO4.7H2O 1.2, NaHCO3 12.0, 
KHCO3 10.0, Taurine 30.0, HEPES 10.0, glucose 11.0, and 2,3-butanedione 
monoxime (BDM) 10.0 and digestion buffer, which is CaCl2 (12.5 µM), collagenase 
(0.045 g) and hyaluronidase (6.25 mg) dissolved in 50 ml of PB1, respectively and 
oxygenated. Tubings were pre-filled with PB1 and the bubble-trap was also filled 
half-full with PB1. The flow rate of the isolation rig was set at 3 ml/min. the heart 
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was excised from the anaesthetised mouse and placed in cold PB1 in a weighing boat 
and immediately perfused with PB1 for 4 minutes and subsequently changed to 
digestion buffer until the 14th minute. At the 13th minute, a weighing boat was placed 
under the heart to collect the drops of digestion buffer. The heart was cut off from 
the rig at the 14th minute and the tissue was gently teased apart with forceps in the 
weighing boat containing the drops of digestion buffer. The tissue suspension was 
then placed in a 50 ml tube and transferred to a 37°C shaking incubator at 177 rpm 
with flow of 100% oxygen for 5 minutes. Following that, the tissue suspension was 
resuspended using a Pasteur pipette and a small drop was placed on a glass slip to 
check for the presence of cells (see Figure 3.2) 
 
 
 
 
Figure 3.2: Cardiomyocytes under a fluorescent microscope. 
 
 The supernatant was collected in a separate 15-ml tube and 250 µl cold FCS was 
added to it. The tube was inverted gently a couple of times. Fresh digestion buffer (5 
ml) was added into the remaining pellet in the 50-ml tube and shaken in the 
incubator for another 10 minutes. Resuspension was performed and the presence of 
cells determined again. The resulting supernatant was transferred to the previous 15-
Live cardiomyocyte 
Dead cardiomyocyte 
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ml tube and the tube was centrifuged at 600 rpm for 3 minutes. Using a Pasteur 
pipette, the supernatant was discarded and 10 ml of low calcium perfusion buffer 
(PB2) containing CaCl2 (12.5 µM) was added to resuspend the cells. Calcium was 
re-introduced in a step-wise manner with the tube horizontal at all times; starting at 
10 µl of 0.1 M calcium chloride for 4 minutes, 10 µl of 0.1 M calcium chloride for 4 
minutes, 20 µl of 0.1 M calcium chloride for 4 minutes, and two addition of 30 µl of 
0.1 M calcium chloride for 4 minutes respectively. The solution was then centrifuged 
at 600 rpm for 3 minutes. The supernatant was discarded using Pasteur pipette and 2 
ml of cardiomyocytes growth medium (M199 buffer: BSA 2 mg/ml, creatine 5 mM, 
taurine 5 mM, carnitine hydrochloride 1.6 mM, Pencillin-Streptomycin 1%) with 25 
µM blebbistatin was added into the tube. The tube was tapped vigorously until pellet 
is dissolved. The cell suspension was pipetted onto the laminin-coated dishes and 
sent into the 37°C incubator for 1 hour. After 1 hour, the dish was washed gently 
with 1 ml culture medium without blebbistatin and 1 ml of fresh M199 with 25 µM 
blebbistatin was added into each well. 
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3.4 Animals 
 
C57BL/6 adult male mice (9 – 12 weeks old) were used in this study. All animals 
were obtained from Charles River UK Limited, (Margate, UK) and received humane 
care in accordance with the Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986 (The Stationery Office, London, UK). Animals were allowed 
to acclimatise or a minimum of 4-5 days prior to use. They were kept in cages of 
four and had free access to fresh water and standard pellet chow (RM1) diet and 
were subjected to a 12 hour light-dark cycle, and maintained at 19°C-22°C, and 55+-
10% humidity. 
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3.5 Nonviral Gene Transfers 
 
 
Viral vectors have been used to generate stable cell lines for expression of 
various proteins 435-438. Nevertheless, generation of viral vectors are time consuming 
and require appropriate expertise, besides the fact that the vector itself can be 
cytotoxic, immunogenic as in the case of adenovirus and can only carry a limited 
size of insert gene as in the case of adeno-associated virus. Use of retroviruses too, 
can cause random integration into the host genome, risks of inducing tumorigenic 
mutations and generating active viral particles through the process of recombination 
439
.  
 
The use of nonviral vectors has gained immense popularity because there are 
not many safety issues concerned based on the fact that the non-viral vectors are 
non-replicative, and have low immunogenicity. Besides that, the ease of production 
as well as ability for repeated administration further justify the increasing tendency 
to use nonviral vectors 440  
 
There are many types of cationic lipid-based nonviral vectors available in the 
market. These may consist of liposomal or nonliposomal vectors which are different 
in terms of size and zeta potential, in vitro transfection activity, resistance to the 
presence of serum, effect of lipid/DNA charge (+/-) or volume/weight (v/w) ratio, 
protective effect against nuclease degradation and stability under different storage 
conditions, incubation time, and degree of cell confluency needed before transfection 
441
.  
 
To ensure efficiency and efficacy of transfection, the entire pathway of 
binding of the transfection reagent/DNA-complexes to the cell surface, entry into the 
cells, dissociation of the complexes, and finally, their transport through the cytosol 
and the uptake of the DNA into the nucleus, plays an  indispensable role 442.  
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3.5.1     Lipofection 
 
 
Different types of lipofection reagents have different methods to deliver the 
DNA into the cytoplasm of the cell. These lipofection reagents are user-friendly, 
non-immunogenic and can accommodate gene constructs of various sizes 443.  
 
One of the methods of lipofection involves a mixture of the cationic lipids 
with the plasmid DNA. The lipid-DNA complex will fuse with the plasma 
membrane of the cell and enter the cell via endocytosis to promote the uptake of 
plasmid DNA by the target cell. The term ‘cationic liposome’ derives from the 
structure of the anionic DNA coated by the cationic layer of lipid micelles 441, 
producing a residual net positive charge which can interact easily with the negatively 
charged plasma membrane of the target cell. Fusion of this complex with the cell 
will enable uptake of DNA into the cell nucleus where it will remain as an 
extrachromosomal DNA with transient expression for approximately 7-10 days.  
This process of gene delivery is influenced by the size of the gene construct, the 
condition of the cells and the stability of the DNA. 
 
The ideal vector should be small in size to facilitate larger gene construct 
while maintaining the integrity of the DNA, promote specific targeting to cells and 
achieve optimum gene expression levels without triggering immune responses from 
the host cell as well as reproducible in large scale processes 439.  
 
 
3.5.1.1   Fugene 6 Transfection Reagent 
 
 
FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals) is a lipid-
based transfection reagent made up of different components that complex with and 
transport DNA into the cell during transfection 444.  
 
The advantages of using FuGENE 6 include very high transfection efficiency 
in many common cell types, the absence of cytotoxic
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both the presence and absence of serum as well as minimal optimisation requirement 
444
. 
 
Due to the fact that FuGENE 6 is non-toxic and able to transfect cells even in 
the presence of serum, the transfection complex can be added into cell culture 
containing serum without the washing step.  
 
For experiments using 35 mm culture dish with a monolayer of cells reaching 
a confluency of 50-80%, transfection can be performed using a ratio of FuGENE 6 
(µl): DNA (µg) of 3:2, 3:1, and 6:1 445. Initially, the Fugene 6 is mixed together with 
the DNA or plasmid to be transfected (an empty plasmid expression vector 
(RcCMV); one expressing mitofusin 1 (pCB6-MYC-Mfn1); one expressing 
mitofusin 2 (pCB6-MYC-Mfn2); one containing Drp1K38A (pcDNA3.1-HA-K38A-
DRP1), the dominant negative mutant form of the mitochondrial fission protein 
Drp1; and one containing hFis1) in serum free medium. The cells to be transfected 
have to be plated one day before the transfection experiment. The growth rate and 
condition of the cells determine the suitable plating density. A crucial point is that 
the cells have to reach a confluency of around 50-80% on the day of the transfection 
445
.  
 
  For the simulated ischaemia-reperfusion injury and mPTP experiments, a 1:2 
ratio of pEGFP expression plasmid (Clontech): plasmid of interest was included in 
order to identify those cells which had been successfully transfected. After 
transfection for 24 hours, the buffer was replaced with fresh culture medium and the 
cells were left in an incubator overnight. 
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3.5.2    Plasmids midiprep 
 
3.5.2.1  Transformation of bacteria with plasmid 
 
Eppendorf tubes (1.5ml) were prepared and left on ice, including one for the 
positive control (known plasmid) and one for the negative control (no DNA). The 
competent cells (HB101, Promega or JM109, Promega) were thawed on ice, flicked 
gently to mix and then pipetted 50 µl into each tube. 50 ng of plasmid DNA was then 
added into each tube and left on ice for 10 minutes. The competent cells were then 
heat-shocked into taking up the plasmids by placing the tubes in a 42°C water bath 
for 45 seconds without shaking. The tubes were then returned to ice for 2 minutes. 
900 µl of sterile Luria-Bertani (LB) broth (10g tryptone, 5g yeast extract, 10g NaCl, 
pH 7.5) was then added into each tube and incubated for 60 minutes in the shaking 
incubator at 37°C. A hundred microlitres of this mixture was then plated onto LB-
agar (15 g agar in 1L LB broth) plates with the appropriate antibiotics and incubated 
at 37°C overnight.   
 
 
3.5.2 .2   Growth of transfected bacteria 
 
A single colony was transferred from the LB-agar plate onto sterile 15 ml 
Falcon tubes containing 4 ml of LB + antibiotics (4 µl of 50 mg/ml ampicillin or 4 µl 
of 40 mg/ml kanamycin). The tube was then incubated in shaking 37°C incubator for 
approximately 8 hours before transferring the solution into a conical flask containing 
70 ml LB + antibiotics (4 µl of 50 mg/ml ampicillin or 4 µl of 40 mg/ml kanamycin) 
for overnight culture in shaking 37°C incubator to achieve maximum growth density.  
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3.5.2.3  Preparing cell lysate 
 
Midiprep for purification of high-quality plasmid DNA from the transfected 
bacteria was performed according to manufacturer’s instructions using the 
PureLinkTM HiPure Plasmid DNA Midiprep Kit (Invitrogen) (see Figure 3.3).  
 
 
 
 
Figure 3.3: The components in the PureLinkTM HiPure Plasmid DNA Midiprep 
Kit from Invitrogen.  
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3.5.2.4 Measuring the DNA concentration 
 
The Jenway 6405 UV/Vis spectrophotometer was blanked using 500 µl 
sterile distilled water. To measure the concentration of the DNA, 1 µl of DNA was 
mixed with 500 µl of distilled water and measured in the cuvette.  
 
 
 
 
3.5.3    Plasmids Transfection 
 
 
Upon reaching 50-80% confluency, the cells were transfected with plasmids 
according to a standardised protocol (see Figure 3.4). A variety of gene constructs 
encoding for different proteins validated through DNA sequencing were used 
throughout this study: caAkt, Mfn1, Mfn2, Drp1K38A and hFis1. These gene 
constructs were inserted into the CMV backbone vector provided by Dr. Luca 
Scorrano, Venetian Institute of Molecular Medicine, Italy. Sterile Eppendorf tubes 
were prepared based on the number of plasmid types used. 1 µg of plasmid encoding 
the fluorescent protein (mtRFP for morphology studies or EGFP for hypoxia-
reoxygenation and mPTP studies) per well was pipetted into each of the Eppendorf 
tubes. Following that, 2 µg of plasmids per well encoding the different fusion/fission 
proteins was added into the tubes. 100 µl of Gibco® serum-free medium MEM 1× 
(SFM) per well was added into each of the tubes for dilution. In a separate 
Eppendorf tube, 100 µl of SFM per well and 9 µl of Roche® Fugene 6 Transfection 
Reagent per well was added in consecutive order. A hundred microlitres per well of 
this mix was then added into each of the 6 tubes and left at room temperature in the 
laminar air flow for 15 minutes. The plates containing the HL1 cell culture were 
taken out from the incubator into the laminar air flow and the medium inside the 
wells was replaced with 2 ml of fresh Claycomb medium per well. After 15 minutes, 
200 µl of the solution from each of the tubes was pipetted into the corresponding 
wells in a circular motion. The plates were then sent back into the 37°C incubator. 
Medium in the plates and flasks were discarded and replaced with fresh medium 
every day. 48 hours after transfection, the cells can be used for subsequent 
morphology, hypoxia-reoxygenation and mPTP experiments.  
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 Sterile Eppendorf tubes prepared 
 
1 µg pEGFP/mtRFP per well was added to each empty tube 
 
 2 µg of respective plasmid per well was added into the tubes 
 
100 µl of serum-free medium per well was added into each tube 
 
 
1 new Eppendorf tube with 100 µl of SFM per well & 9 µl of  
Fugene 6 per well was prepared. 
* SFM has to be added first followed by Fugene 6 
 
100 µl Fugene6-SFM mix per well was pipetted into each Eppendorf tube 
 
Tubes were left for 15 min at RT 
 
 Medium in plates was discarded and replaced with 2 ml fresh medium per well. 
 
200 µl of Fugene-SFM-DNA mix per well was added by dripping. 
 
Figure 3.4: Schematic flow of transfection protocol for HL-1 cells and 
endothelial cells. 
 
 
 
In the following section (Section 3.6), the process of transcription and translation of 
plasmid DNA into protein will be detailed as a natural process occurring in cells.  
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3.6    From plasmids to proteins 
 
3.6.1    Transcription and Translation 
 
The plasmid DNA in the eukaryotic cells is transcripted into a single-
stranded messenger RNA (mRNA) and subsequently translated into a polypeptide 
chain. The enzyme that encodes mRNA from the DNA template is called the RNA 
polymerase and is recognised for its ability to incorporate nucleotides one at a time 
to produce the RNA which is complementary to one of the DNA strands (see Figure 
3.5) 136. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Schematic model of the formation of an mRNA strand. The RNA 
polymerase moves along the DNA template strand in the 3’ – 5’ direction while 
synthesising the mRNA strand in the 5’ – 3’ direction. The RNA polymerase will 
span across approximately 35 base pairs of DNA and the DNA-RNA hybrid consists 
of around 8 base pairs.  
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Prior to the start of transcription, the RNA polymerase has to bind to the 
correct and specific position on the DNA template known as the promoter region 
with the assistance of specific transcription factors. The critical promoter region for 
eukaryotic cells is located between 24 and 32 bases upstream from the initiation site. 
This region is known as the TATA box – the site of the assembly of a preinitiation 
complex containing the general transcription factors (GTFs) and the RNA 
polymerase. The assembly of the preinitiation complex is started off by binding of a 
protein called TATA-binding protein (TBP) that specifically recognises the TATA 
box of eukaryotic promoters. TBP is present as a subunit of a transcription factor for 
polymerase II, fraction D (TFIID). Binding of TFIID allows the subsequent binding 
of TFIIA and TFIIB and the interaction between these three GTFs allow the binding 
of the huge multisubunit polymerase with its attached TFIIF. Once this is completed, 
another pair of GTFs (TFIIE and TFIIH) will join this complex and transform the 
polymerase into an active transcribing machine. TFIIH is the only GTF which has 
enzymatic activities with two of the subunits of TFIIH functioning as helicases to 
unwind and separate the DNA double strands while another subunit functions to 
phosphorylate the RNA polymerase.  After binding, the RNA polymerase moves 
along the template DNA in a 3’ – 5’ direction, thus generating the mRNA in the 5’ – 
3’ direction by incorporating single nucleotides complementary to the template DNA 
strand. The DNA will be temporarily unwound as the polymerase progresses and 
rewind after the polymerase moved past. The mRNA transcript that is initially 
produced is only a primary transcript. This transcript will then be processed in the 
nucleus by specific processes such as addition of 5’ caps, poly(A) tails and RNA 
splicing involving removal of introns to produce a mature mRNA which will then be 
transported into the cytoplasm (see Figure 3.6) 136.  
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Figure 3.6: Model of initiation complex for RNA polymerase II at the TATA box of a 
eukaryotic promoter. The general transcription factors (GTFs) associate with the DNA strand 
and the RNA polymerase II to form the preinitiation complex for eukaryotic mRNA transcription. 
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Upon reaching the cytoplasm, the mRNA will be translated by the ribosome 
and transfer RNA (tRNAs) into a polypeptide chain. The ribosome that attaches to 
the mRNA will move along the mRNA in sets of three nucleotides (from one codon 
to the other) starting from the initiation codon with the nucleotides AUG so that the 
proper reading frame can be adhered to and the entire message can be read. Each 
ribosome consists of three sites, E, P and A specifically to accommodate every tRNA 
that comes in during each of the elongation cycle. 
 
The translation process can be divided into three stages: initiation, elongation 
and termination. Initiation in eukaryotic cells involves at least 10 initiation factors 
consisting of a minimum of 25 polypeptide chains (see Figure 3.7). A number of 
these initiation factors such as eIF1, eIF1A and eIF3 will initially bind to the 40S 
subunit as a preparation for subsequent binding to the mRNA together with the 
initiator tRNAiMet which is associated with another separate initiation factor, eIF2-
GTP. The small ribosome subunit together with all these initiation factors and 
initiator tRNA forms the 43S preinitiation complex which will locate the 5’end of 
the mRNA bearing the methylguanosine cap. On the mRNA itself, a subset of 
different initiation factors exert different functions to facilitate the binding of the 43S 
preinitiation complex. eIF4E will bind to the 5’ cap of the mRNA to facilitate 
recognition by the preinitaition complex while eIF4A will move along the 5’ end of 
the mRNA to remove any double-stranded regions which will restrict the movement 
of the 43S complex. Another initiation factor, eIF4G links the 5’ cap of the mRNA 
with the 3’ polyadenylated end of the mRNA, thus turning the linear form of the 
mRNA into a circular form. The 43S complex will bind to the 5’ end of the mRNA 
and move along the strand until reaching the initiator codon AUG which will leads to 
release of the bound initiator factors and subsequent binding of the large 60S subunit 
to complete the initiation process.  
 
. 
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Figure 3.7: Initiation of translation in a eukaryotic cell. Translation of the mRNA 
is initiated by the formation of two complexes, the 43S complex containing the 40S 
ribosome subunit bound to several initiation factors (eIF1, eIF1A and eIF3) and the 
initiator methionine tRNA as well as the mRNA associated with eIF4E at the 5’ cap, 
eIF4G which binds to both the poly(A) binding protein and eIF4E, and the eIF4A 
which moves long the 5’ end of the mRNA to remove any double-stranded regions 
that would interfere with the movement of the 43S complex. These two complexes 
then join together to scan along the mRNA to identify the first AUG initiation codon, 
coupled with ATP hydrolysis. Once the initiator AUG is identified by the complexes, 
eIF5 facilitates the hydrolysis of GTP bound to eIF2, all the initiation factors are 
released and the large 60S subunit joins the complex to complete initiation of the 
translation process.  
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The first step of elongation begins with the entry of a charged initiator tRNA 
in the P site followed by an aminoacyl-tRNA into the vacant A site (see Figure 3.8). 
However, the aminoacyl-tRNA has to bind to a protein elongation factor (eEF1α in 
eukaryotes) linked to GTP beforehand so that it can bind properly to the mRNA in 
the A site. Upon binding, the GTP is hydrolysed and the Tu-GDP complex released, 
leaving the aa-tRNA bound in the ribosome A site. The two amino acids attached to 
their tRNAs respectively can interact to form a peptide bond between the amino 
group of the aa-tRNA in the A site and the carbonyl group of the aa-tRNA in the P 
site with the peptidyl transferase as a catalyst, thereby causing the tRNA in the A site 
to have a dipeptide while the tRNA in the P site is deacylated and devoid of any 
amino acid.  
 
Translocation then follows, with the ribosome moving three nucleotides (one 
codon) again along the mRNA in the 5; - 3’ direction, hence transferring the 
dipeptide-tRNA from the A site to the P site of the ribosome and the deacylated 
tRNA from the P site to the E site. This process is promoted by another GTP-bound 
elongation factor, known as eEF2 in eukaryotes.  The deacylated tRNA in the E site 
then exits the ribosome leaving the E site empty while the A site is used to 
accommodate a new aminoacyl-tRNA whose anticodon is complementary to the 
corresponding codon of the mRNA.  The dipeptide of the tRNA in the P site is then 
displaced by formation of a second peptide bond with the new amino acid on the 
tRNA in the A site followed by translocation again to remove the deacyulated tRNA 
to the P site and allow the entrance of a new aa-tRNA into the A site.  
 
Upon reaching one of the stop codons: UAA, UAG and UGA, elongation will 
stop in the presence of release factors such as eRF1 and eRF3 in eukaryotes and the 
polypeptide will be released 136.  
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Figure 3.8: Formation and elongation of the polypeptide during translation in 
the eukaryotic cell. The ribosome contains three tRNA-binding sites, E (exit), P 
(peptidyl) and A (aminoacyl). The initiator methionyl tRNA is located in the P site 
while another aminoacyl-tRNA with a complementary anticodon to the codon of the 
mRNA will enter the empty A site with EF1α and GTP hydrolysis. A peptide bond 
will be formed between the methionine and the new amino acid, generating a 
peptidyl-tRNA in the A site and a deacylated tRNA in the P site. Translocation then 
ensues with the ribosome moving three nucleotides along the mRNA mediated by 
eEF2 coupled with GTP hydrolysis. The deacylated tRNA will now occupy the E 
site while the peptidyl-tRNA will be in the P site. The deacylated tRNA will then 
exit the ribosome and a new aminoacyl-tRNA will enter the A site.  
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3.7   Construction of mitochondrial matrix targeted PA-GFP     
   adenoviral vectors 
 
To visualise the mitochondria in the adult rat cardiomyocytes, an adenoviral vector 
has to be generated as lipofection only transfect primary cells at a very low 
efficiency. Adult rat cardiomyocytes was used as rat cardiomyocytes are more robust 
than mouse cardiomyocytes and the period of adenoviral transfection (72 hours) 
necessitate robust cells.  This section was performed by Dr. Sapna Subrayan, a 
postdoctoral research fellow in our laboratory in collaboration with Dr. Sean 
Davidson, a Senior Research Fellow also from our laboratory. The AdEasy XL 
Adenoviral Vector System (Stratagene) was used to generate the adenoviral vectors 
carrying the mtPA-GFP expression cassette. The plasmid encoding the mtPA-GFP 
was a kind gift from Dr. Luca Scorrano. A KpnI restriction site was introduced 
upstream of the COX VIII encoding sequence by PCR using mutagenic 
oligonucleotide primer pair (Left primer  5’-GCTGGTTTAGGGTACCGTCAG-3’; 
Right primer  5’-GGAGGTGTGGGGAGGTTTT-3’). Using the restriction sites 
KpnI and NotI, the PCR product was cloned into the multiple cloning site of shuttle 
vector pShuttle-CMV provided in the kit. The modified shuttle vector was then used 
to prepare the adenovirus vector as per the instructions. An adenovirus stock solution 
of 3-3.5 x 106 pfu/ml was used for the experiments. The multiplicity of infection 
used for the adenovirus was 1000.  
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3.8 Confocal Microscopy 
 
The advent of confocal microscopy has brought cell imaging and physiology 
studies to greater heights than ever before. Using the confocal microscope, we are 
now able to study the single cell originating from thick specimens, generating 3D to 
4D images in real-time without having to resort to physical shearing of the tissue 446. 
The power of the confocal microscope lies in its ability to eliminate out-of-focus 
light and in turn produce high-contrast sharper images compared to conventional 
fluorescent microscopes 446.     
 
The underlying principle in confocal microscopy can be simplified by using 
two sets of light from two different points focused by a pair of lenses causing images 
to be formed at two different locations (see Figure 3.9). Confocal microscopy is used 
to visualise only the image at a certain point and excluding the other image. This is 
done by using a screen with a pinhole to focus the light source at the in-focus or 
desired point and another pinhole to allow only the light from the desired point to 
pass through. The term ‘confocal’ derives from the conjugate position of the pinhole 
(image position) to the focal point of the lens (sample position) 447.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Principle of confocal microscopy. Light from the focal point is allowed 
through the pinhole of the screen. Light away from the focal point is rejected 
 
 
 
Image acquisition of the confocal microscope is based on point-by-point 
illumination of the specimen and exclusion of out-of-focus light. There is however, a 
Focal point Pinhole on screen 
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drawback with the point-by-point illumination system of the confocal microscope – 
fewer emitted photons to collect. The solution is to illuminate each point for a 
sufficient length of time so that enough light can be collected and a higher signal-to-
noise ratio can be obtained. One method is to use a laser light source which has high 
intensity as well as a variety of wavelengths 447.  
 
The 488 nm laser generates the high intensity blue excitation light which 
reflects off a dichroic mirror to vertically and horizontally-assembled scanning 
mirrors that scan the laser across the specimen. This causes excitation of the dye or 
fluophore in the specimen and the emitted fluorescent (green) light is then descanned 
by the same set of mirrors to pass though the dichroic mirror which then focuses it 
onto a pinhole. Only the light going through the pinhole is measured by a detector 
(see Figure 3.10) 447.  
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Figure 3.10: Schematic diagram showing the operation principles of the 
confocal microscope. The blue line shows the excitation light. Green line shows the 
emission light. Excitation light from the laser source passes through the dichroic 
mirror and scanning mirrors and scans the fluorescent dye labelled-sample. Emitted 
light then goes through the pinhole for focusing onto the detector.    
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The principle of fluorescence is based on differences in energy states of an 
excited molecule (see Figure 3.11). A particle or molecule at the lowest energy state 
or ground state will absorb incident light thus entering into a higher energy level and 
then spontaneously emit light of a different colour from the absorbed light when the 
molecule return to the ground state 447.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Principle of fluorescence. The fluorescent molecule is raised to an 
excited state by absorption of a high energy photon followed by dissipation of 
energy to other molecules and finally reverts back to the ground state by releasing 
light of a lower energy. 
 
 
 
 
 
 
There is never a complete image of the specimen because only one point is 
visualised at any one time. Hence, to get an image of the whole specimen, the 
detector is linked to a computer which generates the image of the whole specimen 
one pixel at a time resulting in a thin optical section of the specimen 447. 
 
Recent advancements have seen an addition of an enhanced light source 
consisting of air-cooled krypton argon ion laser for multiple wavelength lasers. This 
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laser can produce wavelengths at 488 nm, 568 nm and 647 nm, corresponding to the 
most common fluorophores: fluorescein, rhodamine and cyanine 5, consecutively 448.  
The light path in the microscope has been modified to enable proper filtering of the 
emitted signal from the three fluorophores to three different PMTs 448. Another 
modification would be to use three separate lasers: the 488 nm line of an argon laser 
for the fluorescein channel, a green helium neon laser (543 nm) for the rhodamine 
channel and a red diode laser (635 nm) for the cyanine 5 channel 448. Certain 
microscopes are also equipped with the 405 nm UV laser.  
 
 
3.8.1     Limitations of the confocal microscope 
 
 
3.8.1.1 Resolution 
 
In confocal microscopy, the point of light focused on the specimen actually 
produces an airy disk in the focal plane and the size of this airy disk is dependent on 
the wavelength of the laser and the numerical aperture of the objective lens. The 
resolution of the microscope is limited by the airy disk to about 200 nm 447. 
 
 
3.8.1.2 Pinhole Size 
 
The pinhole is used to reject out-of-focus light emitted from the specimen 
and theoretically, making the pinhole as small as possible would be desired. 
However, the decrease in pinhole size will also decrease the number of photons from 
the specimen detected by the detector and therefore cause a reduced signal-to-noise 
ratio. Increasing the fluorescence emitted from the specimen by increasing the 
excitation light intensity can compensate for this phenomenon but high intensities of 
lasers can cause damage to the specimen and degrade the fluorophore.  Therefore, 
adjusting the pinhole to about the size of an airy disk is the optimum solution 447. 
 
 
3.8.1.3 Fluorophores 
 
The fluorophore chosen should be able to attach to the correct part or interior 
of the specimen and be sensitive enough to the corresponding excitation wavelength. 
Besides that, usage of fluorophore for imaging under the high intensities of lasers 
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should not interfere with the normal physiological characteristics of the specimen 
and vice versa. The time needed for imaging and data collection should be carefully 
determined so that the adverse effects of photodamage and ROS generation can be 
minimised 447.  
 
 
3.8.1.4  Intensity of Incident Light 
 
The amount of fluorescence is dependent on the concentration of 
fluorophores and light intensity, both of which are factors to be taken into account 
when attempting to increase the fluorescence intensity. A compromise has to be 
reached when using either of these factors to increase fluorescence. Quenching 
occurs under high fluorophores concentrations and can reduce the fluorescence 
amount deep inside the specimen. The light source is absorbed by the nearest 
fluorophores, causing a lack of light reaching the other parts of the specimen. 
Increasing the intensity of the excitation light however, will induce higher amount of 
fluorophores into the excited states and eventually saturation. When the excitation 
rate becomes similar to the decay rate, a phenomenon known as ground state 
depopulation is formed leading to inhibition of fluorescence increase 447.  
 
 
3.8.1.5  Multicolor Fluorescence 
 
One of the advantages of using the confocal microscope is that different 
fluorophores can be used simultaneously to differentiate between different proteins 
or organelles within a cell. The fluorophores to be used can be determined by either 
selecting fluorophores sensitive to a multiwavelength laser or a fluorophore that 
emits different wavelengths following excitation by a single wavelength laser. The 
emitted light is then separated by suitable filters which are linked to different 
detectors. Nonetheless, there may be some overlap between the emission spectra of 
certain fluorophores causing complete channel separation to be difficult. To 
overcome this, the level of overlapping emission spectra has to be predetermined and 
then deducted out using computer statistical applications 447. 
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3.9   Electron Microscopy 
The transmission electron microscope generates images by using electrons to 
transmit through the specimen that is partly transparent and partly impermeable 
where the electrons are scattered (see Figure 3.12). The electron source is a tungsten 
filament cathode in a device known as ‘electron gun’ where an anode functions to 
accelerate the electrons through the specimen. The electron beam that passes through 
the specimen is magnified through the objective lens of the microscope and projected 
onto a fluorescent screen coated with phosphor to enable direct visualisation. The 
image can also be recorded using a camera connection to the computer. The 
advantage of using electron microscopy over confocal microscopy is that the use of 
electrons significantly increases the resolution power for fine specimens. However, 
the process of preparing specimens to very fine slices for transmission of electrons is 
tedious and time-consuming. Processing of the specimens may also causes a certain 
level of damage to the specimen. Another drawback to using electron microscopy is 
only a very small area can be analysed at a time, therefore impairing the judgement 
of the characteristic of the whole sample.  
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Figure 3.12: Diagram of the operating components of the electron microscope. 
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3.10   Mitochondrial Morphology Determination 
 
3.10.1  HL-1 and endothelial cells 
The shapes of the mitochondria in HL-1 and endothelial cells transfected with 
mtRFP were determined using a Zeiss 510 CLSM confocal microscope equipped 
with 63x oil immersion, quartz objective lens (Plan Apochromat, NA 1.3). The cells 
were illuminated using the 543-nm emission line of a HeNe laser and the 
fluorescence of mtRFP collected using a 560-nm long pass filter. Images were 
analysed using the Zeiss software (LSM Image Browser v3.5 or 4.0). After the stage 
where the Hatter Institute acquired our own confocal microscope, we started doing 
mitochondrial morphology imaging work on the Leica TCS SP5 Confocal Laser 
Scanning Microscope (CLSM) equipped with HCX PL APO lambda blue 63x / 1.40 
oil objective lens (see Figure 3.13).  
 
 
 
Figure 3.13: Picture of the Leica TCS SP5 Confocal Laser Scanning Microscope 
(CLSM). 
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The cells were illuminated using the 543-nm emission line of a HeNe laser. The 
fluorescence of mtRFP was collected at 555-700 nm. Images were analysed using 
the LAS AF Version 2.0.0 Build 1934 software programme. Krebs buffer comprising 
(in mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, 
KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) was used as imaging buffer. 
Images of twenty randomly chosen cells were taken and this was repeated for each 
group in at least four independent transfection experiments giving a total number of 
approximately 80 cells per treatment group. Three investigators, blinded to the initial 
treatment, independently assigned the cells as displaying either predominantly 
(>50%) elongated or (>50%) fragmented mitochondria, indicating that either 
mitochondrial fusion or fission, respectively, was the predominant process in that 
cell at that particular time, a method which has been adapted from previously 
published studies.  
 
 
 
 
3.10.2  Real-time changes in mitochondrial morphology during  ischaemia and 
reperfusion  
 
In order to determine the effect of simulated ischaemia-reperfusion injury on 
changes in mitochondrial morphology, HL-1 cells were imaged in real-time using an 
air-tight hypoxic chamber mounted on the confocal microscope. HL-1 cells 
transfected with mtRFP and either RcCMV or Drp1K38A were seeded onto coverslips, 
and placed into a Warner PM-2 heated perfusion chamber (Harvard Apparatus, USA) 
(see Figure 3.14).  
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Figure 3.14: Picture of the Warner PM-2 heated perfusion chamber  
(Harvard Apparatus, USA). 
 
 
Initially, the HL-1 cells were perfused with normoxic buffer specific for the real-
time imaging experiments  (in mM: NaCl 110, KCl 4.7, KH2PO4 1.2, MgSO4 1.25, 
CaCl2 1.2, NaHCO3 25.0, glucose 15.0, HEPES 20.0, pH 7.4) equilibrated with 95% 
O2-5% CO2. HL-1 cells with predominantly (>50%) elongated mitochondria were 
then located and imaged using the 63x objective lens. The cells were then perfused 
with hypoxic ischaemic buffer specific for the real-time imaging experiments  (in 
mM: NaCl 125, KCl 8, KH2PO4 1.2, MgSO4 1.25, CaCl2 1.2, NaHCO3 6.25, Na-
lactate 5.0, HEPES 20.0, 2-deoxyglucose 2.5, pH 6.6) equilibrated with 95% N2–5% 
CO2, at a rate of 1 ml/min, for 120 minutes to simulate ischaemia. After this, to 
simulate reperfusion, the HL-1 cells were reoxygenated with normoxic buffer. 
Images of the same HL-1 cells were acquired prior to simulated ischaemia, after 120 
minutes simulated ischaemia, at the immediate onset of simulated reperfusion and 
after 30 minutes of simulated reperfusion. For each treatment group 7-10 cells were 
counted. This experiment was repeated on three independent occasions giving a total 
of 21-30 cells per treatment group. 
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3.10.3  Pharmacological inhibition of Drp1 to induce mitochondrial fusion 
 
The recently described pharmacological inhibitor of Drp1, called mdivi-1 
(mitochondrial division inhibitor-1) (Key Organics Ltd, UK), was used in my PhD 
research to investigate the effects of pharmacologically inducing mitochondrial 
fusion on cardioprotection. Using the HL-1 cardiac cells we determined the optimum 
time required for mdivi-1 treatment in order to induce maximal mitochondrial fusion. 
HL-1 cells were transfected with mtRFP and were treated with mdivi-1 dissolved in 
Krebs imaging buffer at two different concentrations: at 50 µM, the dose shown 
previously to induce maximum mitochondrial fusion, and at 10 µM. HL-1 cells with 
predominantly fragmented mitochondria were identified and the subsequent changes 
in mitochondrial morphology monitored over a period of 40 minutes. Twelve HL-1 
cardiac cells from each treatment group were imaged for mitochondrial 
morphological analysis and this was repeated for each group in at least four 
independent experiments giving a total number of approximately 50 cells per 
treatment group. To further validate the results in a population of cells, a separate 
group of HL-1 cardiac cells were incubated in mdivi-1 at 50 µM or 10 µM dissolved 
in Krebs imaging buffer for forty minutes, and mitochondrial morphology 
determined. Twenty cells from each treatment group were imaged for subsequent 
mitochondrial morphological analysis and this was repeated for each group in at least 
four independent experiments giving a total number of 80 cells per treatment group. 
 
3.10.4   Adenovirus-mediated transduction of mtPA-GFP in adult rat 
cardiomyocytes 
 
All animal experiments were carried out in accordance with the United Kingdom 
Home Office Guide on the Operation of Animal (Scientific Procedures) Act of 1986. 
After 1 hour of incubation in the cardiomyocytes growth medium (M199 buffer: 
BSA 2 mg/ml, creatine 5 mM, taurine 5 mM, carnitine hydrochloride 1.6 mM, 
Pencillin-Streptomycin 1%), the cells were incubated with plating medium 
containing an appropriate titre of virus for 4 hours, after which the medium was 
replaced by fresh virus-free plating medium.  The cells were imaged using confocal 
microscopy for the expression of mtPA-GFP after 72 hours. After excitation of the 
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cells with the ultraviolet laser to activate mtPA-GFP, images were collected to 
determine the length of the mitochondria as confirmed by co-localisation of TMRM, 
a cell-permeable red-fluorescent dye that is sequestered by mitochondria according 
to the mitochondrial membrane potential. A background image of the cardiomyocyte 
was obtained initially using the 488nm laser to avoid auto-fluorescence signal. Next 
PA-GFP within a specified Region of Interest (ROI) was photo-activated by 
scanning with the 405 nm wavelength ultraviolet laser. The cell was immediately re-
imaged at 488nm and the difference in the intensity of green fluorescence between 
the two images – prior to and after photo-activation, was determined using Image J 
software (NIH, US). If all mitochondria are fragmented and disconnected, the photo-
activated GFP should remain within the boundaries of the ROI. However, the fact 
that photo-activated GFP was able to spread outside the ROI would imply that it has 
diffused throughout an elongated mitochondria or alternatively fusion had occurred 
between neighbouring mitochondria hence enabling the exchange of matricial 
contents (see Figure 3.15).  
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(A) 
   
(B)    
 
Figure 3.15: Tracking of mitochondrial-targeted photoactivatable green 
fluorescent protein (mtPA-GFP) in an adult cardiomyocyte. (A) prior to 
irradiation with UV laser and (B) following irradiation with UV laser.  
 
 
The spread of GFP beyond the ROI was expressed as a fold increase relative to the 
intensity within the ROI, to account for different efficiency of activation in different 
transfectants. Results were obtained from 30 randomly chosen cells isolated from 3 
rats (N=3 experiments with 30 cells). The imaging parameters were identical the 
same for all the experiments. 
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3.10.5   Detecting mitochondrial fusion in adult cardiomyocytes using 
electron microscopy 
  
C57BL/6 male mice treated with either the vehicle control or mdivi-1, were 
anesthetised and the hearts rapidly excised and perfused with a fixative containing 
fresh paraformaldyhyde 1%, glutaraldehyde 1%, CaCl2 0.5 mM), glucose 0.031% in 
phosphate buffer 0.1 M (pH 7.3), and left in fixative overnight before sampling. A 2 
mm transverse slice through the whole heart, 3 mm from the apex, was obtained 
from each heart. These heart slices were then post-fixed in OsO4 (1%) in phosphate 
buffer (0.1 M) pH 7.3 at 3.0ºC for 1.5 hrs. They were then washed in phosphate 
buffer (0.1 M) pH 7.4 and Enbloc stained with 0.5% uranyl acetate in distilled water 
at 3.0ºC for 30 minutes. After rinsing with distilled water, the specimens were 
dehydrated in a graded ehthanol-water series and infiltrated with Agar-100 resin 
overnight (Agar Scientific, UK). Semi-thin sections were cut at 1µm, and mounted 
on glass slides and stained with toluidine blue (1%) in distilled water for light 
microscopy. Ultra-thin sections were then cut at 70-80 nm using a diamond knife on 
a Reichert Ultracut E microtome (Reichert Microscope Services, USA). Sections 
were collected on 200 mesh copper grids, stained with uranyl acetate and lead citrate. 
The heart specimens were then viewed and recorded with a Jeol 1010 transition 
electron microscope (Jeol Ltd, UK).  
  The assessment of mitochondrial morphology was accomplished by 
randomly selecting 4 random electron micrographs of longitudinally-arranged 
cardiomyocytes from each adult heart (N=4 hearts). The arrangement and 
morphology of the interfibrillar mitochondria were noted and the number of 
mitochondria whose length was greater than 2 µm (the length of a single sarcomere) 
was determined.  
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3.11   Cell survival Assay 
 
Figure 3.16: Hypoxia-reoxygenation chamber. 
 
3.11.1   HL-1 cell death following simulated ischaemia-reperfusion injury 
 
In order to determine the effect of inducing mitochondrial fusion on the 
susceptibility to simulated ischaemia-reperfusion injury, HL-1 cells were subjected 
to a lethal episode of simulated ischaemia and reperfusion. The culture medium was 
removed and replaced by hypoxic ischaemic buffer specific for the cell-death 
experiments (comprising in mM: KH2PO4 1.0, NaHCO3 10.0, MgCl2.6H2O 1.2, 
NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 and NaLactate 20 at pH 6.2, bubbled 
with 100% nitrogen) and then placed in an airtight custom-built hypoxic chamber 
(see Figure 3.16) kept at 37ºC for 12 hours to simulate ischaemia. Following the 
period of simulated ischaemia, the cells were removed from the hypoxic chamber 
and placed in normoxic Claycomb medium (containing 3 µM propidium iodide) and 
returned to a tissue culture incubator, to simulate reperfusion. After 1 hour of 
simulated reperfusion at 37ºC, the percentage of GFP-transfected cells stained with 
propidium iodide was determined using a Nikon Eclipse TE200 fluorescent 
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microscope (see Figure 3.17) in order to calculate the percentage cell death in each 
treatment group.  
 
 
 
 
Figure 3.17: Picture of the Nikon Eclipse TE200 fluorescent microscope used 
for cell death counting.  
 
 
 
 
 
For each treatment group 80 cells were counted, taken from four randomly-selected 
fields of view. This experiment was repeated on at least four separate occasions 
giving a total of 320 cells per treatment group. For a time-matched normoxic control 
group, HL-1 cells were placed in normoxic buffer specific for cell-survival 
experiments  (comprising in mM: KH2PO4 1.0, NaHCO3 10.0, MgCl2.6H2O 1.2, 
NaHEPES 25.0, NaCl 98.0, KCl 3, CaCl2 1.2, d-glucose 10.0, Na pyruvate 2.0 at pH 
7.4, bubbled with 5% CO2/95% O2) for the total 13 hours duration of the experiment 
and the percentage cell death was determined.  
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3.11.2   Pharmacological inhibition of Drp1 to induce mitochondrial fusion 
and delay mPTP opening in HL-1 cells 
 
  In order to examine the effects of pharmacological inhibition of Drp1 on cell 
survival following a period of simulated ischaemia-reperfusion injury, HL-1 cells 
were incubated with 0.01% DMSO (vehicle control), 10 µM mdivi-1 or 50 µM 
mdivi-1 for 40 minutes and were then subjected to 12 hours of simulated ischaemia 
followed by 1 hour of simulated reperfusion in the presence of the mdivi-1. For each 
treatment group 80 cells were counted, taken from four randomly-selected fields of 
view. This experiment was repeated in at least four independent experiments giving 
a total of 320 cells per treatment group.   
 
3.11.3   Cell survival assay in adult myocytes 
All cells were subjected to 45 minutes of simulated ischaemia then 30 minutes of 
simulated reperfusion to simulate ischaemia-reperfusion injury, a model which we 
have previously established in our laboratory Simulated ischaemia was induced in a 
custom-made airtight hypoxic chamber, using a hypoxic ischaemic buffer specific 
for cell survival experiments (in mM: KH2PO4 1, NaHCO3 10, MgCl2.6H2O 1.2, 
NaHEPES 25, NaCl 74, KCl 16.0, CaCl2 1.2 and Na lactate 20.0, pH 6.2), bubbled 
with 100% nitrogen. Simulated reperfusion was achieved by replacing the buffer 
with M199 culture medium. Cells were seeded onto laminin-coated cover-slips and 
randomized to the following treatment groups: (1) vehicle control, and (2) mdivi-1 
treatment at either 10 µM or 50 µM (N>250 cells per experiment for 4 experiments). 
At the end of the simulated reperfusion, 5 µl of propidium iodide (PI, 1 µg/ml) was 
added to the cells for 5 minutes. The percentage of dead cells (as indicated by red 
fluorescence, PI positive) was calculated by fluroscence microscopy and was 
expressed as a percentage of the total number of cardiomyocytes (PI positive and PI 
negative)  
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3.12   In vivo murine model of acute myocardial infarction 
We used an in vivo murine model of myocardial infarction to determine the effect of 
inducing mitochondrial fusion on the susceptibility of the heart to myocardial 
infarction. C57BL/6 male mice (8-12 weeks of age and weighing 25-30g) were 
anesthetised by intraperitoneal injection with a combination of ketamine, xylazine 
and atropine (0.01 ml/g, final concentration of ketamine, xylazine and atropine were 
10 mg/ml, 2 mg/ml and 0.06 mg/ml respectively) and body temperature was 
maintained at 37°C. The external jugular vein and carotid artery were isolated and 
cannulated for drug administration and mean arterial blood pressure (MABP) 
measurement, respectively. A tracheotomy was performed for artificial respiration at 
120 strokes/min and 200 µl stroke volume using a rodent Minivent (type 845, 
Harvard Apparatus, Kent, UK) and supplemental oxygen was supplied. A limb lead I 
electrocardiogram (ECG) was recorded. A left anterior thoracotomy and a chest 
retractor were used to expose the heart. Ligation of the left anterior descending 
(LAD) coronary artery was performed ~2 mm below the tip of the left atrium using a 
8/0 prolene monofilament polypropylene suture. Successful LAD coronary artery 
occlusion was confirmed by the presence of ST-segment elevation and a reduction in 
arterial blood pressure. At the end of reperfusion, the heart was isolated and the 
aortic root was cannulated and used to inject TTC (5 ml of 1%) in order to demarcate 
the infarcted tissue. The LAD coronary artery was then re-ligated and Evans blue 
dye (2 ml of 0.5%) was perfused to delineate the area at risk (AAR). The heart was 
frozen and sectioned perpendicularly to the long axis (1-2 mm thick). The slices 
were then transferred to 10 % neutral buffer formalin for 2 hours at room 
temperature to stabilise the staining. AAR and infarct size were determined by 
computerised planimetry using the NIH software Image. AAR was expressed as a 
percentage of the left ventricle and infarct size was expressed as a percentage of the 
AAR. 
 
  C57BL/6 male mice were randomly assigned to one of three treatment groups: 
(1) Vehicle control (n=6): an intravenous bolus of DMSO (0.1ml of 0.1%) was given 
15 minutes prior to the index myocardial ischaemic episode, (2) mdivi-1 (n=6): an 
intravenous bolus of mdivi-1 (0.24 mg/kg) was given 15 minutes prior to the index 
myocardial ischaemic episode, and (3) mdivi-1 (n=6): an intravenous bolus of mdivi-
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1 (1.2 mg/kg) was given 15 minutes prior to the index myocardial ischaemic episode. 
These mdivi-1 concentrations were estimated from the ex vivo concentrations of 10 
µM and 50 µM used in the isolated adult murine cardiomyocytes experiments. 
Hearts were subjected to 30 min of ischaemia followed by 120 min of reperfusion at 
the end of which infarct size was determined by triphenyl-tetrazolium staining.  
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3.13  mPTP assay 
Detection of the mPTP 
 
Opening of the mPTP at the onset of reperfusion was first demonstrated by 
the groups of Crompton and Halestrap in 1993 63, 449. The opening of the mPTP can 
be inhibited by ciclosporin A which prevents binding of CypD to the ANT or 
silencing of the Ppif gene which encodes for CypD, hence reducing infarct size 263, 
264, 387, 450
. There are several limitations in the study of mPTP. First of all, certain 
mPTP inhibitors are consistently present in normal myocytes during IR and we have 
to assume that mPTP is conferred by the presence of other pro-mPTP factors such as 
the production of reactive oxygen species, pH increase, free fatty acid accumulation 
451
.   
 
It has been relatively easier for the study and identification of the mPTP 
using isolated mitochondria in electrophysiology and isolated cells with specific dyes 
in confocal microscopy compared to the in vivo model where MPTP is only 
indirectly studied using either genetic ablation of the constituent proteins or the 
pharmacological inhibitors such as CsA. 
 
Opening of the mPTP will lead to depolarisation of the inner membrane 
potential, swelling of the matrix and subsequent rupture of the OMM leading to 
release of cytochrome c which is responsible for caspases-dependent cell death.  
 
mPTP inhibition was first postulated to be the effector of IPC by the group of 
Yellon and co-workers 17 and IPost by the group of Ovize through studies using CsA   
230
 as well as the non-immunosupressive derivatives and the analysis of changes in 
the calcium retention capacity of isolated mitochondria.  
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3.13.1  Techniques for measuring the mPTP in isolated mitochondria 
 
The most direct method in measuring mPTP in isolated mitochondria is the sucrose-
entrapment technique by Crompton and co-workers where 14C sucrose is used to 
permeabilise through the pore and the rate is monitored hence allowing the 
characterisation of the kinetics and specifics of the pore 452. Nevertheless, this 
technique is extremely laborious and continuous monitoring of this process is not 
easy. The most commonly used method however, is the light scattering method 
where the degree of light scattering in a spectrophotometer depends on the swelling 
magnitude of the mitochondria. 376 Upon mPTP opening, small molecular mass 
solutes equilibrate through while higher molecular mass solutes promote entrance of 
water into the matrix by providing the required osmotic force.   
 
Quantification of mPTP opening can be performed by using either the TMRE or 
calcium rention capacity in isolated mitochondria. The calcium retention method was 
originally developed in liver mitochondria where the release of calcium into the 
extramitochondrial environment was monitored 453. Nevertheless, the respiratory 
capability of the mitochondria has to be ascertained by measurement of complex I 
activity as Complex I plays a crucial role in maintaining the sensitivity of mPTP 
opening to ensure the viability of the mitochondria 454 Proper controls should be 
determined when studying the function and viability of the mitochondria such as the 
use of FCCP or dinitrophenol and stimulation of respiration with ADP 455. 
 
3.13.2   ROS generation by lasers induce mPTP opening as visualised by the 
increase of TMRM fluorescent intensity  
 
TMRM, a cationic fluorescent dye has been reported to be used as a 
photoactivable dye to generate oxidative stress upon illumination and consequently 
for studying MMP with depolarisation signifying mPTP opening. TMRM loaded 
into cells accumulate in the mitochondria due to the negative charge located in the 
mitochondria matrix and the solubility of the TMRM in both the inner mitochondrial 
membrane and matrix space 232, 456.  Once accumulated in the mitochondria, TMRM 
exhibit a red shift in both the absorption and fluorescence emission spectra 456. The 
relatively high concentration of TMRM localised in the mitochondria will induce 
Sang Bing, Ong 
 161
auto-quenching of fluorescence, which will reduce the red fluorescent intensity of 
the TMRM 232.   
 
The lasers of the confocal microscope are able to break down TMRM to its 
chemical derivatives in the mitochondria, thus generating ROS which induces mPTP 
opening. This model has been widely used and accepted as a form of reoxygenation-
induced cell injury synonymous with generation of oxidative stress and radical 
species from mitochondria at the onset of reperfusion 31, 232, 457, 458. The red 
fluorescent intensity of TMRM will increase once the mPTP is opened, showing 
depolarisation of the mitochondrial membrane potential and leakage of the TMRM 
from the mitochondria into the cytosol 232.  
 
TMRM has several advantages over other indicators of MMP such as lowest 
binding affinity to mitochondria and other organelles, accumulation in mitochondria 
only occurs in response to membrane potentials, nontoxic to cells, and is not a 
substrate for other ionic channels 459. The ratio of red fluorescent intensity in the 
mitochondria to that of the cytosol allows the MMP to be assessed reliably 
regardless of the efficiency of dye loading 459.  
 
 
 
 
3.13.3   Use of ciclosporin A to inhibit the mPTP 
 
Ciclosporin A, a cyclic undecapeptide isolated originally from the fungus 
Tolypocladium inflatum inhibits the mPTP by binding to the cyclophilin D 
component of the mPTP. The cyclophilin D acts as a mitochondrial enzyme, 
peptidylprolyl cis-trans isomerase (PPIase) which is involved in changing the shape 
of proteins by altering the conformation of the peptide bond around proline residues. 
This provides the impetus for the deduction of the mPTP where a membrane protein 
can be converted into a channel by action of the PPIase. Many groups speculated that 
this might be the ANT protein which functions to transport the ATP out of and ADP 
into the mitochondria. Under conditions favouring the mPTP opening such as 
presence of ROS, low ATP and high pHi, cyclophilin D binds to the ANT, changing 
this specific transporter into a non-specific pore. The use of ciclosporin A to inhibit 
mPTP opening is limited to a narrow concentration range of 0.2 µM due to the fact 
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that ciclosporin A inhibits calcineurin, a Ca2+-dependent protein phosphotase 
through Ca2+-calmodulin-dependent inhibition 373 by binding with the cytosolic 
cyclophilin (CyP-A) to form a complex with a high affinity to the catalytic subunit of 
calcineurin and hence preventing dephosphorylation of NFAT and its translocation 
to the cell nucleus.    
 
3.13.4   Induction and detection of mPTP opening 
In order to determine the effect of inducing mitochondrial fusion on the 
susceptibility to mPTP opening, we used a well-characterised and validated model of 
oxidative stress to induce and detect mPTP opening. The culture medium was 
removed and replaced with Krebs imaging buffer. The HL-1 cells were then loaded 
with the fluorescent dye tetramethylrhodamine methyl ester (TMRM, 3 µM) for 15 
min at 37ºC and then washed with Krebs imaging buffer. Confocal laser-stimulation 
of TMRM generates reactive oxygen species (ROS) within the mitochondria, thereby 
simulating mitochondrial ROS production during reperfusion, which induces mPTP 
opening. The opening of the mPTP is visualised as mitochondria membrane 
depolarisation and the dequenching of TMRM fluorescence as it moves into the 
cytoplasm (see Figure 3.18).  
 
  
Figure 3.18: Representative confocal images of HL-1 cells transfected with GFP 
and loaded with TMRM at baseline (left) and demonstrating subsequent mPTP 
opening as indicated by mitochondrial membrane depolarisation (an increase in 
TMRM fluorescence resulting from dequenching) after oxidative stress from 
confocal laser breakdown of TMRM (right). 
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The time taken to induce mitochondrial membrane depolarisation is recorded as a 
measure of susceptibility to mPTP opening. This was defined as the time taken to 
reach half the maximum TMRM fluorescence intensity. Twenty transfected cells 
were randomly selected for the induction and detection of mPTP opening from each 
treatment group, and this was repeated in at least four independent experiments 
giving a total of 80 cells per treatment group. As a positive control and in order to 
confirm that mitochondrial membrane depolarisation was indicative of mPTP 
opening following TMRM loading, a group of cells were pre-treated for 10 minutes 
with the mPTP inhibitor, ciclosporin A  (0.2 µM). In order to confirm that this model 
was actually measuring mPTP opening, we pre-treated cells for 10 minutes with 
Sanglifehrin A (SfA, 1.0 µM), which does not inhibit calcineurin. In a previous study, 
we have also confirmed that the mitochondrial membrane depolarisation induced by 
oxidative stress in this experimental model reflects mPTP opening as evidenced by 
the redistribution of mitochondrial-loaded calcein.  
 
  To confirm the efficacy of the experimental protocol used for inducing and 
detecting mPTP opening, we also examined the effect of laser-induced mitochondrial 
oxidative stress on the redistribution of the fluorescent dye, calcein, from the 
mitochondrial matrix. We used an established method for detecting mPTP opening in 
the intact cell. HL-1 cells were loaded for 10 minutes at room temperature with 1µM 
calcein-AM + 1 mM CoCl2. In this model, calcein-AM, which is membrane 
permeable, enters the cytosol and mitochondria, where on de-esterification the 
calcein becomes entrapped within the cytosol and the mitochondria. The CoCl2 
quenches the calcein signal within the cytosol only, leaving calcein fluorescence 
selectively visible within the mitochondria. Because of its relatively large size (620 
Da), the only way calcein can exit the mitochondria is if the mPTP opens. Therefore, 
the extent of mPTP opening can be measured by the loss of mitochondrial calcein 
fluorescence.  
 
    HL-1 cells were visualised using a Zeiss 510 CLSM confocal microscope 
equipped with 40x oil immersion, quartz objective lens (Plan-Neofluar, NA 5 1.3) 
using the 488-nm of an Argon laser and the 543-nm emission line of a HeNe laser. 
Time scans were recorded with simultaneous excitation at 488 nm (for GFP and 
calcein) and 543 nm (for TMRM), collecting fluorescence emission at 505–530 nm 
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and >560 nm, respectively. For these mPTP experiments, all conditions of the 
confocal imaging system (laser power, confocal pinhole - set to give an optical slice 
of 1 micron - pixel dwell time, and detector sensitivity) were identical to ensure 
comparability between experiments. Images were analysed using the Zeiss software 
(LSM Image Browser v3.5 or 4.0).    
 
 
3.13.5    Pharmacological inhibition of Drp1 to induce mitochondrial fusion 
and delay mPTP opening in HL-1 cells 
 
  In order to examine the effects of pharmacological inhibition of Drp1 on the 
susceptibility to mPTP opening in response to oxidative stress, HL-1 cells were 
treated with either 0.01% DMSO (vehicle control), 10 µM mdivi-1 or 50 µM mdivi-1 
for 40 minutes. The HL-1 cells were then loaded with TMRM; 3 µM with either 
0.01% DMSO, 10 µM 10 µM mdivi-1 or 50 µM mdivi-1 for 15 min at 37ºC and then 
washed with either Krebs imaging buffer containing 0.01% DMSO, 10 µM mdivi-1 
or 50 µM mdivi-1.  Twenty cells were randomly selected for the induction and 
detection of mPTP opening from each treatment group, and this was repeated in at 
least four independent experiments giving a total of 80 cells per treatment group. 
 
 
3.13.6   mPTP assay in adult myocytes 
   In adult cardiomyocytes a different model of mPTP opening was used 
because we found that it was difficult to measure changes in red fluorescent intensity 
in adult myocytes treated with mdivi-1 using the confocal laser-stress induced ROS 
model. For the adult myocytes, we opted to use the simulated ischaemia-reperfusion 
model for mPTP assay which we have previously established in our laboratory. The 
cells were subjected to 45 minutes of simulated ischaemia then 30 minutes of 
simulated reperfusion. Simulated ischaemia was induced in a custom-made airtight 
hypoxic chamber, using a hypoxic ischaemic buffer specific for cell-survival 
experiments (5) (in mM: KH2PO4 1, NaHCO3 10, MgCl2.6H20 1.2, NaHEPES 25, 
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NaCl 74, KCl 16.0, CaCl2 1.2 and Na lactate 20.0, pH 6.2), bubbled with 100% 
nitrogen. Simulated reperfusion was achieved by replacing the buffer with M199 
culture medium containing 100 nM TMRM, or a combination of M199 containing 
100 nM TMRM with either 50µM mdivi-1 or 1 µM Sanglifehrin A. At the end of the 
simulated reperfusion, the M199 reperfusion medium was replaced with fresh M199 
medium alone and images of the cells were obtained to determine differences in 
fluorescent intensities. Therefore, in this model of the resultant TMRM flurescence 
at reperfusion provides a measure of mPTP sensitivity.   
 
 
 
3.14   Statistical Analysis 
All values are expressed as mean ± standard error of the mean (SEM). Data were 
analysed by 1-way analysis of variance (ANOVA) followed by a Tukey multiple-
comparison post hoc test. Differences were considered significant at values of 
P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sang Bing, Ong 
 166
     Chapter Four:   
 
MODULATION OF MITOCHONDRIAL MORPHOLOGY IN 
CARDIAC CELLS 
 
4.1  Introduction                                    168 
 
4.2  Hypothesis & Objectives                            170 
   Mitochondrial morphology can be modulated in cardiac cells 
 
4.3     Aim (1): To determine whether mitochondrial morphology can    171         
             be modulated in the HL-1 cardiac cell line using genetic    
               manipulation. 
 
      4.3.1  Materials                               171 
      4.3.2  Experimental protocol                         172
      4.3.3  Results                                172 
 
4.4 Aim (2): To determine whether mitochondrial morphology can    178    
       be modulated in the HL-1 cardiac cell line using        
      pharmacological manipulation. 
 
      4.4.1  Materials                               178 
      4.4.2  Experimental protocol                        178 
      4.4.3  Results                                179 
 
4.5 Aim (3): To determine whether mitochondrial morphology can    184        
       be modulated in endothelial cells using genetic         
      manipulation  
 
      4.5.1  Materials                               184 
      4.5.2  Experimental protocol                        184 
      4.5.3  Results                                185 
 
 
4.6 Aim (4): To determine whether elongated mitochondria can be   188
      detected in the adult cardiomyocytes 
 
      4.6.1  Materials                               188 
      4.6.2  Experimental protocol                        188 
      4.6.3  Results                                191 
 
 
4.7 Aim (5):  To determine whether the presence of elongated        194
      mitochondria can be increased in the adult cardiomyocytes  
      using pharmacological manipulation 
 
 
Sang Bing, Ong 
 167
      4.7.1  Materials                               194 
      4.7.2  Experimental protocol                        194 
      4.7.3  Results                                195 
 
 
4.8 Discussion                                  200 
 
4.9 Conclusion                                  206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sang Bing, Ong 
 168
4.1  Introduction  
 
Mitochondria have been demonstrated to exist in a dynamic equilibrium 
state, with two opposing morphologies: a fused or fragmented state which is 
maintained by different proteins: Mfn1, Mfn2 and OPA1 for promotion of 
mitochondrial fusion and Drp1, hFis1 for promoting the fragmented state of 
mitochondria 149, 158, 175, 176, 192, 460. The morphology of the mitochondria varies 
depending on cell type and condition of the cells 90. Neonatal cells, endothelial cells 
and certain types of cell lines such as the HL-1 have similar mitochondrial 
arrangements in the form of ‘spaghetti (fused) and meatball (fragmented)’ like-
shapes 213. Cells which are unhealthy and subjected to stress or injury will also have 
mitochondria that are either swollen or fragmented.  
 
Previous studies have shown that the fused state of mitochondria may be 
beneficial in terms of viability, e.g. in neurons while the fragmented states play a 
role in cell death 87, 160, 162, 205, 207, 418, 461. A study by the group of David Chan in 
2010 showed that the fused state of mitochondria prevents the deleterious effects of 
the loss and mutated DNA 214. Excessive fragmentation of the mitochondria 
however, is linked to depolarisation of the MMP, uncoupling of the respiratory 
chain, loss of ATP and release of the pro-apoptotic cytochrome c 70, 173, 209, 462.  
 
Manipulation of mitochondrial morphology has been performed before in 
different cell types; neurons, yeast and mammalian cell lines 152, 159, 169, 412, 460. 
However, there is still a lack of information pertaining to manipulation of 
mitochondrial morphology in cardiac cells, especially in which the mitochondria is 
arranged in tightly regulated rows along the myofibrils. The consensus at the time 
when this study was carried out was that mitochondria in the adult cardiomyocytes 
move only at a very minute range and therefore, general dynamics such as fusion and 
fission are virtually immeasurable 154. mito-PAGFP has been used in several studies 
to monitor mitochondrial dynamics but are limited to cells such as beta-cells 463, 
HeLa cells 206, primary hippocampal neurons 206 or zebrafish embryo 464. Karbowski 
and co-workers used mito-PAGFP to visualise mitochondrial fusion in human 
myocytes but the mitochondria arrangement in the human myocyte depicted differs 
from the mitochondrial arrangement in a cardiomyocyte 206. Interestingly, giant 
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swollen mitochondria were observed in adult myocytes using electron microscopy 
but proper quantification was not performed 148, 465.  
  
    A number of different substances have been reported to modulate 
mitochondrial morphology such as the kinase PKA 182 and the drug mdivi-1 418. PKA 
has been documented to inhibit mitochondrial fission by phosphorylating the fission 
protein Drp1 at Ser637 182. Similarly, the drug, mitochondrial division inhibitor-1 
(mdivi-1) was formulated after a yeast screening assay. The mdivi-1 drug works by 
phosphorylating the Drp1 at an allosteric site not exclusive to the GTPase domain 
and has been shown to increase the percentage of cells with elongated mitochondria 
in yeast, mammalian COS and HeLa cells 418.  
 
In this section of the study, I aim to determine whether mitochondrial fusion 
can be promoted in a cardiac cell line using genetic manipulations such as the 
overexpression of fusion-promoting proteins such as Mfn1, Mfn2 as well as 
pharmacological manipulations such as using the drug mdivi-1 in the hope that 
manipulation of mitochondrial morphology may serve as a potential mediator of 
cardioprotection against ischaemia-reperfusion injury in the heart. Following the cell 
line, I shall proceed on to using endothelial cells and primary cardiomyocytes to 
determine whether mitochondria elongation can be increased.  
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4.2  Hypothesis & Objectives 
 
   Mitochondrial morphology can be modulated in cardiac cells 
 
The first part of the study was to determine whether mitochondrial 
morphology in the HL-1 cardiac cell line can be manipulated or changed. Fusion 
(Mfn1, Mfn2) or fission (hFis1) promoting proteins were used in this study were 
plasmids containing genes encoding for these proteins were transfected together with 
plasmids encoding for mitochondrial-targeted fluorescent proteins into these cells to 
promote overexpression of these proteins in the cells. Following transfection, 
mitochondrial morphology in the cells was determined using confocal microscopy.  
     
    In the second part of the study, we investigated whether the drug mdivi-1, also 
increased the proportion of elongated mitochondria in HL-1 cardiac cells. The mdivi-
1 drug has been shown to successfully increase the proportion of elongated 
mitochondria in yeast, HeLa and COS cells 418. Due to the fact that this is the first 
time that mdivi-1 has been used on the HL-1 cells, we conducted a time and dose 
response. 
  
     In the third part of the study, we investigated whether mitochondrial 
morphology in the endothelial cells can be similarly manipulated as in the HL-1 
cardiac cells. The endothelial cells were isolated directly from the blood vessels and 
may function as an intermediate cell type between HL-1 and adult cardiomyocytes..  
 
     The presence of elongated mitochondria in adult myocytes was determined 
subsequently using confocal microscopy and electron microscopy. Any mitochondria 
longer than the standard length of a sarcomere (2 µm) will be considered as 
elongated mitochondria.  
 
     The effect of mdivi-1 in promoting mitochondrial elongation in primary 
cardiomyocytes was also determined. A single intraperitoneal dose of mdivi-1 was 
injected into C57BL/6 mice and the hearts were examined under electron 
microscopy for determination of mitochondrial length.  
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4.3     Aim (1) 
  
To determine whether mitochondrial morphology can be modulated 
in the HL-1 cardiac cell line using genetic manipulation. 
 
In this section, we wanted to confirm whether mitochondrial morphology in HL-1 
cardiac cells can be manipulated using genetic overexpression of fusion-promoting 
proteins (Mfn1, Mfn2), fission-promoting protein (hFis1) or the dominant negative 
form of the fission protein, Drp1K38A.  
 
4.3.1 Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); one expressing mitofusin 
1(pCB6-MYC-Mfn1); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; one 
containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant 
form of the mitochondrial fission protein Drp1 205; and one containing hFis1. 
Drp1K38A has a mutation in the GTPase domain that results in replacement of lysine 
38 with alanine (designated as Drp1K38A), disabling its ability to induce 
mitochondrial fission by sequestering endogenous Drp1 181, 205. For the 
mitochondrial morphology studies a ratio of 1:2 mitochondria-targeted red 
fluorescent protein (mtRFP: Mitochondria-targeted dsRED) expression plasmid: 
plasmid of interest was included in order to permit visual assessment of 
mitochondrial morphology. All plasmids were a generous gift of Dr Luca Scorrano 
(Padova, Italy). Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-
Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and 
HEPES 10.0 (pH 7.4) was used as imaging buffer for confocal microscopy studies. 
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4.3.2 Experimental protocol for mitochondrial morphology 
determination 
 
Upon reaching confluency of around 50 – 60% (~24 hours after seeding), the cells 
were transfected with one of the following plasmids: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1 - fission-promoting protein 
 
mtRFP was always co-transfected to visualise the mitochondria as well as to indicate 
uptake and expression of the plasmids. As this was the first time that these proteins 
were overexpressed in a HL-1 cardiac cell line, we had to determine the optimum 
duration of plasmids expression to induce significant changes in mitochondrial 
morphology. Images of twenty randomly chosen cells for both experiments with 
either 24 hours expression duration or 48 hours of expression duration were obtained 
and this was repeated for each group in at least four independent transfection 
experiments giving a total number of approximately 80 cells per treatment group. 
Three investigators, blinded to the initial treatment, independently assigned the cells 
as displaying either predominantly (>50%) elongated or (>50%) fragmented 
mitochondria, indicating that either mitochondrial fusion or fission, respectively, was 
the predominant process in that cell at that particular time, a method which has been 
adapted from a previously published study 165. 
 
 
 
4.3.3 Results 
 
The first objective was to ensure that the mitochondrial fusion/fission proteins were 
performing their respective functions in the HL-1 cardiac cell line. The mitochondria 
in the HL-1 cells were illuminated red in colour due to the expression of the mtRFP. 
HL-1 cells were determined as either containing predominantly fragmented (globular 
and dot-like) (see Figure 4.1 (A & E) for an example) or predominantly fused 
mitochondria (thin and elongated) (see Figure 4.1 (B – D) for an example).  
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(A) 
 
 
(B) 
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(E) 
 
 
Figure 4.1: Representative confocal images of HL-1 cells transfected with red 
fluorescent protein targeted to the mitochondrial matrix in addition to (A) 
empty vector control, (B) Mfn1, (C) Mfn2, (D) Drp1K38A (all demonstrating 
predominantly [>50%] elongated mitochondria in B-D), and hFis1 (E) 
(demonstrating predominantly fragmented mitochondria). 
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Cells with has an overexpression of Mfn2 show a marked increase in elongated 
mitochondria after 24 hours (68.0 ± 4.4%) compared to cells with the empty vector, 
RcCMV (43.0 ± 6.9%), (n=4; *P<0.05). The overexpression of the dominant 
negative form of the fission protein, Drp1K38A, showed a trend of increasing the cells 
with elongated mitochondria but was not significant (64.8 ± 6.1%). Fragmentation of 
the mitochondria by the overexpression of hFis1 was also not significant (26.1 ± 
5.9%) compared to the vector control (see Figure 4.2).    
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Figure 4.2: Effect of overexpression of different proteins to the morphology of 
mitochondria in HL-1 cells over a period of 24 hours. A trend of increasing cells 
with elongated mitochondria was seen for cells with an overexpression of Mfn2 and 
Drp1K38A with only the Mfn2 achieving significance. Overexpression of the hFis1 at 
24 hours did not fragment the mitochondria significantly (N=4 experiments with 80 
cells per group; *p<0.05 compared to vector control; †p<0.05 compared to Mfn2 and 
Drp1K38A).  
 
 
 
 
 
 
 
HL-1 mitochondrial morphology 24 hours after transfection 
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Compared to the cells which were transfected with the empty vector for 48 
hours, cells which were transfected with plasmids encoding for Mfn1, Mfn2 and 
Drp1K38A demonstrated a significant increase in numbers of fused mitochondria (65.3 
± 4.1%, 69.1 ± 4.9% and 62.8 ± 6.3% vs.. 45.7 ± 5.6% with RcCMV, n = 4; *p < 
0.05)  (see Figure 4.4). We used a mutated form of Drp1 (a known fission protein), 
Drp1K38A to demonstrate that the potential effects of fused mitochondria were indeed 
caused by the overexpression of the proteins and not other factors present in the cell. 
Cells with overexpression of hFis1 as a negative control has markedly reduced 
number of cells with fused mitochondria (19.0 ± 8.5% vs. 45.7 ± 5.6% with RcCMV, 
n = 4; *p < 0.05) (see Figure 4.3). 
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Figure 4.3: Effects of overexpression of different proteins to the morphology of 
mitochondria in HL-1 cells over a period of 48 hours. Mitochondrial elongation 
was significantly increased in cells with an overexpression of Mfn1, Mfn2 and 
Drp1K38A. Mitochondrial fragmentation was significantly induced in cells with an 
overexpression of hFis1. N=4 experiments with 80 cells per group; *p < 0.05 
compared to Vector Control; †p<0.05 compared to hFis1.  
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4.4       Aim (2)    
 
To determine whether mitochondrial morphology can be modulated 
in the HL-1 cardiac cell line using pharmacological manipulation. 
 
In this section, we investigated the use of a small molecule inhibitor of the Drp1 
fission protein, mdivi-1 as a pharmacological agent in modulating mitochondrial 
morphology in HL-1 cells.  
 
 
4.4.1     Materials 
 
To monitor the changes in mitochondrial morphology, 1 ug per well of 
mitochondria-targeted red fluorescent protein (mtRFP: Mitochondria-targeted 
dsRED) expression plasmid was transfected to enable viewing of mitochondria using 
the confocal microscope. Mdivi-1 drug was purchased from Key Organics Ltd., UK. 
The drug was dissolved in DMSO (Sigma UK) to achieve a working concentration 
of 10 mM and 50 mM and subsequently in Krebs buffer comprising (in mM): NaCl 
118.0, NaHCO3 25.0, d-Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, 
CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) to achieve a final concentration of 10 µM 
and 50 µM.   
 
 
4.4.2     Experimental protocol  
 
HL-1 cardiac cells were transfected with plasmids encoding for mitochondrial-
targeted red fluorescent protein (mtRFP). Cells with predominantly fragmented 
mitochondria were selected using confocal microscopy and monitored over time for 
the changes in mitochondrial morphology following treatment with either one of the 
following three treatments: 
 - Vehicle control (<0.01% DMSO in Krebs) 
 - 10 uM mdivi-1 
 - 50 uM mdivi-1 
Following the determination of the optimum duration of incubation with the 
optimum concentration of mdivi-1, a separate batch of cells were imaged using 
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confocal microscopy to determine number of cells with elongated mitochondria  
prior to incubation with mdivi-1 and repeated after incubation with mdivi-1.  
 
 
4.4.3     Results 
 
In order to determine the optimum concentration of mdivi-1 drug to be used for 
enhancing proportion of cells with elongated mitochondria as well as the optimum 
duration of treatment, a time and dose response was carried out. Three different 
doses were initially tested for this study. However, there was a problem of solubility 
for 100 µM of the drug where crystal-like particles was still visible under the 
microscope. A point worth mentioning here is that mdivi-1 has to be vortexed and 
sonicated prior to use. A population of cells with pre-dominantly fragmented 
mitochondria was selected for monitoring throughout the whole duration of 1 hour 
with 3 different concentrations of mdivi-1. Percentage of cells with elongated 
mitochondria increased to (8 ± 8.4% for 10 µM mdivi-1) and (17 ± 7.1% for 50 µM 
mdivi-1) after 20 minutes. Interestingly, the percentage of cells with elongated 
mitochondria treated with 0.1% DMSO also increased to (19 ± 10.8%) within the 
same time duration. Nevertheless there was no significance between these values. 
Forty minutes of incubation with 50 µM mdivi-1 increased the cells with elongated 
mitochondria to (60.0 ± 7.5%) compared to (19.0 ± 2.8% for 10 µM mdivi-1) and 
(13.0 ± 10.8% for vehicle control) (n = 4; *p<0.05 compared to vehicle control and 
10 µM; † p<0.05 compared to time 0’) (see Figure 4.4). After 60 minutes, number of 
cells with elongated mitochondria decreased to (16.0 ± 9.7% for 50 µM) while the 
number of cells with elongated mitochondria remained approximately the same for 
10 µM (19.0 ± 2.8%). The number for vector control however, reduced to 0% after 1 
hour. These results suggest that mdivi-1 at a concentration of 50 µM seem to 
increases the number of cells with elongated mitochondria following a treatment 
duration of 40 minutes (see Figure 4.5).  
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(C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D) 
Figure 4.4: Representative images of mitochondria in HL-1 cells treated with 
vehicle control at (A) time 0’ and (B) 40’ or 50 µM mdivi-1 at (C) time 0’ and 
(D) 40’.  
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Figure 4.5: Time & dose response changes in HL-1 mitochondrial morphology 
for 60 minutes. In HL-1 cells identified as containing predominantly fragmented 
mitochondria at the beginning of the experiment, treatment with mdivi-1 at 50 µM 
but not at 10 µM for 40 minutes significantly increased the proportion of cells 
displaying elongated mitochondria. N=4 experiments with 30 cells per treatment 
group. *P<0.05.  
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To verify the dosage and duration that we obtained, a separate set of HL-1 cells was 
incubated in either 0.1% DMSO as vehicle control or 50 µM mdivi-1 for a period of 
40 minutes and the percentage of cells with elongated mitochondria determined. 
Number of cells with elongated mitochondria at time 0’ was (24.2 ± 8.5% for vehicle 
control) and (25.9 ± 6.9% for 50 µM mdivi-1). After 40 minutes of 37°C incubation, 
the percentage increased to (67.3 ± 3.8% for 50 µM mdivi-1 vs. 29.0 ± 8.1% for 
vehicle control; n=4; *p<0.05 compared to vehicle control at 40 minutes) (see Figure 
4.6).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Effects of 40 minutes mdivi-1 treatment to the morphology of 
mitochondria in HL-1 cells. In HL-1 cells containing either fragmented or 
elongated mitochondria under basal conditions, treatment with mdivi-1 at 50 µM but 
not at 10 µM for 40 minutes also significantly increased the proportion of cells 
displaying elongated mitochondria. n 5 experiments with 80 cells per treatment 
group. *P<0.05 vs. time 0; †P<0.05 vs. control at 40 minutes.  
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4.5  Aim (3)  
 
To determine whether mitochondrial morphology can be modulated 
in endothelial cells using genetic manipulation 
 
In this part of the study, we aimed to investigate whether mitochondrial morphology 
can be manipulated in endothelial cells using the same mitochondrial-shaping 
proteins used for the HL-1 cells.  
 
 
4.5.1 Materials 
 
Plasmids included in the study of mitochondrial morphology of endothelial cells are 
similar to the study in HL-1 cells: an empty plasmid expression vector (RcCMV); 
one expressing mitofusin 1(pCB6-MYC-Mfn1); one expressing mitofusin 2 (pCB6-
MYC-Mfn2) 165; one containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the 
dominant negative mutant form of the mitochondrial fission protein Drp1 205; and 
one containing hFis1. Drp1K38A has a mutation in the GTPase domain that results in 
replacement of lysine 38 with alanine (designated as Drp1K38A), disabling its ability 
to induce mitochondrial fission by sequestering endogenous Drp1 181, 205. For the 
mitochondrial morphology studies a ratio of 1:2 mitochondria-targeted red 
fluorescent protein (mtRFP: Mitochondria-targeted dsRED) expression plasmid: 
plasmid of interest was included in order to permit visual assessment of 
mitochondrial morphology. All plasmids were a generous gift of Dr Luca Scorrano 
(Padova, Italy). Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-
Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 
10.0 (pH 7.4) was used as imaging buffer for confocal microscopy studies. 
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4.5.2 Experimental protocol for mitochondrial morphology 
determination 
 
Upon reaching confluency of around 50 – 60% (~24 hours after seeding), the cells 
were transfected with one of the following plasmids: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1 – fission-promoting protein 
 
mtRFP was always co-transfected to visualise the mitochondria as well as to indicate 
uptake and expression of the plasmids. Similar to the HL-1 study, this was the first 
time these proteins were overexpressed in endothelial cells. Therefore, we had to 
determine the optimum duration of plasmids expression to induce significant 
changes in mitochondrial morphology. Images of twenty randomly chosen cells were 
taken after 24 hours for one set of experiments and 48 hours for another set of cells 
and this was repeated for each group in at least four independent transfection 
experiments giving a total number of approximately 80 cells per treatment group. 
Three investigators, blinded to the initial treatment, independently assigned the cells 
as displaying either predominantly (>50%) elongated or (>50%) fragmented 
mitochondria, indicating that either mitochondrial fusion or fission, respectively, was 
the predominant process in that cell at that particular time, a method which has been 
adapted from a previously published study 165. 
 
 
 
4.5.3     Results 
 
 
 
Endothelial cells have a similar mitochondrial arrangement to the HL-1 cardiac cell 
line where the mitochondria resemble a network of elongated tubules (see Figure 
4.7).  
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Figure 4.7: Representative image of mitochondria in an endothelial cell with an 
overexpression of mtRFP under the confocal microscope.  
 
 
 
Nevertheless, endothelial cells are smaller and rounded hence the mitochondria are 
also much more tubular and elongated. It is precisely due to this fact that the 
percentage of cells with elongated mitochondria in cells with the vector control, 
RcCMV alone is considerably higher (65.3 ± 1.2%) than that of the HL-1 cells (45.7 
± 5.6%). Endothelial cells with elongated mitochondria which have an 
overexpression of Mfn1, Mfn2 or Drp1K38A were scored at 66.7 ± 5.7%, 67.5 ± 4.7% 
and 80.1 ± 1.3% respectively after 48 hours, none of which are significant compared 
to vector control. The overexpression of the fission protein, hFis1 however, 
significantly reduced the number of cells with elongated mitochondria to (17.7 ± 
7.5%; n=4; *p<0.05 compared to vector control; †p<0.05 compared to hFis1) (see 
Figure 4.8). 
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Figure 4.8: Effects of overexpression of different proteins to the morphology of 
mitochondria in endothelial cells over a period of 48 hours A trend of increasing 
cells with elongated mitochondria was seen for cells with an overexpression of 
Drp1K38A. Overexpression of the hFis1 at 48 hours fragments the mitochondria 
significantly N=4 experiments with 80 cells per group; *p < 0.05 compared to 
Vector Control; †p<0.05 compared to hFis1.  
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4.6       Aim (4)   
 
To determine whether elongated mitochondria can be detected in 
the adult cardiomyocytes 
 
Due to the difference in spatial arrangement of the mitochondria in adult 
cardiomyocytes, we aimed to investigate whether elongated mitochondria (> 2 µm) 
exists in adult cardiomyocytes using both confocal and electron microscopy in this 
section.  
 
 
4.6.1     Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 1 M in 100% DMSO and subsequently 
in saline to achieve a final concentration of 1 mM of mdivi-1 in 0.1% DMSO (~ 50 
µM mdivi-1 in plasma). 
 
 
4.6.2     Experimental protocol  
 
     For confocal microscopy studies on adult cardiomyocytes, ventricular 
cardiomyocytes were isolated from adult Sprague-Dawley rats by perfusion and 
digestion of ventricles with collagenase according to a previously described method. 
The cells were incubated with plating medium containing an appropriate titer of 
virus for 4 hours and were imaged 72 hours later. mtPA-GFP within a prespecified 
region of interest (ROI) was photoactivated by scanning adult rat cardiomyocytes 
with the 405-nm wavelength ultraviolet laser. The cell was immediately reimaged at 
488 nm, and the difference in the intensity of green fluorescence between the 2 
images before and after photoactivation was determined with Image J software 
(National Institutes of Health, Bethesda, Md). The spread of GFP beyond the ROI 
was expressed as a fold increase relative to the intensity within the ROI. Results 
were obtained from 30 randomly chosen cells isolated from 3 rats.  
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     For electron microscopy studies on adult cardiomyocytes, hearts were 
excised from C57BL/6 male mice after an intravenous injection of either vehicle 
control (0.1 mL of 0.1% dimethyl sulfoxide) or mdivi-1 (0.24 mg/kg) after 15 
minutes of stabilization (n=4 mice). The excised hearts were perfused with a fixative 
overnight, following which a 2-mm transverse slice, 3 mm from the apex, was 
obtained from each heart. Ultrathin sections were viewed with a Jeol 1010 transition 
electron microscope (Jeol Ltd, Warwickshire, UK). In 6 randomly selected electron 
micrographs of longitudinally arranged cardiomyocytes, the proportions of 
interfibrillar mitochondria with lengths that were <2, 2, or >2 µm (the length of a 
single sarcomere) were determined (see Figure 4.9). For each heart, the lengths of 
>500 to 600 interfibrillar mitochondria were assessed. 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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(B) 
 
 
 
(C) 
 
 
 
(D) 
 
 
Figure 4.9: (A) Representative electron micrograph depicting interfibrillar 
mitochondria with lengths that are     <2,     2, or      >2 µm (the length of a 
single sarcomere) in an adult cardiomyocyte. (B) Enlarged micrograph of a 
mitochondria < 2 µm in length. (C) Enlarged micrograph of a mitochondria 2 
µm in length.  (D) Enlarged micrograph of a mitochondria > 2 µm in length.                        
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4.6.3      Results 
 
Using confocal microscopy, we were able to visualise mitochondrial morphology in 
adult rat cardiomyocytes infected with adenoviral vector harbouring plasmids 
encoding for mitochondrial-targeted photo-activatable green fluorescent protein 
(mtPA-GFP) which is non-fluorescent but can be activated in a highly localised 
manner by scanning with the ultraviolet confocal laser line 405 nm. The photo-
activated GFP diffuses rapidly within the mitochondrial matrix to the full extent of 
the inner mitochondrial membrane and can therefore be used to “tag” individual 
mitochondria. Using this experimental approach, we were able identify elongated, 
interfibrillar mitochondria in primary adult cardiomyocytes. The length of these 
elongated mitochondria ranged from 2 to 6 µm (corresponding to 1 to 3 sarcomeres). 
In addition, we observed the spread of photo-activated mitochondrial GFP outside 
the initial area of photo-activation (2.17 ± 0.06-fold increase in the area of GFP; 
Figure 4.10). This finding was confirmed by observing the changes in mitochondrial 
membrane potential taking place in individual mitochondria in response to low levels 
of oxidative stress generated by laser scanning of TMRM. This results in 
“flickering” of individual mitochondria as they depolarise and repolarise, with 
coincident loss and re-accumulation of TMRM dye. Both mitochondrial membrane 
depolarisation and re-polarisation were found to occur in a synchronous fashion 
along the entire length of the elongated mitochondria. 
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Figure 4.10: Representative example of an adult rat ventricular cardiomyocyte 
expressing mitochondrial matrix targeted photo-activatable green fluorescent 
protein (mtPA-GFP). Photo-activation of mtPA-GFP within a Region of Interest 
(ROI) resulted in an increase in GFP fluorescence within the ROI. Interestingly, 
immediately following photo-activation, the GFP was found to spread beyond the 
boundaries of the ROI, demonstrating that individual mitochondria extend up to 5 
µm beyond the edge of the ROI. This indicates transfer of the GFP along the full 
length of elongated mitochondria which overlap the boundaries of the ROI, 
suggesting the presence of elongated mitochondria (extending 2-3 sarcomeres in 
length), which display exactly synchronous depolarisation and repolarisation in 
mitochondrial membrane potential in response to minimal oxidative stress 
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In the vehicle control-treated hearts, percentage of interfibrillar mitochondria with a 
longitudinal length less than 1 sarcomere (<2 µm), 1 sarcomere (=2 µm) and more 
than 1 sarcomere (>2 µm) is 82.0 ± 1.9%, 10.5 ± 1.8% and 7.3 ± 0.5% respectively. 
For the mdivi-1 treated hearts, percentage of interfibrillar mitochondria with a 
longitudinal length less than 1 sarcomere (<2 µm), 1 sarcomere (=2 µm) and more 
than 1 sarcomere (>2 µm) is 86.3 ± 2.7%, 8.0 ± 1.7% and 6.0 ± 1.7% respectively 
(see Figure 4.11).    
 
 
 
 
Figure 4.11: Proportion of varying lengths of interfibrillar mitochondria in non-
ischaemic hearts. The percentages of mitochondria of lengths < 1 sarcomere, equal 
to 1 sarcomere (1:1), or >1 sarcomere were determined by electron microscopy in 
hearts treated with placebo and mdivi-1 in vivo before ischaemia 
 
 
 
 
 
 
 
 
 
 
 
Length of interfibrillar mitochondria in non-ischaemic hearts 
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4.7       Aim (5)   
 
To determine whether the presence of elongated mitochondria can 
be increased in the adult cardiomyocytes  using pharmacological 
manipulation 
 
In this section, we aimed to determine whether the use of the small molecule 
inhibitor of Drp1 fission protein, mdivi-1 as a pharmacological agent inhibits 
mitochondrial fission in the adult cardiomyocytes.   
 
4.7.1      Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 1 M in 100% DMSO and subsequently 
in saline to achieve a final concentration of 1 mM of mdivi-1 in 0.1% DMSO (~ 50 
µM mdivi-1 in plasma). 
 
 
4.7.2      Experimental protocol  
 
Hearts were excised from C57BL/6 male mice, following an intravenous injection of 
either vehicle control (0.1ml of 0.1% DMSO) or mdivi-1 (0.24 mg/kg), after 15 
minutes stabilization followed by 20 minutes regional ischaemia (N=4 mice). The 
excised hearts were perfused with a fixative overnight, following which a 2mm 
transverse slice, 3mm from the apex, was obtained from each heart. Ultra-thin 
sections were viewed with a Jeol 1010 transition electron microscope (Jeol Ltd, UK). 
In six randomly selected electron micrographs of longitudinally-arranged 
cardiomyocytes, the proportion of interfibrillar mitochondria whose lengths were 
less than, equal to or greater than 2µm (the length of a single sarcomere) were 
determined. For each heart, the lengths of over 500-600 interfibrillar mitochondria 
were assessed. 
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4.7.3      Results 
 
 
The interfibrillar mitochondria for this section of the study derived from the outer 
layer of the tissue, where the ischaemic insult was less severe as the mitochondria in 
the inner section of the tissue was too severely disrupted for further analysis (see 
Figure 4.12).  
 
 
 
Figure 4.12: Representative electron micrographs depicting severely disrupted 
mitochondria and sarcomeres in the inner layer of the tissue.  
 
 
 
In vehicle control-treated hearts subjected to ischaemia, proportion of mitochondria 
less than 1 sarcomere was 85.6 ± 2.4% whereas the proportion was 67.5 ± 5.4% in 
mdivi-1 treated hearts subjected to ischaemia. The proportion of mitochondria 
equivalent to a sarcomere’s length was 10.9 ± 2.1% in vehicle control-treated hearts 
and 18.0 ± 2.7% in mdivi-1 treated hearts. The proportion of mitochondria longer 
than 1 sarcomere was 3.6 ± 0.5% in vehicle control-treated hearts whereas this 
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proportion increased significantly to 14.5 ± 2.8% in mdivi-1 treated hearts following 
ischaemia; n=4 animals per treatment group, *P<0.05 (see Figure 4.13 - 4.15).   
 
 
 
 
Figure 4.13: Representative electron micrographs depicting relatively 
fragmented mitochondria in a placebo-treated ischaemic adult murine heart.  
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(C) 
 
 
(D) 
 
Figure 4.14: (A) Representative electron micrographs depicting elongated 
mitochondria (marked with     ) in an mdivi-1–treated ischaemic adult murine 
heart. (B – D) Enlarged micrographs of elongated mitochondria (> 2 µm)  
 
 
 
 
 
 
 
 
 
 
 
 
2 
3 
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Figure 4.15: Proportion of varying lengths of interfibrillar mitochondria in 
ischaemic hearts. The percentages of mitochondria of lengths <1 sarcomere, equal 
to 1 sarcomere (1:1), or >1 sarcomere were determined by electron microscopy in 
hearts treated with placebo and mdivi-1 in vivo after ischaemia. After ischaemia, 
mdivi-1 pre-treatment increased the percentage of mitochondria >1 sarcomere 
compared with placebo. N=4 animals per treatment group. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
Length of interfibrillar mitochondria in ischaemic hearts 
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4.8      Discussion 
 
 
Modulation of mitochondrial morphology in HL-1 cells by genetic 
manipulation 
 
In this section of the study, we showed that overexpression of the fusion proteins 
Mfn1, Mfn2 and the mutant form of the fission protein, Drp1K38A over a duration of 
48 hours promotes mitochondrial elongation in the HL-1 cardiac cells. Conversely, 
hFis1 overexpression fragments the mitochondria.   
 
    Different transfection periods were tested before significant mitochondrial 
elongation in the cells could be observed. Overexpression for 24 hours failed to 
achieve significance in mitochondrial elongation, apart from Mfn2 (fusion) and 
hFis1 (fragmentation), compared to the significant mitochondrial elongation effects 
following 48 hours of overexpression. The use of mtRFP as a marker of successful 
transfection and overexpression of the respective plasmids in addition to illuminating 
the mitochondria has also been applied and verified by numerous different studies 87, 
164, 165, 169, 171, 466-469
 In our study, only the cells with the brightest mitochondria were 
selected to ensure impartiality and successful overexpression of the plasmids. 
 
    This study employed three blinded operators to determine the condition of the 
mitochondria in the cells in each image and categorise them as either predominantly 
elongated or fragmented. We initially thought of adding in another category of 
‘balanced state of elongation and fragmentation’ but refrained from doing so because 
the extra category would further complicate the analysis where there will be a natural 
tendency to group cells into this particular category. Furthermore, this analysis 
method of blinded operators was previously verified by the group of Luca Scorrano 
in Padova, Italy where they demonstrated that this technique produces similar results 
to a 3D computer re-modelling of the mitochondrial structure from z-stacks.  
 
    Studies in various cell types using the mitochondrial-shaping proteins showed 
varying durations of overexpression to achieve significant changes in the 
morphology of the mitochondria. Most of the studies conducted previously showed 
that the cells only require approximately 24 hours to show fusion / fragmentation 
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under the confocal microscope 165, 169, 171, 467. As an example, significant elongation 
of mitochondria was achieved after 24 hours of overexpression of OPA1 in MEFs 
165
. Fragmentation of the mitochondria in MEFs by overexpression of hFis1 was also 
observed after 24 hours 467. Nevertheless, the original morphology of the 
mitochondria plays a significant role in determining the results of manipulation 
where Cipolat et al claimed that the overexpression of OPA1, a known fusion-
promoter protein may actually fragment mitochondria in HeLa cells where the 
mitochondria are already in an interconnected network 165. Our study showed that 48 
hours is needed for adequate expression to achieve significant mitochondrial 
elongation. This is possibly due to the fact that the mitochondria in HL-1 cardiac 
cells are quite elongated to begin with. Therefore, more time is needed until a 
significant change can be detected in the morphology of the mitochondria of HL-1 
cells. The mitochondria in HL-1 cardiac cell line move constantly in a huge range 
thus increasing the time needed for neighbouring mitochondria to connect to each 
other to become elongated or ‘spaghetti-like’ or for longer mitochondria to 
sufficiently fragment to achieve an easily-recognisable fragmented state.  Another 
factor will probably be the dependency of transfection and expression of plasmids on 
the variability in cell types. One point worth mentioning here is that expression of 
the vector control, RcCMV alone seem to promote mitochondrial elongation to a 
certain extent, though not significantly compared to cell with mtRFP alone (data not 
shown). In the initial set of data for 24 hours of overexpression, Mfn1 was not used 
as the plasmid was only prepared at a later stage in my PhD. hFis1 fragmented the 
mitochondria but not significantly when compared to the vector control, RcCMV. 
The trend led us to believe that a longer duration of overexpression was much more 
feasible. Having successfully shown that mitochondrial morphology in the HL-1 
cardiac cell line can be manipulated using the mitochondrial-shaping proteins, we 
were interested to determine whether the morphology of mitochondria can also be 
manipulated using the pharmacological agent, mdivi-1 which supposes prevents 
fragmentation of mitochondria.  
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Modulation of mitochondrial morphology in HL-1 cells by 
pharmacological manipulation 
 
In order to effectively promote mitochondrial fusion or inhibit mitochondrial fission 
in adult cardiomyocytes or in an in vivo model, we have to employ the use of a drug 
because transfection of cardiomyocytes is not easily performed and viruses have to 
be used. Furthermore, the overexpression of a certain protein in a whole mouse is not 
easily achieved. We were fortunate in the sense that a new drug that inhibits 
mitochondrial fission, mdivi-1 was discovered at the time this study was carried out 
in 2008. The mdivi-1 drug was discovered following a screening of the yeast library 
by Cassidy-Stone et al in 2008 418. The mode of action for this drug was by 
inhibition of the fission protein Drp1. Previous studies of Cassidy-Stone et al., 
Brooks et al., and Cui et al have shown that the drug promotes mitochondrial fusion 
in mammalian COS 418, rat proximal tubular cells (RPTC) 215 and neuronal cell lines 
470
. However, this was not shown before in a cardiac cell line. A time and dose 
response was performed and we found that the dosage of 10 µM did not promote 
mitochondrial fusion compared to the 50 µM concentration. We also tried 100 µM 
accordingly but we had a problem in dissolving the drug at 100 µM. We were still 
able to detect crystal-like structures under the microscope using 100 µM of the drug. 
The 50 µM concentration correlates with the dosage used in the study of Cassidy-
Stone and co-workers 418. The study of Brooks et al. used 50 mg/kg mdivi-1 in 
C57BL/6 mice to prevent mitochondrial fragmentation and reduce damage in renal 
tissue 215. Cui et al., gave a treatment of 10 µM mdivi-1 in a neuronal cell line for up 
to 24 hours to rescue the adverse effects of mitochondrial fragmentation 470. The time 
response study carried out in this section showed an optimum duration of 40 minutes 
of incubation prior to confocal imaging. The different cell types used may underlie 
the difference in treatment durations of the various studies. We have tried extending 
the duration of drug incubation to 1 hour but we found that the mitochondria of the 
cells start to fragment, possibly due to the cold temperature in the confocal room as 
the experiment was carried out with the cover slips on the metal rings. A better 
alternative will be to conduct the experiments using the heated perfusion chamber 
that we have for this particular time response study.   
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    To further verify our results, we determined the number of cells with 
predominantly elongated mitochondria before and after drug treatment for the 
stipulated duration of 40 minutes and we found that the proportion of cells with 
elongated mitochondria following treatment with 50 µM mdivi-1 increased 
significantly compared to using the vector control alone or with 10 µM mdivi-1. 
Nevertheless, we discovered that compared to genetic interventions such as 
overexpression of mitochondrial fusion-promoting proteins, the mitochondrial 
elongation effect of the mdivi-1 drug is slightly weaker. This is not surprising as the 
drug treatment is considered an ex vivo effect whereas the plasmids transfection goes 
directly into the nucleus where the proteins are expressed and acts directly on the 
mitochondria. Furthermore, the duration of plasmid transfection (48 hours) is longer 
than the drug treatment protocol (40 minutes). The concentration of the drug (50 
µM) and cell type variability are also important factors to explain this phenomenon.  
 
Modulation of mitochondrial morphology in endothelial cells by genetic 
manipulation 
 
 
    Endothelial cells were used because it serves as an alternative to adult 
cardiomyocytes and easier to isolate. The mitochondria in endothelial cells come in a 
relatively uniform network of tubular threads. The arrangement of the mitochondria 
in endothelial cells is similar to the HL-1 cells with the significant difference being 
that the cells are smaller and rounder in shape compared to the HL-1 cells. 
 
    As mentioned in the previous section, due to the highly tubular arrangement 
of the endothelial mitochondria, which is even more than the HL-1 cells (~70% in 
endothelial cells compared to ~50% in the HL-1 cells), it has proved to be quite 
difficult to enhance further elongation of the endothelial mitochondria by genetic 
manipulation. We did not detect any significant mitochondrial elongation following 
48 hours of overexpression. Nevertheless, we managed to fragment the mitochondria 
significantly with an overexpression of the hFis1 plasmid. Compared to the 
mitofusins, inhibiting fragmentation with the mutant form of the fission protein, 
Drp1K38A appear to slightly increase the number of cells with elongated 
mitochondria, albeit not significant.  
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    To rectify the issue of not detecting significant mitochondrial fusion in the 
endothelial cells, we might need to subject the endothelial cells to a brief period of 
simulated ischaemia to induce some mitochondrial fragmentation before determining 
the effects of different fusion proteins in maintaining the fused state of the 
mitochondria. However, this aspect will need further investigation as to the optimum 
duration of simulated ischaemia and the requirement of DOG.  
 
 
Detecting the presence of elongated mitochondria in adult 
cardiomyocytes 
 
 
    Following the demonstration that mitochondrial elongation can be promoted 
in the HL-1 cardiac cell line, we aimed to investigate whether elongated 
mitochondria exist in the adult cardiomyocyte where the spatial arrangement of the 
mitochondria is totally different from a cardiac cell line. According to the studies of 
Shimada et al in 1984, the interfibrillar mitochondria are positioned along the 
myofibril, with the length of each mitochondria less than or approximately the length 
of a sarcomere (~2 µm) 471. Nevertheless, there were also studies by Sun et al as 
early as 1969 465 and Bakeeva et al in 1983 472 where they detected mitochondria 
with lengths spanning to 7 sarcomeres in myocytes. Certain injury or stress such as 
hypoxia also causes the formation of giant mitochondria, the underlying mechanisms 
or function of which are unknown 473, 474. Using electron microscopy, we detected 
mitochondria longer than 2 µm in the interfibrillar area, albeit we did not detect an 
increase in the number of interfibrillar mitochondria longer than a sarcomere in the 
mdivi-1 treated hearts. The groups of Hom et al and Beraud et al have maintained the 
claim that mitochondria in the adult cardiomyocytes are very limited in movement 
and hence do not experience fusion and fission 154, 414. Yet, the presence of 
mitochondrial-shaping proteins were successfully detected using Western Blots 
leading us to believe that fusion and fission will still occur, albeit to a lesser extent 
compared to a cell line 154. The discrepancy in opinions regarding fusion and fission 
in myocytes lies in the fact that mathematical simulations were used in certain 
studies to projectile the possible outcomes of fusion and fission compared to 
conventional imaging techniques combined with fluorescence proteins to determine 
mitochondria size or length.  
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Investigating the effects of mdivi-1 on mitochondria morphology in adult 
cardiomyocytes following ischaemia 
 
In this section of the study, we investigated whether the mdivi-1 drug will produce 
the same elongation effect as can be detected in the HL-1 cardiac cell line. We 
injected C57BL mice with the mdivi-1 drug and harvested the hearts for electron 
microscopy. Based on the previous section, the proportion of elongated mitochondria 
was not significantly different from the control non-treated hearts, even with 
different methods of quantification. Therefore, we decided to test the same protocol, 
but with the presence of stress in the form of a short period of simulated ischaemia to 
determine the possibility that the drug may be more potent under stress. We found 
for the first time that the proportion of elongated interfibrillar mitochondria longer 
than 2 µm was significantly increased following treatment of the mdivi-1 drug before 
20 minutes of simulated ischaemia in the murine heart. This may be due to several 
reasons: 
1) The arrangement of the mitochondria in adult myocytes is different from the 
cardiac cell line. Percentage of elongated mitochondria in the adult myocyte 
is very low and it might prove to be difficult to increase the percentage to a 
significant level in basal non-ischaemic hearts.  
2) In the settings of adult myocytes, the mode of action of the mdivi-1 drug may 
be more obvious following stress to induce mitochondrial fragmentation. We 
chose ischaemia as it is directly linked to IRI and ischaemia has been proven 
to induce mitochondrial fragmentation. With non-excessive, moderate 
fragmentation and disruption to the mitochondria, we were then able to detect 
a difference in number of elongated interfibrillar mitochondria against total 
interfibrillar mitochondria. 
3) The combined duration of drug treatment following ischaemia (15 minutes 
stabilisation + 20 minutes ischaemia) is longer than the basal non-treated 
hearts (15 minutes stabilisation only), hence allowing more time for the drug 
to act. 
 
It should be noted that even following ischaemia, the mitochondria in the inner area 
of the heart when ischaemia is the most severe, are too disrupted to be taken into 
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account in this study. We therefore, included only the mitochondria in the outer layer 
of the heart slices in this study. This area can be identified by the higher proportion 
of longitudinal mitochondria available. It would also be interesting to determine the 
effects of this drug on the number of elongated mitochondria in basal non-treated 
hearts for the whole duration of 35 minutes without ischaemia. In the settings of 
renal ischaemia reperfusion, Brooks et al showed the use of mdivi-1 reduced IR 
damage to renal tissues and cellular apoptosis, albeit in a different drug treatment 
and IR protocol in which mdivi-1 was administered to the C57BL/6 mice 1 hour 
prior to 30 minutes of ischaemia followed by 48 hours of reperfusion 215. The 
proportion of mitochondria equivalent to a single sarcomere (2 µm) was increased in 
mdivi-1 treated hearts following ischaemia compared to the vehicle control-treated 
hearts while the proportion of mitochondria less than a sarcomere was reduced in 
mdivi-1 treated hearts. These two observations may provide a notion of the effects of 
mdivi-1 in inhibition of fragmentation of mitochondria but the values are not 
significant compared to the vehicle control-treated hearts.   
 
 
 
 
4.9       Conclusion 
 
In this chapter of the thesis, we have demonstrated that mitochondrial morphology 
can be modulated in cardiac cells including adult cardiomyocytes, albeit to varying 
degrees. The arrangement of the mitochondria in the different cell types may 
influence the manipulation used, e.g. methodology, duration and degree of 
manipulation. In the next chapter, we will be exploring whether modulation of 
mitochondrial morphology protects the cardiac cells against simulated ischaemia-
reperfusion.   
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5.1  Introduction 
 
Myocardial reperfusion has long been known to generate a paradoxical situation in 
which early coronary artery reperfusion by thrombolysis or primary percutaneous 
coronary intervention (PCI) is mandatory for limiting infarct size but at the same 
time constitutes a detrimental stage at which most cardiac cells die 12, 16, 23-25, 49, 231, 
342, 475
. The cause of reperfusion injury as an effect arising from the prolonged 
ischaemic period or the stimulus of reperfusion itself has been under debate 22, 342. 
The state of mitochondria has been shown to impact on cell fate following IR. 
Multiple parameters such as levels of intramitochondrial calcium, ROS, ATP and 
hydrogen ions at the onset of reperfusion determine subsequent condition of the 
mitochondria and the host cell 31, 145, 380, 391, 400, 401, 452. Previous studies have shown 
that mitochondrial fragmentation predisposes the cells to cell death, either by 
apoptosis or necrosis 190, 207, 209, 211, 215, 412, 476. Fragmentation of the mitochondria can 
be caused by calcium overload, particularly during ischaemia when excessive 
calcium is transferred from the ER to the mitochondria and the calcium-sensitive 
phosphatase, calcineurin is activated hence promoting Drp1 translocation to the 
mitochondria and subsequent fragmentation of the mitochondria 189. The site of 
translocation of Drp1 on the mitochondria has been identified as hFis1 178. 
Nevertheless, there have been studies demonstrating the actions of Drp1 and hFis1 to 
be independent of each other. Release of cytochrome c from the intermembrane 
space of the mitochondria causes cell death. In the settings of IR, the opening of the 
mPTP is a crucial mediator of cell death. Opening of the mPTP in the mitochondria 
will lead to uncoupling of oxidative phosphorylation, reversal of ATP synthase, 
mitochondrial swelling and release of the pro-apoptotic cytochrome c 35, 52, 61, 63, 88, 
232, 368, 377, 409, 452, 477-479
. Therapeutic interventions aimed at reducing cell death 
following IR have focused on activation of the endogenous cardioprotective 
strategies such as the RISK pathway. Indeed, the drugs formulated such as 
erythropoietin (EPO) 480, 481, insulin 260, 305, 337, 482, 483 and statins 256, 261, 484, 485 have 
been shown to activate the RISK pathway. This cascade of pro-survival kinases 
(including Akt and ERK 1/2) functions to phosphorylate different downstream 
effectors which will culminate in the inhibition of the opening of the mPTP and 
prevention of release of cytochrome c 229, 258, 308, 482, 486. Along the same train of 
thought, we aim to investigate whether promoting mitochondrial fusion or inhibiting 
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mitochondrial fragmentation using genetic or pharmacological manipulations can 
lead to enhanced cell survival in the settings of IR.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sang Bing, Ong 
 211
5.2  Hypothesis & Objectives 
    Modulation of mitochondrial morphology protects the heart      
    against ischaemia-reperfusion injury 
 
In the first part of the study, we investigated whether the promotion of mitochondrial 
fusion in the HL-1 cardiac cell line by genetic or pharmacological manipulation can 
protect the cells against sIR. A time response was carried out in which the HL-1 cells 
with an overexpression of fusion proteins or treated with the mdivi-1 drug were 
subjected to different durations of simulated ischaemia and reoxygenation to 
determine the optimum percentage of cell death in cells over-expressing the vector 
control. 
 
    In the second part of the study, we tried to investigate the response of the 
endothelial cells over-expressing the fusion proteins towards sIR. A time response 
was also carried out.  
 
    We also aimed to investigate the effects of inhibiting mitochondrial 
fragmentation on the survival response of primary cardiomyocytes toward sIR. A 
previously established model of sIR in primary mouse myocytes was used for this 
study where mdivi-1 as an inhibitor of the Drp1 fission protein was used to treat the 
cells for the whole duration of sIR. 
 
    Similarly, mdivi-1 drug was used in the settings of sIR in an in vivo mouse 
model where the effects of inhibiting mitochondrial fragmentation was correlated 
with infarct size reduction as an endpoint.  
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5.3 Aim (1) 
 
To determine the changes in mitochondrial morphology in HL-1 cardiac   
cells following sIR 
 
Prior to determining the impact of changes in mitochondrial morphology to cell 
survival, we need to determine the resulting changes in mitochondrial morphology in 
cells subjected to simulated ischaemia-reperfusion. Using HL-1 cells as a basic 
model in this section, we aimed to investigate the differences in mitochondrial 
morphology in HL-1 cells transfected with either the empty vector control or the 
dominant negative form of the Drp1 fission protein, Drp1K38A following simulated 
ischaemia-reperfusion.  
 
5.3.1 Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); and one containing 
Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant form of the 
mitochondrial fission protein Drp1 205. Drp1K38A has a mutation in the GTPase 
domain that results in replacement of lysine 38 with alanine (designated as Drp1K38A), 
disabling its ability to induce mitochondrial fission 205. For mitochondrial 
morphology, a ratio of 1:2 mitochondria-targeted red fluorescent protein (mtRFP: 
Mitochondria-targeted dsRED) expression plasmid: plasmid of interest was included 
in order to permit visual assessment of mitochondrial morphology. All plasmids 
were from Dr Luca Scorrano (Padova, Italy). To simulate ischaemia, the cells were 
perfused with hypoxic ischaemic buffer specific for real-time imaging experiments 
(in mM: NaCl 125, KCl 8, KH2PO4 1.2, MgSO4 1.25, CaCl2 1.2, NaHCO3 6.25, Na-
lactate 5.0, HEPES 20.0, 2-deoxyglucose 2.5, pH 6.6) equilibrated with 95% N2–5% 
CO2. Normoxic buffer specific for real-time imaging experiment (in mM: NaCl 110, 
KCl 4.7, KH2PO4 1.2, MgSO4 1.25, CaCl2 1.2, NaHCO3 25.0, glucose 15.0, HEPES 
20.0, pH 7.4) equilibrated with 95% O2-5% CO2. 2-deoxyglucose (2-DOG) was 
dissolved in water to achieve a working concentration of 5 M. 
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5.3.2 Experimental Protocol 
 
HL-1 cells containing predominantly (>50%) elongated mitochondria under basal 
conditions were identified and subjected to 120 minutes of  simulated ischaemia and 
30 minutes of simulated reperfusion (SIRI) with a Warner PM-2 heated perfusion 
chamber (Harvard Apparatus, Holliston, Mass) mounted on the confocal microscope. 
The real-time effects of SIRI on changes in mitochondrial morphology were 
determined in HL-1 cells over-expressing red fluorescent protein targeted to the 
mitochondrial matrix and either empty vector or Drp1K38A. Over 3 independent 
experiments, 10 cells for each treatment group were analysed.  
 
5.3.3      Results 
 
By the end of the simulated ischaemia period, the percentage of cells displaying 
elongated mitochondria had fallen from 100% to 11.0 ± 11.0% in control cells and to 
91.0 ± 5.6% in the Drp1K38A-transfected cells (N=3 experiments with 7 to 10 cells 
per treatment group; *P<0.05), a difference that persisted into simulated reperfusion 
(see Figure 5.1 & 5.2).  
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Figure 5.1: Representative confocal microscope images depicting HL-1 cells 
subjected to SIRI. The mitochondria in the control cell undergo fission; the 
mitochondria in the cell transfected with Drp1K38A are maintained in an 
elongated formation. 
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Figure 5.2: Changes in HL-1 mitochondrial morphology following sIR in the 
presence of 2-deoxyglucose (2-DOG). HL-1 cells containing predominantly (>50%) 
elongated mitochondria under basal conditions were identified and subjected to SIRI. 
By 2 hours of simulated ischaemia, the majority of control cells displayed 
fragmented mitochondria, whereas in those cells transfected with Drp1K38A, 
mitochondrial fission induced by simulated ischaemia was largely prevented. N=3 
experiments with 7 to 10 cells per treatment group. *P<0.05. 
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5.4       Aim (2)  
 
To determine whether modulating mitochondrial morphology by genetic 
manipulation protects the HL-1 cells against sIR 
 
In this section of the study, we aimed to determine whether manipulation of 
mitochondrial morphology in HL-1 cells protects against simulated ischaemia-
reperfusion.  
 
5.4.1 Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); one expressing mitofusin 
1(pCB6-MYC-Mfn1); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; one 
containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant 
form of the mitochondrial fission protein Drp1 205; and one containing hFis1. 
Drp1K38A has a mutation in the GTPase domain that results in replacement of lysine 
38 with alanine (designated as Drp1K38A), disabling its ability to induce 
mitochondrial fission 205. For the survival assay, a ratio of 1:2 plasmid enhanced 
green fluorescent protein (pEGFP) (Clontech) expression plasmid: plasmid of 
interest was included in order to permit detection of cells with plasmids of interest. 
All plasmids were a generous gift of Dr Luca Scorrano (Padova, Italy). Simulated 
ischaemia was performed in hypoxic ischaemic buffer comprising (in mM): KH2PO4 
1.0, NaHCO3 10.0, MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 
and NaLactate 20 at pH 6.2, bubbled with 100% nitrogen. Reoxygenationwas 
performed using Claycomb medium. Propidium iodide (Sigma UK) was dissolved in 
distilled water and added to the Claycomb medium such that the final concentration 
was 3 uM.  
 
 
5.4.2      Experimental protocol 
 
 
Next, we investigated the role of the fusion proteins in protecting the HL-1 
cardiomyocytes against simulated ischaemia-reperfusion injury. My first objective 
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was to characterise a suitable model of simulated ischaemia-reperfusion injury given 
that our laboratory had not previously established such a model in HL-1 cells. 
 
The HL-1 cells transfected with plasmids encoding for the different proteins 
were initially subjected to 24 hours of hypoxia followed by 1 hour reoxygenation: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1` - fission-promoting protein 
 
 However, it was found that the hypoxia was too severe and the percentage of 
total cell death as determined by PI staining was too high (>90%) hence rendering 
the effects of the overexpressed proteins insignificant. Therefore, the hypoxia period 
was reduced from 24 hours to 16 hours and 12 hours followed by 1 hour 
reoxygenation. A cell count was performed to determine the number of dead 
transfected cells against live transfected cells. Dead cells transfected with the desired 
proteins were represented as green cells with a red spot in the nucleus while live 
transfected cells were green cells without any red spot (see Figure 5.3). Cell death 
was reduced to approximately 40% for 12 hours hypoxia followed by 1 hour 
reoxygenation. 
 
 
 
Figure 5.3: Image of cells stained using 3 µM PI under the fluorescent 
microscope. Following 12 hours of hypoxia and 1 hour of reoxygenation, cells 
were stained with PI to determine number of dead transfected cells (green + 
red) against live transfected cells (green).  
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5.4.3      Results 
 
In cells with an overexpression of fusion proteins, 24 hours of simulated ischaemia 
followed by 1 hour of reoxygenation in the presence of 3 µM PI saw a cell death of 
48.6 ± 3.1% in vector control, 33.8 ± 2.5% in Mfn1, 40.2 ± 2.1% in Mfn2, 42.8 ± 
2.8% in Drp1K38A and 45.7 ± 7.2% in hFis1. In this model, Mfn1 overexpression 
reduced cell death significantly compared to the vector control. N=4 experiments 
with 80 cells per treatment group. *P<0.05 vs. control (see Figure 5.4). 
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Figure 5.4: Percentage of HL-1 cell death following 24 hours simulated 
ischaemia and 1 hour reoxygenation. Only the overexpression of Mfn1 protects 
the HL-1 cells in this model. N=4 experiments with 80 cells per treatment group. 
*P<0.05 vs. control 
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Overexpression of the fusion proteins enhanced the resistance of HL-1 cells to 12 
hours of simulated ischaemia followed by 1 hour reoxygenation with a reduction in 
cell death; Mfn1, 11.6 ± 3.0 %, Mfn2, 16.2 ± 3.9% and Drp1K38A 12.1 ± 2.9% vs.. 
41.8 ± 4.1% for vector control, N=4 experiments with 80 cells per treatment group. 
*P<0.05 vs. control; †p<0.05 compared to hFis1. Overexpression of the hFis1 
increases the cell death significantly to 65.5 ± 2.1% vs. 41.8 ± 4.1% for vector 
control; N=4 experiments with 80 cells per treatment group. *P<0.05 vs. control (see 
Figure 5.5).  
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Figure 5.5: Cell death in HL-1 cells transfected with plasmids encoding for 
different proteins promoting mitochondrial fusion against empty vector, 
RcCMV following 12 hours hypoxia and 1 hour reoxygenation. Overexpression 
of HL-1 cells with Mfn1, Mfn2, or Drp1K38A decreased cell death after a period of 
SIRI, whereas overexpression with hFis1 increased cell death compared with 
control; n = 4; *p < 0.05 compared to vector control; †p<0.05 compared to hFis1.   
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In order to test a longer period of reoxygenation to mimic the clinical settings, cell 
death following 24 hours of reoxygenation was also investigated. Cell death for the 
vector control was lower (29.6 ± 4.2%) than the data set for 1 hour reoxygenation 
(41.8 ± 4.1%). Only cells with an overexpression of Mfn1 has a significant reduction 
of cell death (14.0 ± 2.2%; n=4; *p<0.05 compared to vector control; †p<0.05 
compared to hFis1) while Mfn2 has a percentage of cell death at (19.9 ± 3.1%), 
Drp1K38A at (14.0 ± 2.8%; n=4; †p<0.05 compared to hFis1) and hFis1 at (36.0 ± 
4.6%) (see Figure 5.6).   
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Figure 5.6: Cell death in HL-1 cells transfected with plasmids encoding for 
different proteins promoting mitochondrial fusion against empty vector, 
RcCMV following 12 hours hypoxia and 24 hour reoxygenation. Overexpression 
of HL-1 cells with Mfn1 decreased cell death after a period of SIRI; n = 4; *p < 0.05 
compared to vector control; †p<0.05 compared to hFis1 
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5.5      Aim (3)  
 
To determine whether modulating mitochondrial morphology by 
pharmacological manipulation protects the HL-1 cells against sIR 
 
Using the small molecule inhibitor of Drp1, mdivi-1 as a pharmacological agent to 
inhibit mitochondrial fission, we investigated the effects of inhibiting mitochondrial 
fission in HL-1 cells in protecting against simulated ischaemia-reperfusion.  
 
 
5.5.1     Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 10 mM and 50 mM and subsequently 
in hypoxic ischaemic buffer comprising (in mM): KH2PO4 1.0, NaHCO3 10.0, 
MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 and NaLactate 20 at 
pH 6.2, bubbled with 100% nitrogen and Claycomb medium to achieve a final 
concentration of 10 µM and 50 µM.  
 
 
5.5.2     Experimental protocol  
 
HL-1 cells were pre-treated with either one of the following treatments: 1) vehicle 
control; 2) 10 µM mdivi-1 or 3) 50 µM mdivi-1 for 40 minutes in the 37C incubator 
and subjected to simulated ischaemia for 12 hours in the presence of hypoxic buffer 
followed by 1 hour reoxygenation with Claycomb medium. The hypoxic buffer and 
Claycomb medium used for reoxygenation will contain whichever treatment used 
prior to simulated ischaemia. 
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5.5.3     Results 
 
 
HL-1 cells that were incubated for 40 minutes in the presence of 50 µM of mdivi-1 
followed by 12 hour hypoxia and 1 hour reoxygenation in the presence of 50 µM of 
mdivi-1 have a reduced cell death (20.5 ± 3.4% vs.. 36.8 ± 5.8% for RcCMV, n = 4; 
p<0.05) (see Figure 5.7). Cells that were treated with 10 U/ml EPO for the same 
period of time also showed a significant reduction in cell death (17.0 ± 2.7% vs.. 
43.1 ± 2.7% for cells with normal Krebs) (see Figure 5.7).    
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Figure 5.7: Cell death in HL-1 cells treated with different drugs following 12 
hours hypoxia and 1 hour reoxygenation. Treatment with mdivi-1 at 50 but not 10 
µM for 40 minutes resulted in less cell death after SIRI. N=4 experiments with 80 
cells per treatment group. *P<0.05 compared to vehicle control; †p<0.05 compared 
to hFis1. 
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5.6    Aim (4)  
 
To determine whether modulating mitochondrial morphology by genetic  
manipulation protects the endothelial cells against sIR 
 
In this section, we investigated whether manipulation of mitochondrial morphology 
in endothelial cells using the mitochondrial-shaping proteins protects against sIR.   
 
 
5.6.1  Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); one expressing mitofusin 
1(pCB6-MYC-Mfn1); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; one 
containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant 
form of the mitochondrial fission protein Drp1 205; and one containing hFis1. 
Drp1K38A has a mutation in the GTPase domain that results in replacement of lysine 
38 with alanine (designated as Drp1K38A), disabling its ability to induce 
mitochondrial fission 205. For the survival assay, a ratio of 1:2 plasmid enhanced 
green fluorescent protein (pEGFP) (Clontech) expression plasmid: plasmid of 
interest was included in order to permit detection of cells with plasmids of interest. 
All plasmids were a generous gift of Dr Luca Scorrano (Padova, Italy). Simulated 
ischaemia was performed in hypoxic ischaemic buffer comprising (in mM): KH2PO4 
1.0, NaHCO3 10.0, MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 
and NaLactate 20 at pH 6.2, bubbled with 100% nitrogen. Reoxygenationwas 
performed using Claycomb medium. Propidium iodide (Sigma UK) was dissolved in 
distilled water and added to the Claycomb medium such that the final concentration 
was 3 uM. 2-deoxyglucose (2-DOG) was dissolved in water to achieve a working 
concentration of 5 M.  
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5.6.2      Experimental protocol 
 
 
Next, we investigated the role of the fusion proteins in protecting the endothelial 
cells against simulated ischaemia-reperfusion injury. My first objective was to 
characterise a suitable model of simulated ischaemia-reperfusion injury given that 
our laboratory had not previously established such a model in endothelial cells. 
 
The endothelial cells transfected with plasmids encoding for the different 
proteins were initially subjected to 24 hours of hypoxia followed by 1 hour 
reoxygenation: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1  – fission-promoting protein 
 
Following 48 hours after transfection, the cells were subjected to either one of the 
following IR protocols: 
 
1. 12 hours of simulated ischaemia: 1 hour reoxygenation 
2. Overnight serum starvation: 12 hours of simulated ischaemia: 1 hour 
reoxygenation 
3. 24 hours serum starvation: 12 hours of simulated ischaemia: 1 hour 
reoxygenation 
4. 24 hours serum starvation: 12 hours of simulated ischaemia with 2.5 mM 
DOG: 1 hour reoxygenation 
5. 24 hours serum starvation: 12 hours of simulated ischaemia with 2.5 mM 
DOG: 24 hour reoxygenation 
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5.6.3    Results 
 
In the model of 24 hours of serum starvation followed by 12 hours of simulated 
ischaemia in the presence of 2.5 mM 2-DOG and 1 hour reoxygenation, over- 
expression of the fusion proteins in endothelial cells reduced cell death significantly 
in cells with Mfn1 and Mfn2 (29.5 ± 4.2% & 28.3 ± 4.5% respectively vs. 48.5 ± 
2.9% for vector control); n = 4; *p < 0.05 compared to vector control. 
Overexpression of hFis1did not kills the cells significantly (51.5 ± 7.4%) (see Figure 
5.8).  
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Figure 5.8: Cell death in endothelial cells transfected with plasmids encoding 
for different proteins promoting mitochondrial fusion against empty vector, 
RcCMV following 24 hours serum starvation, 12 hours simulated ischaemia in 
the presence of 2.5 mM 2-DOG and 1 hour reoxygenation. Overexpression of 
Mfn1 and Mfn2 decreased cell death after a period of SIRI; n = 4; *p < 0.05 
compared to vector control. 
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Using a model of 24 hours of serum starvation followed by 12 hours of simulated 
ischaemia in the presence of 2.5 mM 2-DOG and 24 hours reoxygenation, 
overexpression of Mfn1 lost its cardioprotective effect (24.3 ± 2.6%) compared to 
vector control (34.8 ± 5.4%). Overexpression of Mfn2 still protects significantly 
(18.4 ± 1.8% vs. 34.8 ± 5.4% for control; n = 4; *p < 0.05) compared to vector 
control while cells with an overexpression of hFis1 showed a percentage of cell 
death at 44.4 ± 5.0% (see Figure 5.9).  
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Figure 5.9: Cell death in endothelial cells transfected with plasmids encoding 
for different proteins promoting mitochondrial fusion against empty vector, 
RcCMV following 24 hours serum starvation, 12 hours simulated ischaemia in 
the presence of 2.5 mM 2-DOG and 24 hour reoxygenation. Overexpression of 
Mfn2 decreased cell death after a period of SIRI; n = 4; *p < 0.05 compared to 
vector control. 
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5.7    Aim (5)  
 
To determine whether modulating mitochondrial morphology by 
pharmacological manipulation protects adult cardiomyocytes against sIR 
 
In this section, we investigated whether inhibiting mitochondrial fission in adult 
cardiomyocytes, using mdivi-1 as a pharmacological Drp1 inhibitor, protects adult 
cardiomyocytes against sIR. 
 
 
5.7.1       Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 10 mM and 50 mM and subsequently 
in hypoxic ischaemic buffer comprising (in mM): KH2PO4 1.0, NaHCO3 10.0, 
MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 and NaLactate 20 at 
pH 6.2, bubbled with 100% nitrogen and cardiomyocyte growth medium (M199 
buffer: BSA 2 mg/ml, creatine 5 mM, taurine 5 mM, carnitine hydrochloride 1.6 mM, 
Pencillin-Streptomycin 1%) to achieve a final concentration of 10 µM and 50 µM.  
 
 
 
5.7.2       Experimental protocol  
 
Ventricular cardiomyocytes were isolated from adult C57BL/6 male mice by 
perfusion and digestion of ventricles with collagenase, according to a previously 
described method 487. The cells were then randomised to receive pre-treatment with 
either vehicle control or mdivi-1 treatment at either 10µM or 50µM (N>250 cells per 
experiment for 4 experiments), before being subjected to 45 minutes of simulated 
ischaemia followed by 30 minutes of simulated reperfusion, at the end of which cell 
death was measured by propidium iodide staining 487. 
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5.7.3      Results 
 
 
In this specific model of 45 minutes simulated ischaemia against 30 minutes 
reoxygenation, myocytes treated with 50 µM mdivi-1 throughout the whole duration 
of sIR have a significantly reduced percentage of cell death (33.7 ± 1.9% vs. 46.0 ± 
1.1% for vehicle control; N=4experiments with 20 cells per treatment group; 
*P<0.05). Myocytes treated with 10 µM mdivi-1 showed a percentage of cell death at 
48.2 ± 3.2% while treatment with insulin reduces the percentage of myocytes cell 
death significantly to 25.9 ± 3.3% ; N=4 experiments with 20 cells per treatment 
group; *P<0.05 (see Figure 5.10).  
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Figure 5.10. Cardiomyocyte death following 45 minutes simulated ischaemia 
and 30 minutes reoxygenation. Pre-treatment of adult rat cardiomyocytes with EPO 
or mdivi-1 at 50 but not 10 mol/L reduced cell death after an episode of SIRI. N=4 
experiments with 20 cells per treatment group. *P<0.05. 
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5.8   Aim (6)  
 
To determine whether modulating mitochondrial morphology  by 
pharmacological manipulation reduces infarct size in the in vivo murine 
model of IR 
 
In this section, we investigated whether the pro-survival effects of mdivi-1 by 
inhibition of mitochondrial fragmentation in adult cardiomyocytes can be 
extrapolated to the settings of the in vivo animal model of IR. 
 
 
5.8.1      Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 10 mM and 50 mM and subsequently 
in saline to achieve a final concentration of 10 µM and 50 µM 
 
 
 
5.8.2      Experimental protocol 
 
Mice were randomly assigned to receive by intravenous injection either vehicle 
control (0.1 mL of 0.1% dimethyl sulfoxide) or mdivi-1 (at either 0.24 or 1.2 mg/kg, 
doses that were equivalent to the ex vivo concentrations of 10 and 50 µmol/L, 
respectively) 15 minutes before myocardial ischaemia (n=6 mice per treatment 
group). 
 
 
 
5.8.3       Results 
 
There were no significant differences in mean arterial blood pressure or heart rate 
over left ventricular volume with mdivi-1 treatment in the in vivo murine heart 
compared with control (see Figure 5.11). 
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Figure 5.11: Mean arterial blood pressure (MABP) and Heart Rate (HR) for the 
mice.  
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Area-at-risk for the mice injected with the vehicle control, 10 µM mdivi-1 and 50 
µM mdivi-1 are 53.6 ± 5.6%, 55.8 ± 3.9% and 54.5 ± 6.5% respectively (see Figure 
5.12) .   
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Figure 5.12: Area at risk over left ventricular volume with mdivi-1 treatment in 
the in vivo murine heart compared with control.  
 
 
Infarct sizes measured by TTC staining following sIR (see Figure 5.13) were 
recorded at 48.5 ± 4.5% for vehicle control, 41.9 ± 4.9% for 10 µM mdivi-1 and a 
significant reduction to 21.0 ± 2.2% for 50 µM mdivi-1; N=6 animals per treatment 
group. *P<0.05 (see Figure 5.14).  
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Figure 5.13: Representative transverse slices of hearts treated with control and 
mdivi-1 at the 2 doses. The Evan blue area depicts the non-risk zone; tetrazolium-
stained area, area at risk; and white area, area of infarction. N=6 animals per 
treatment group. *P<0.05. 
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Figure 5.14: Pre-treatment with mdivi-1 at dose 2 (1.2 mg/kg IV) but not dose 1 
(0.24 mg/kg IV) resulted in a significant reduction in myocardial infarct size in the in 
vivo murine heart. N=6 animals per treatment group. *P<0.05 
 
 
5.9      Discussion 
 
Effects of sIR on mitochondrial morphology in HL- 1 cells  
 
 
    As shown in this section of the study, 120 minutes of simulated ischaemia 
fragments the mitochondria of the cells transfected with the empty vector, RcCMV. 
Cells with an overexpression of the mutant form of the fission protein Drp1K38A 
however, maintained the fused state of the mitochondria throughout the whole 
duration of sIR. This result is in line with the phenomenon observed in the study of 
Brady et al in 2006 488.  
 
    This section is of utmost importance as it shows that ischaemia distorts the 
proper mitochondrial morphology by fragmenting the mitochondria. A previous 
study by Chen and co-workers in 2009 showed a decrease in OPA1 levels in the 
settings of heart failure 211. Following ischaemia, fragmentation of the mitochondria 
will lead to depolarisation of mitochondrial membrane potential, uncoupling of 
oxidative phosphorylation and subsequent cell death 160, 207, 417, 489, 490. For the HL-1 
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cells, manipulation of mitochondrial morphology can only be carried out and is 
deemed feasible if the balance of morphology was tilted to one end of the extreme 
initially.  
 
    The duration of simulated ischaemia was also based on the study by Brady et 
al in 2006 488. A shorter duration of hypoxia was necessary to track the changes of 
morphology of mitochondria. The heated perfusion chamber was used as monitoring 
of mitochondrial morphology in this study was performed ‘real-time’. DOG was 
used to inhibit glycolysis as the cells will revert to glycolysis during a short period of 
ischaemia. The revertion to glycolysis may enable the cells to maintain normal 
mitochondrial morphology although this has yet to be proven. 
 
    Ischaemia causes fragmentation of the mitochondria probably due to the 
increase in calcium levels in the mitochondria hence activating the calcium-sensitive 
phosphatase, calcineurin leading to dephosphorylation and subsequent activation of 
Drp1 189. The activation of Drp1 causes translocation of the protein to the 
mitochondria to perform fragmenting function. Overexpression of Drp1K38A, the 
mutant form of the fission protein inhibits the function of the endogenous Drp1, by 
preventing its translocation and hence impairing the mitochondrial fragmenting 
function of Drp1.  
 
 
Protecting the HL-1 cells against sIR by modulation of mitochondrial 
morphology via genetic manipulation 
 
 
    Studies conducted previously have shown that mitochondrial fission precedes 
cell death in different cell lines caused by various stimuli 408, 491-493. In our study, we 
demonstrated that the overexpression of the fusion proteins in HL-1 cardiac cells 
over a period of 48 hours renders the cells more resistant to 12 hours simulated 
ischaemia and 1 hour reoxygenation. Conversely, overexpression of the 
fragmentation-promoting protein, hFis1 renders the cells more susceptible to sIRI. In 
order to simulate a more relevant clinical setting of a longer period of reoxygenation 
to a shorter period of ischaemia, we employed the protocol of 24 hours 
reoxygenation to 12 hours of ischaemia. The 12 hours of simulated ischaemia was 
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kept constant in both of the protocols because the onset of reoxygenation is when the 
mitochondrial permeability transition pore (mPTP) starts to open leading to necrotic 
cell death and therefore, the reoxygenation period is the main injury source. In the 24 
hour reoxygenation protocol, the cardioprotective effect was lost for Mfn2 while 
hFis1 also does not appear to render the cells more susceptible to sIRI. A possible 
explanation is that following the long period of reoxygenation, the dead cells will 
have floated off, and we would have under-estimated the percentage of cell death, as 
can be seen from the ~30% cell death in cells with an overexpression of vector 
control, RcCMV. Mfn1 still produces significant reduction in cell death in this 24 
hour reoxygenation model but we also lost the protection for Drp1K38A.  The 
overexpression of hFis1 in this case also did not kill the cells significantly but it 
should be noted that the percentage of cell death was recorded at ~35% compared to 
~65% in the 1 hour reoxygenation model, once again highlighting the possibility that 
there is an underestimation of cell death. Due to the fact that the dead cells may 
actually float off following a long period of reoxygenation and possible 
underestimation of cell death, we decided to use the 12 hours simulated ischaemia 
followed by 1 hour reoxygenation model for the survival assay.  
 
Protecting the HL-1 cells against sIR by modulation of mitochondrial 
morphology via pharmacological manipulation 
 
 
In this section of the study, we demonstrated that pre-treatment of HL1 cardiac cell 
line with 50 µM of mdivi-1 prior to simulated ischaemia for 12 hours and 1 hour of 
reoxygenation in the presence of the same concentration of drug protects the cells 
against simulated ischaemia-reperfusion injury.  Brooks et al have shown that using 
the same dose of drug, they managed to reduce IR-induced tubular damage to renal 
cortical and outer medulla tissues as well as prevent apoptosis 215. Different studies 
using different types of cardioprotective drugs have varied protocols. Some of the 
studies used the drugs throughout the whole duration of IR with a specific pre-
treatment period 494, while there also exist studies where the drugs were administered 
at the onset of reperfusion 487, 495. The deciding factor of when to apply the drug 
depends on the endpoint of the study; whether to test the efficacy of the drug in 
reducing infarct size, the efficacy of the drug at the onset of reperfusion or reducing 
injury caused by ischaemia. In our study, the drug was administered throughout the 
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whole duration of simulated ischaemia and reperfusion to mimic the clinical settings 
where the drug would have been present throughout surgery and reperfusion. The 
cardioprotection conferred is probably dependent on the mitochondrial elongation 
property of the drug, similar to overexpression of mitochondrial fusion-promoting 
proteins.  
 
 
 
 
Protecting the endothelial cells against sIR by modulation of 
mitochondrial morphology via genetic manipulation 
 
 
 Using the survival assay generated for HL-1 cardiac cells as a basic model, we 
attempted to test this model on endothelial cells using the mitofusins to promote 
mitochondrial fusion and hFis1 to induce fragmentation. Upon embarking on this 
model, we found that the endothelial cells were extremely hardy toward sIR. We 
tried several protocols until we finalised on 24 hours of serum starvation followed by 
12 hours of simulated ischaemia in the presence of 2.5 mM 2-DOG and 1 hour 
reoxygenation to achieve approximately 50% of cell death in cells with vector 
control. DOG was used to inhibit glycolysis which will be initiated during simulated 
ischaemia. In the model of 24 hours of serum starvation followed by 12 hours of 
simulated ischaemia in the presence of 2.5 mM DOG and 1 hour reoxygenation, 
cardioprotection was elicited by the overexpression of the mitofusins. Nevertheless, 
we did not manage to detect a significant cell death in response to hFis1 
overexpression. It is certainly strange to see significant mitochondrial fragmentation 
with the overexpression of hFis1 in endothelial cells yet failed to detect a significant 
percentage of cell death following sIR but we should bear in mind that mitochondrial 
fragmentation pre-disposes the cells to the death pathway but do not definitely lead 
to cell death. This may hold true for the endothelial cells which are hardy enough to 
withstand mitochondrial fragmentation in the settings of sIR hence producing a 
percentage of cell death which was similar to the cells transfected with the vector 
control alone.  
 
We then investigated a longer period of reoxygenation where the model of 24 hours 
of serum starvation followed by 12 hours of simulated ischaemia in the presence of 
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2.5 mM DOG and 24 hours reoxygenation was used. In this model, we lost the 
cardioprotection by Mfn1 while Mfn2 still protects the cells. We noticed a similar 
trend to the HL-1 cells in which a long period of reoxygenation leads to an 
underestimation of cell death.  
 
Protecting the adult cardiomyocytes against sIR by modulation of 
mitochondrial morphology via pharmacological manipulation 
 
In this part of the study, we determined the cardioprotective effects of the mdivi-1 
drug in adult myocytes. The 45 minutes simulated ischaemia followed by 30 minutes 
reoxygenation was established by Lim et al in 2008 487. In this study, only the rod-
shaped non-PI stained cardiomyocytes were defined as alive. Cells undergoing 
hypercontracture were not taken into account. We found that the usage of 10 µM 
mdivi-1 drug doesn’t protects the cardiomyocytes against sIR in agreement with our 
previous findings that 10 µM was not the optimum concentration. Only 50 µM 
showed protection against sIR as this was the optimum concentration to inhibit Drp1 
and subsequent mitochondrial fragmentation.  
 
From the results of the previous section, we postulate that the mdivi-1 drug inhibits 
mitochondrial fission in the HL-1 cardiac cell line thus increasing the proportion of 
cells with elongated mitochondria, increases the number of elongated interfibrillar 
mitochondria in the heart cell, delays the opening of the mPTP in cardiomyocytes 
following sIR and protects cardiomyocytes against sIR. Our next objective is to 
determine whether mdivi-1 reduces the infarct size in a murine model following sIR. 
 
 
 
Infarct size reduction in an in vivo murine infarct model by modulation 
of mitochondrial morphology in the heart 
 
 
The results obtained show that application of the mdivi-1 drug at stabilisation for 15 
minutes followed by 30 minutes of ischaemia and 120 minutes of reperfusion 
reduces myocardial injury as can be seen from the reduction in infarct size after TTC 
staining. The selected protocol was established from the study of Lim et al in 2007 
496
.  Various types of drugs have been used to demonstrate the cardioprotective 
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effects using this model; e.g.visfatin 487, rimonobant 497, apelin 498, necrostatin 499. 
Selection of C57BL mice was fixed at male mice at the age of 9 – 12 weeks old to 
standardise the subjects. Male mice were chosen because there have been previous 
claims of cardioprotective effects of oestrogen in female mice 500, 501. Compared to 
50 µM of mdivi-1, 10 µM of mdivi-1 did not reduced infarct size significantly. This 
is the first study showing the cardioprotective effects of mdivi-1 in an in vivo setting. 
Based on the results obtained, we can conclude that the mitochondrial fragmentation 
inhibiting capability of the mdivi-1 drug may provide beneficial cardioprotective 
effects and this effect may be linked to inhibition of mPTP opening 
 
 
 
5.10     Conclusion 
 
 
In this chapter of the thesis, we have demonstrated that modulating mitochondrial 
morphology by tilting the equilibrium towards a more fused state protects the cardiac 
cells against sIR. In the next chapter, we will be exploring whether this protective 
effect is elicited via delaying the opening of the mPTP, a crucial mediator of cell 
death following sIR.  
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6.1     Introduction 
 
In the previous chapter, it was demonstrated that modulating mitochondrial 
morphology in cardiac cells by tilting the balance towards a more fused state protects 
the cells against ischaemia-reperfusion injury. Previous studies have shown that the 
cardioprotection elicited by various interventions, particularly IPC and IPost mainly 
lies in the inhibition of the mPTP opening at the onset of reperfusion 17, 52, 67, 235, 236, 
238, 306, 374, 502-508
. In this chapter, the potential role of mitochondrial fusion in 
delaying the opening of the mPTP was examined to determine whether the 
cardioprotection conferred by modulation of mitochondrial morphology was linked 
to delaying of mPTP opening.  
 
     Interestingly, the link between mitochondrial morphology and mPTP has 
never been thoroughly investigated before this, although it has been speculated that 
these two phenomena may be interrelated. It is well-known that following ischaemia-
reperfusion, the function of cardiac myocytes becomes compromised and this is due 
to mitochondrial damage as a result of calcium overloading 29, 33, 34, 55, 143, 145, 363, 364, 
384, 400, 401, 452, 509
, elevated ROS levels 23, 31, 32, 35, 62, 137, 408, 457, 510, leading to mPTP 
opening and subsequent uncoupling of oxidative phosphorylation and release of 
cytochrome c 61, 63, 111, 367, 382, 396, 401, 403, 452, 457, 477. These factors have been shown to 
be modified (e.g. reduction of Ca2+, ROS and ATP hydrolysis) by cardioprotective 
strategies such as IPC induced by ischaemia 17, 49, 52, 234-236, 249, 258, 503, 504, 506, 511, IPost 
67, 68, 230, 242, 243, 246, 247, 258, 351, 475, 508
 or opening of the mitoKATP channel 8, 221, 222, 246, 
451
. 
 
     Therefore, protecting the heart against myocardial reperfusion injury can be 
mediated by attenuation of mitochondrial Ca2+ overloading, reduction of ROS levels 
and preservation of mitochondrial energy production by maintenance of the 
respiratory chain. These factors, combined prevent the opening of the mPTP at the 
onset of reperfusion. In this section of the study, we wanted to investigate whether 
making the mitochondria longer by promoting fusion or inhibiting fragmentation 
protects the heart by inhibiting the opening of the mPTP as we believe that a longer 
mitochondria may be more robust and can withstand a higher threshold of Ca2+ 
overloading, ROS while maintaining a competent respiratory chain following IR.  
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6.2      Hypothesis 
 
Modulating mitochondrial morphology in the heart delays the opening of 
the mPTP 
 
The first part of the study (section 6.3) was to determine whether promotion of 
mitochondrial fusion by overexpression of fusion-promoting proteins in HL-1 cells 
delays the opening of the mPTP using a confocal laser-induced ROS model. The use 
of CsA serves as an indicator that the mPTP is indeed targeted in this study as CsA 
binds to the CypD component of the mPTP to inhibit its opening. Drp1K38A serves to 
verify that it is indeed mitochondrial fusion that is conferring the effects, and 
eradicating the effects of the presence of the proteins alone.  
 
     In the second part of the study (section 6.4), we aimed to investigate 
whether pharmacological manipulation of the mitochondrial morphology also delays 
the opening of the mPTP in HL-1 cells. Due to the fact that mdivi-1 requires a period 
of pre-treatment to modulate mitochondrial morphology, we pre-treated the cells and 
subjected them to confocal laser irradiation in the presence of mdivi-1 to maintain its 
pharmacological effects. 
 
     In section 6.5, similar to the previous sections, we were interested to 
investigate whether genetic manipulation of mitochondrial morphology in 
endothelial cells similarly delays mPTP opening. 
 
     In the final section of this chapter (section 6.6), we investigated whether 
pharmacologically inhibiting mitochondrial fragmentation by the use of mdivi-1 
delays the opening of the mPTP in a simulated ischaemia-reperfusion model of 
mPTP opening.  
 
 
 
 
Sang Bing, Ong 
 242
6.3      Aim (1)  
 
To determine whether modulation of mitochondrial morphology via 
genetic manipulation delays the opening of the mPTP in HL-1 cardiac 
cells 
 
Having demonstrated in the previous section that mitochondrial fusion is 
cardioprotective, we aimed to investigate whether this protection is elicited through 
the inhibition of mPTP opening. Using HL-1 cells to start off, we investigated 
whether promotion of mitochondrial fusion using the mitochondrial-shaping proteins 
delays the opening of the mPTP using confocal laser-induced ROS stress.  
 
 
6.3.1 Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); one expressing mitofusin 
1(pCB6-MYC-Mfn1); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; one 
containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant 
form of the mitochondrial fission protein Drp1 205; and one containing hFis1. 
Drp1K38A has a mutation in the GTPase domain that results in replacement of lysine 
38 with alanine (designated as Drp1K38A), disabling its ability to induce 
mitochondrial fission 205. For the mPTP assay, a ratio of 2:1 plasmid enhanced green 
fluorescent protein (pEGFP) (Clontech) expression plasmid was included in order to 
select the cells of interest. All plasmids were a generous gift of Dr Luca Scorrano 
(Padova, Italy). Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-
Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 
10.0 (pH 7.4) was used as imaging buffer for confocal studies. TMRM was dissolved 
in DMSO and added to the Krebs byuffer such that the final concentration is 3 µM.  
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6.3.2     Experimental protocol 
 
 
To test the hypothesis that fused mitochondria protects the cells against ischaemia-
reperfusion injury by preventing opening of mPTP in the mitochondrial membrane; 
we subjected the HL-1 cells transfected with either one of the following: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1 - fission-promoting protein 
 
to confocal laser-induced reactive oxygen species release to trigger the opening of 
the mPTP. For each transfected cell as represented in green, ROI analysis was 
performed on the section of the cell containing TMRM. For each treatment group, 
approximately 60 cells were subjected to ROI analysis. The varying fluorescent 
intensities for the cells were converted to Excel format and subsequently into line 
graphs, and the half-times to achieve maximum fluorescent intensity determined to 
compare the time needed for mPTP opening upon lasers-induced release of free 
oxygen radicals from TMRM.  
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6.3.3     Results 
 
 
Overexpression of the fusion proteins delayed the sensitivity of mPTP opening in the 
HL-1 cardiac cell line in a confocal laser-induced ROS model. Cells which have an 
overexpression of Mfn1, Mfn2 and the mutant form of the fission protein, Drp1K38A 
showed a delayed normalised time until mPTP opening (2.4 ± 0.5 fold, 2.3 ± 0.7 fold 
and 2.4 ± 0.3 fold vs. 1.0 ± 0.1 for vector control; N=4 experiments with 20 cells per 
treatment group; *P<0.05). The time needed for mPTP opening in HL-1 cells with an 
over-expresssion of hFis1 was recorded at 0.9 ± 0.7. CsA as a positive control also 
significantly delayed the time until mPTP opening by 2.2 ± 0.4 fold; N=4 
experiments with 20 cells per treatment group; *P<0.05 (see Figure 6.1).  
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Figure 6.1: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells transfected with different fusion proteins under confocal-lasers 
induced oxidative stress. CsA acts as a positive control.  Over-expressing Mfn1, 
Mfn2, or Drp1K38A delayed the time taken to induce mPTP opening, whereas over-
expressing hFis1 had no significant effect on mPTP opening sensitivity. As 
expected, CsA delayed the time taken to induce mPTP opening. N=4 experiments 
with 20 cells per treatment group. *P<0.05. 
Time until mPTP opening for HL-1 cells 
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Based on the changes in absolute red fluorescent intensities of TMRM over the 
whole 8 minute cycle of confocal-laser induced ROS, overexpression of the fusion 
proteins Mfn1, Mfn2, and Drp1K38A caused a significant reduction in the increase of 
absolute red fluorescent intensities at times 80 seconds (517.3 ± 61.7, 564.7 ± 58.1, 
716.9 ± 183.9 respectively) and 160 seconds (745.8 ± 101.9, 951.8 ± 147.3, 1123.8 
± 315.1 respectively) compared to the vector control (1365.2 ± 254.3 at 80 seconds 
and 1755.1 ± 254.3 at 160 seconds) (N=4 experiments with 20 cells per treatment 
group; *P<0.05). CsA as a positive control also reduced the amount of increase in 
red fluorescent intensity at the two time points (571.6 ± 88.0 at time 80 s and 857.6 ± 
187.2 at time 160 s) (N=4 experiments with 20 cells per treatment group; *P<0.05 ) 
(see Figure 6.2).  
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Figure 6.2: Changes in absolute red fluorescent intensities of TMRM over the 8 
minute cycle of confocal-lasers induced oxidative stress in HL-1 cells transfected 
with different proteins. A significant reduction in red fluorescent intensity emmited 
was observed at time 80 and 160s for cells with an overexpression of Mfn1, Mfn2 
and Drp1K38A. N=4 experiments with 20 cells per treatment group. *P<0.05. 
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6.4       Aim (2) 
 
To determine whether modulation of mitochondrial morphology via 
pharmacological manipulation delays the  opening of the  mPTP in HL-1 
cardiac cells 
 
We have demonstrated the promotion of mitochondrial fusion in HL-1 cells delays 
the opening of the mPTP in the previous section. In this section, we investigated the 
effects of pharmacological inhibiting mitochondrial fission in HL-1 cells on mPTP 
inhibition.  
 
 
6.4.1       Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of and subsequently in Claycomb 
medium or Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 
11.0, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 
(pH 7.4) to achieve a final concentration of 10 µM or 50 µM.   
 
 
6.4.2       Experimental protocol  
 
HL-1 cells were pre-treated with 50 uM mdivi-1 for 40 minutes in the 37oC incubator 
and subjected to confocal-laser induced stress to determine susceptibility to mPTP 
opening.  
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6.4.3       Results 
 
HL-1 cells treated with 50 µM mdivi-1 showed a significant delay in time until 
mPTP opening by 2.1 ± 0.5 fold vs. 1.0 ± 0.1 for cells treated with vehicle control; 
N=4 experiments with 20 cells per treatment group; *P<0.05. Time until mPTP 
opening for cells treated with 10 µM mdivi-1 was at 0.6 ± 0.1 fold while the positive 
control, CsA delayed the time until mPTP opening by 2.3 ± 0.5 fold; N=4 
experiments with 20 cells per treatment group; *P<0.05 (see Figure 6.3).  
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Figure 6.3: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells treated with different drugs under confocal-lasers induced 
oxidative stress. CsA acts as a positive control. Treatment with mdivi-1 at 50 but 
not 10 µM for 40 minutes resulted in a significant delay in the time taken to induce 
mPTP opening. As expected, CsA delayed the time taken to induce mPTP opening. 
N=4 experiments with 20 cells per treatment group. *P<0.05 
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6.5 Aim (3) 
 
To determine whether modulation of mitochondrial morphology via 
genetic manipulation delays the opening of the mPTP in endothelial cells 
 
In this section, we investigated whether genetically promoting mitochondrial fusion 
in endothelial cells produces similar results as in HL-1 cells for mPTP inhibition.  
 
 
6.5.1   Materials 
 
The plasmids used for the endothelial mPTP assay is similar to the ones used in the 
HL-1 mPTP assay as well as the endothelial morphology study to investigate 
potential connections between mitochondrial morphology and mPTP sensitivity: an 
empty plasmid expression vector (RcCMV); one expressing mitofusin 1(pCB6-
MYC-Mfn1); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; one containing 
Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative mutant form of the 
mitochondrial fission protein Drp1 205; and one containing hFis1. Drp1K38A has a 
mutation in the GTPase domain that results in replacement of lysine 38 with alanine 
(designated as Drp1K38A), disabling its ability to induce mitochondrial fission 205. For 
the mPTP assay, a ratio of 1:2 plasmid enhanced green fluorescent protein (pEGFP) 
(Clontech) expression plasmid: plasmid of interest was included in order to select the 
cells of interest. All plasmids were a generous gift of Dr Luca Scorrano (Padova, 
Italy). Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 11.0, 
KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) 
was used as imaging buffer for confocal studies. TMRM was dissolved in DMSO 
and added to the Krebs buffer such that the final concentration is 3 µM.  
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6.5.2   Experimental Protocol 
 
To test the hypothesis that fused mitochondria protects the cells against ischaemia-
reperfusion injury by preventing opening of mPTP in the mitochondrial membrane; 
we subjected the endothelial cells transfected with either one of the following: 
1. RcCMV – empty vector (Vector Control) 
2. Drp1K38A – the dominant negative form of the fission protein  
3. Mfn1 – fusion-promoting protein 
4. Mfn2 – fusion-promoting protein 
5. hFis1 – fission-promoting protein 
 
to confocal laser-induced reactive oxygen species release to trigger the opening of 
the mPTP. For each transfected cell as represented in green, ROI analysis was 
performed on the section of the cell containing TMRM. For each treatment group, 
approximately 60 cells were subjected to ROI analysis. The varying fluorescent 
intensities for the cells were converted to Excel format and subsequently into line 
graphs, and the half-times to achieve maximum fluorescent intensity determined to 
compare the time needed for mPTP opening upon lasers-induced release of free 
oxygen radicals from TMRM.  
 
 
6.5.3   Results 
 
 
Endothelial cells transfected with Mfn1 and Mfn2 showed a delay in time until 
mPTP opening by 1.9 ± 0.4 fold and 2.1 ± 0.4 fold respectively compared to 1.0 ± 
0.1 for vector control. Overexpression of the fission protein, hFis1 in endothelial 
cells recorded a time until mPTP opening at 1.1 ± 0.2 fold whereas CsA as a positive 
control delayed the time until mPTP opening by 1.7 ± 0.5 fold, albeit not 
significantly (see Figure 6.4).  
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Figure 6.4: Normalised half-times to reach maximum red fluorescent intensity 
for endothelial cells transfected with different fusion proteins under confocal-
lasers induced oxidative stress. CsA acts as a positive control 
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6.6     Aim (4)  
 
To determine whether modulation of mitochondrial morphology via 
pharmacological manipulation delays the  opening of the mPTP in adult 
cardiomyocytes 
 
In this section, we aimed to investigate whether the use of mdivi-1 as a 
pharmacological agent to inhibit mitochondrial fragmentation in adult 
cardiomyocytes also delays the opening of the mPTP in an sIR model of mPTP 
opening.  
 
 
6.6.1    Materials 
 
Mdivi-1 drug was purchased from Key Organics Ltd., UK. The drug was dissolved in 
DMSO to achieve a working concentration of 50 mM and subsequently in hypoxic 
ischaemic buffer to achive a final concentration of 50 µM.  Sanglifehrin A (SfA) was 
dissolved in DMSO to achieve a working concentration of 1 mM and subsequently 
in hypoxic ischaemic buffer to achieve a final concentration of 1 µM. Simulated 
ischaemia was performed in hypoxic ischaemic buffer comprising (in mM): KH2PO4 
1.0, NaHCO3 10.0, MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 
and NaLactate 20 at pH 6.2, bubbled with 100% nitrogen. Reoxygenationwas 
performed using cardiomyocyte growth medium (M199 buffer: BSA 2 mg/ml, 
creatine 5 mM, taurine 5 mM, carnitine hydrochloride 1.6 mM, Pencillin-
Streptomycin 1%). 
 
 
6.6.2    Experimental protocol  
 
For the adult cardiomyocytes we used a different model to assess mPTP opening, in 
which its opening is measured following 45 minutes of simulated ischaemia and 30 
minutes of simulated reperfusion by measuring the resultant TMRM fluorescence. 
Twenty cells were randomly selected for each treatment group, and this was repeated 
in at least four independent experiments. 
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6.6.3    Results 
 
Using the hypoxic chamber for mPTP assay in adult cardiomyocytes, the normalised 
TMRM fluorescent intensity for adult cardiomyocytes following sIR was reduced 
significantly to 0.8 ± 0.1 compared to 1.0 ± 0.1 for normoxic control; N=4 
experiments with 20 cells per treatment group; *P<0.05. sIR in the presence of 50 
µM mdivi-1 maintained the TMRM fluorescent intensity at 1.0 ± 0.1 while sIR in the 
presence of SfA confers a recorded TMRM intensity at 0.9 ± 0.1 (see Figure 6.5).  
 
mPTP opening in adult myocytes
0
0.2
0.4
0.6
0.8
1
1.2
Normoxia Ctrl sI/R Ctrl sI/R 50 uM
mdivi-1
sI/R 1 uM SfA
N
o
rm
a
lis
e
d 
TM
R
M
 
flu
o
re
s
c
e
n
t i
n
te
n
s
iti
e
s
 
(A
U
)
*
 
 
Figure 6.5: Normalised TMRM fluorescent intensities for measurement of 
mPTP opening in adult cardiomyocytes. Pre-treatment of adult rat cardiomyocytes 
with mdivi-1 at 50 µM inhibited mPTP opening as evidenced by the preserved 
TMRM fluorescence after SIRI. N=4 experiments with 20 cells per treatment group. 
*P<0.05 
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6.7      Discussion  
 
 
Delaying the opening of the mPTP in HL-1 cells by genetic modulation 
of mitochondrial morphology 
 
In this section of the study, we demonstrated that the overexpression of the fusion 
proteins that promote mitochondrial elongation delays the sensitivity to mPTP 
opening. Previous studies conducted have demonstrated the feasibility of this 
confocal-laser induced ROS model to induce mPTP opening in cultured cells where 
the increase in overall red fluorescent intensities is due to the de-quenching of the 
TMRM was used to measure mPTP opening 457, 458, 512 and this has been repeated in 
subsequent studies 236, 259, 263, 462, 513, 514. Half-times were taken as the time taken to 
reach maximum red intensities is very subjective. In addition to that, the 8-minutes 
period of laser stress produces different maximum values of red intensities for 
different cells. Therefore, half-times were chosen for data analysis. Normalisation of 
the half-times to the vector control was also performed to make the data more logical 
and comprehensible. The efficiency of CsA to delay the sensitivity of mPTP opening 
shows that the mPTP was indeed targeted in this study instead of other factors that 
causes the release of TMRM from the mitochondria such as unspecific pores or 
channels. The mutant form of the fission protein Drp1K38A was included to exclude 
the effects of the presence of the fusion proteins. CsA was used as a positive control 
to confirm that the mPTP was indeed targeted in this study as CsA has been proven 
by various previous studies to be a potent inhibitor of the mPTP 17, 63, 449, 515-517. The 
time until mPTP opening was measured as half-time until maximum fluorescence 
intensity achieved within the specified time period of laser stress. This method was 
chosen because we had to find a balance between killing the cells with an extended 
period of laser stress and detecting sufficient pore opening within an optimum time 
frame. Different methods have been used to quantify opening of the mPTP; e.g. 
mitochondrial entrapment of 2-deoxy [3H] glucose-6-phosphate ([3H]DOG-6P) or 
calcein re-distribution. We found that using the TMRM confocal laser-induced ROS 
model proved practical and efficient. In addition to that, we have also used the re-
distribution of calcein to verify our findings. Surprisingly, overexpression of the 
fission protein, hFis1 did not increase the sensitivity of the mPTP opening in our 
study. Yet, it has been previously reported that overexpression of either Drp1 or 
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hFis1 in COS epithelial cells increased the sensitivity of cells towards calcium-
induced mPTP opening. The limitation in the resolution of our model to detect 
sensitivity to mPTP opening may explain our findings. Another alternative 
explanation is that the cell death caused by hFis1 is independent of the mPTP.   
 
Delaying the opening of the mPTP in HL-1 cells by pharmacological 
modulation of mitochondrial morphology 
 
 
In this part of the study, we have demonstrated that the use of 50 µM mdivi-1 to treat 
HL-1 cardiac cells for 40 minutes successfully delayed the opening of the mPTP 
following confocal laser-induced mPTP opening. This was the first time that mdivi-1 
has been shown to inhibit mPTP opening. This suggests that promotion of 
mitochondrial fusion by either genetic manipulation or pharmacological 
manipulation can prevent the opening of the mPTP. CsA was used as to indicate that 
the mPTP was properly targeted in this study. The finding that 10 µM mdivi-1 did 
not prevent mPTP opening correlates with results from the previous section where 
this same concentration of drug was not found to induce mitochondrial elongation.  
 
Delaying the opening of the mPTP in endothelial cells by genetic 
modulation of mitochondrial morphology 
 
The results obtained from this section showed the trend of delaying the sensitivity of 
mPTP in endothelial cells, albeit no significance was achieved. This may be 
achieved if the number of experiments, n number was increased. Similar to the HL-1 
cells, overexpression of the hFis1 protein did not increase the sensitivity of the 
endothelial cells to mPTP opening.  
 
 
Delaying the opening of the mPTP in adult cardiomyocytes by 
pharmacological modulation of mitochondrial morphology 
 
In this section, we determined whether treatment of the mdivi-1 drug at its optimum 
concentration of 50 µM in cardiomyocytes can reduce the opening of the mPTP 
following simulated ischaemia-reperfusion. We successfully demonstrated that the 
use of the mdivi-1 drug can inhibit mPTP opening following sIR. The positive 
control for inhibition of mPTP opening was changed from CsA to SfA because SfA 
Sang Bing, Ong 
 255
is more potent than CsA. The model in detection of mPTP opening was changed 
from the confocal laser-induced mPTP opening (quenching concentration of TMRM, 
3 µM) to the simulated ischaemia-reperfusion model (non-quenching concentration 
of TMRM, 100 nM) because: 
1) the opening of the mPTP was not delayed significantly by the SfA using the 
confocal model 
2) mdivi-1 drug seemed to hyperpolarise or increase the membrane potential of 
the mitochondria in the presence of a quenching concentration of TMRM (3 
µM), hence making it difficult to detect any difference in re-distribution of 
TMRM 
3) the simulated ischaemia-reperfusion model is more relevant to the settings of 
the adult myocytes 
 
To our knowledge, this is the first time that mdivi-1 has been proven to inhibit mPTP 
opening in adult myocytes. Compared to the normoxia control, simulated ischaemia-
reperfusion causes the mPTP to open and the non-quenching concentration of 
TMRM to leave the mitochondria and enter the cytosol, hence causing a decrease in 
red fluorescent intensity. The treatment of mdivi-1 drug and SfA however, 
successfully reduced the opening of the mPTP and maintained the TMRM in the 
mitochondria.  
 
 
6.8     Conclusion  
 
 
Opening of the mPTP has been established as the cause of reperfusion injury and 
inhibition of the mPTP has been shown to alleviate the effects of reperfusion injury. 
Numerous studies have sought to inhibit the opening of the mPTP; either by 
pharmacological methods 17, 232, 482, 518-524 or genetic ablation methods such as 
knocking out the Cyclophilin D component of the mPTP 404, 525-528. We demonstrate 
in this chapter that promotion of mitochondrial fusion delays the time until mPTP 
opening and this delay may underlie the cardioprotective effects of mitochondrial 
fusion.  
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7.1      Introduction 
 
     Kinases and their phosphorylation effects have always been a central focus 
on studies in cardioprotection, particularly kinases forming the RISK pathway or 
SAFE pathway 258, 276, 305, 350, 482. Some of the well-known kinases include Protein 
Kinase A (PKA), Protein Kinase B (PKB), and Protein Kinase C (PKC). 
Cardioprotective effects of PKA lies in the fact that PKA can modulate the opening 
of the mitochondrial Ca2+-activated K+ channels 281, 529, 530, while PKB which consist 
of isoforms Akt1 (PKB-α), 2 (PKB-β) and 3 (PKB-γ) have been known to promote 
growth and metabolism 287, 288, 531, 532, glucose homeostasis 289, 533-536 and neuronal 
repair respectively 291, 292. The story of PKC is controversial with the fact that PKC 
epsilon protects 10, 360, 537-540  whereas PKC delta is deleterious 495, 541-543.  
      
     One of the documented effects of PKA is its ability to phosphorylate and 
inhibit the fission protein Drp1 182. Using an activator of PKA, we intend to find out 
whether activation of PKA increases the proportion of HL-1 cells with elongated 
mitochondria, delays opening of mPTP and protects cells against sIR. Similarly, we 
were also curious to see whether the activation of Akt as a well-known pro-survival 
kinase (crucial component of the RISK pathway), confers any effect on 
mitochondrial morphology. Although activation of Akt influences many downstream 
effectors such as glycogen synthase kinase 3 (GSK3beta) 544, 545, Forkhead family of 
transcription factors (FOXO) 303, 546, 547 and the pro-apoptotic protein Bcl2 antagonist 
of cell death (BAD) 297, 298, there is generally a lack of a consensus factor in which 
the end-effectors of Akt activation act upon. We believe it to be mitochondrial 
morphology, a notion we seek to investigate in this section.  But before we can 
attempt to investigate the role of Akt in modulation of mitochondrial morphology, 
we have to prove that the overexpression or activation of Akt in our cardiac cell line 
also delays the time until mPTP opening and protects the cells against sIR.  
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7.2   Hypothesis & Objectives 
     
Pro-survival kinases elicit cardioprotection via modulation of 
mitochondrial morphology in the heart 
 
In the first section of the study, we investigated the documented effects of PKA 
activation on inhibition of the fission protein, Drp1 in HL-1 cells.  
 
In the second section of the study, we investigated the pro-survival effects of PKA 
activation in HL-1 cells following sIR. 
 
Following this, we investigated whether the protective effects of PKA activation was 
based on delaying the opening of the mPTP in HL-1 cells. 
 
In addition to investigating the effects of PKA, we were also interested to investigate 
the effects of PKB/Akt. First and foremost, we had to determine whether 
upregulation of Akt protects the cells against sIR as that is a very crucial function of 
Akt.  
 
Following that, we investigated whether upregulation of Akt delays the opening of 
the mPTP in HL-1 cells using the confocal laser-induced stress model. 
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7.3      Aim (1)  
 
To determine whether pharmacologically activating PKA modulates 
mitochondrial morphology in HL-1 cells 
 
 
Following the findings from previous sections demonstrating the beneficial effects of 
modulating mitochondrial morphology in protecting the heart against IRI, we were 
intrigued to investigate the possible links between pro-survival kinases and 
cardioprotection. In this section, we investigated the role of PKA in inhibiting the 
mitochondria fission-promoting protein, Drp1 in HL-1 cells.  
 
7.3.1     Materials 
 
Sp-5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole-3', 5'-monophosphorothioate 
(Sp-5, 6 – DCl – cBiMPS) (hereafter referred to as cBiMPS) was purchased from 
Biomol International. cBiMPS binds to cAMP-binding sites of the cAMP protein 
kinases hence leading to their activation 419, 548. The drug was dissolved in water to 
achieve a working concentration of 1 mM and subsequently in Krebs buffer 
comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 11.0, KCl 4.7, 
MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) to 
achieve a final concentration of 0.1 mM. 
 
7.3.2     Experimental protocol 
 
HL-1 cardiac cells were transfected with plasmids encoding for mitochondrial-
targeted red fluorescent protein (mtRFP). For a time-response study, 24 hours after 
transfection, the cells were imaged using confocal microscopy to determine 
percentage of cells with elongated mitochondria. The cells were then treated with 0.1 
mM of cBiMPS and imaged after 20, 40 and 60 minutes to determine percentage of 
cells with elongated mitochondria. 
To verify the optimum duration of incubation determined by the time-response 
study, a separate batch of cells transfected with mtRFP was imaged using the 
confocal microscope to determine number of cells with elongated mitochondria and 
then treated with cBiMPS for the determined duration before re-imaging.  
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7.3.3     Results 
 
 
Cells incubated with cBiMPS as a PKA activator had 20% of cells with elongated 
mitochondria at time 0’. This percentage increases to 96.0% after 20 minutes of 
incubation, drops slightly to 63.0% at time 40 minutes and increases back to 86.0% 
after an hour (see Figure 7.1).  
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Figure 7.1 Changes in mitochondrial morphology of HL-1 cells following 
treatment with cBiMPS, a PKA activator. Number of cells with elongated 
mitochondria (%) increased following cBiMPS treatment as early as 20 minutes. 
 
 
 
At time 0’, the percentage of cells with elongated mitochondria incubated with 
vehicle control was 24.2 ± 8.5% while percentage of cells with elongated 
mitochondria incubated with cBiMPS was 25.7 ± 6.3%. After 40 minutes of 
incubation with the respective treatments, cBiMPS increased the percentage of cells 
Time-response for changes in HL-1 mitochondrial morphology following 
treatment with a PKA activator, cBiMPS 
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with elongated mitochondria to 55.3 ± 11.5% compared to 29.0 ± 8.1% for vehicle 
control (see Figure 7.2).  
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Figure 7.2: Effects of 40 minutes cBiMPS treatment to the morphology of 
mitochondria in HL-1 cells. In HL-1 cells containing either fragmented or 
elongated mitochondria under basal conditions, treatment with cBiMPS at 0.1 mM 
for 40 minutes increased the proportion of cells displaying elongated mitochondria. 
N=5 experiments with 80 cells per treatment group.  
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7.4      Aim (2)  
 
To determine whether pharmacologically activating PKA protects the 
HL-1 cells against sIR 
 
Following the previous sections where we have shown that inhibition of 
mitochondrial fission by the use of mdivi-1 protects cells against sIR, we were 
interested to determine whether upregulation of PKA using an activator of PKA 
protects the HL-1 cells against sIR by inhibiting mitochondrial fission in this study.  
 
7.4.1     Materials 
 
Sp-5, 6 – DCl – cBiMPS was purchased from Biomol International. The drug was 
dissolved in water to achieve a working concentration of 1 mM and subsequently in 
hypoxic ischaemic buffer comprising of (in mM): KH2PO4 1.0, NaHCO3 10.0, 
MgCl2.6H2O 1.2, NaHEPES 25.0, NaCl 74.0, KCl 16, CaCl2 1.2 and NaLactate 20 at 
pH 6.2, bubbled with 100% nitrogen, or the reoxygenation medium, Claycomb 
medium to achieve a final concentration of 0.1 mM. EPO (Neorecormon, Roche) 
was diluted in distilled water to achieve a working concentration of 5000 U / ml. 
Propidium iodide (PI) (Sigma UK) was dissolved in distilled water and added to the 
Claycomb medium such that the final concentration was 3 uM. 
 
 
7.4.2     Experimental protocol 
 
HL-1 cells transfected with mtRFP for 24 hours were treated with cBiMPS for 40 
minutes prior to 12 hours of simulated ischaemia followed by 1 hour of 
reoxygenation in the presence of cBiMPS throughout. Cell death was measured by 
propidium iodide (PI) staining.  
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7.4.3    Results 
 
 
Following pre-treatment of cBiMPS or EPO for 40 minutes prior to 12 hours 
simulated ischaemia and 1 hour of reoxygenation in the presence of the drugs, cell 
death for cells treated with cBiMPS or EPO was reduced significantly to 20.5 ± 4.3% 
and 17.0 ± 2.7% respectively vs. 42.1 ± 4.8% for vehicle control; N=4 experiments 
with 80 cells per treatment group; *P<0.05 (see Figure 7.3).    
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Figure 7.3: Cell death in HL-1 cells treated with different drugs following 12 
hours hypoxia and 1 hour reoxygenation. Treatment with cBiMPS at 0.1 mM for 
40 minutes resulted in less cell death after SIRI. As expected, EPO also reduced cell 
death. N=4 experiments with 80 cells per treatment group. *P<0.05 compared to 
vehicle control. 
  
 
 
 
 
 
 
 
 
 
 
HL-1 cell death following 12 hours simulated ischaemia and 1 hour reoxygenation 
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7.5      Aim (3)  
 
To determine whether pharmacologically activating PKA delays opening 
of mPTP in HL-1 cells 
 
In previous sections, we have shown that the modulating mitochondrial morphology 
by tilting the balance towards a more fused state delays the opening of the mPTP. In 
this section, we were interested to determine whether activating PKA using a PKA 
activator inhibits mitochondrial fission and delays opening of mPTP in HL-1 cells 
following confocal laser-induced ROS stress.  
 
 
7.5.1    Materials 
 
Sp-5, 6 – DCl – cBiMPS was purchased from Biomol International. The drug was 
dissolved in water to achieve a working concentration of 1 mM and subsequently in 
Krebs buffer comprising (in mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 11.0, KCl 
4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) to 
achieve a final concentration of 0.1 mM. EPO (Neorecormon, Roche) was diluted in 
distilled water to achieve a working concentration of 5000 U / ml. 
 
 
7.5.2    Experimental protocol 
 
HL-1 cells were treated with vehicle control, EPO, or cBiMPS for 40 minutes in the 
37°C incubator. The cells were then loaded with TMRM in Krebs buffer containing 
cBiMPS for 15 minutes prior to confocal imaging for laser-induced ROS stress in 
Krebs buffer containing cBiMPS to image mPTP opening.  
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7.5.3     Results 
 
Normalised times until mPTP opening was delayed slightly to 1.2 ± 0.1 fold. 
Treatment with the positive controls EPO and CsA significantly delayed the times 
until mPTP opening by 1.7 ± 0.2 fold and 1.9 ± 0.5 fold respectively, compared to 
1.0 ± 0.1 for vehicle control (see Figure 7.4).  
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Figure 7.4: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells treated with different drugs under confocal-lasers induced 
oxidative stress. CsA acts as a positive control. Treatment with cBiMPS at 0.1 
mM for 40 minutes showed no difference in the time taken to induce mPTP opening 
when compared to vehicle control. Treatment with EPO at 10 U/ml delayed the time 
significantly compared to control. As expected, CsA delayed the time taken to 
induce mPTP opening. N=4 experiments with 20 cells per treatment group. *P<0.05 
 
 
 
 
 
 
 
 
 
            Time until mPTP opening in HL-1 cells 
Sang Bing, Ong 
 267
7.6      Aim (4)  
 
To determine whether genetic or pharmacological upregulation of Akt 
protects the HL-1 cells against sIR 
 
Before progressing to investigate effects of Akt on mitochondrial morphology, we 
had to verify that the genetic overexpression of Akt in HL-1 cells confers 
cardioprotection against sIR, as it is vital that the pro-survival effects of Akt be 
maintained in the HL-1 basic model.  
 
 
7.6.1     Materials 
 
Plasmids: an empty plasmid expression vector (RcCMV); one expressing mitofusin 2 
(pCB6-MYC-Mfn2) 165; one containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the 
dominant negative mutant form of the mitochondrial fission protein Drp1205;  one 
expressing constitutively activated Akt (pcDNA3-HA-myrAkt) 346 and one 
containing the dominant negative form of Akt, Akt-AA (pcDNA3-HA-Akt-AA) 549. 
The constitutively active Akt construct has the c-src myristoylation sequence fused 
in-frame to the N terminus of the HA-Akt (wild-type) coding sequence. The 
myristolated sequence of Akt targets it to the plasma membrane of the cells where it 
is constitutively activated 346. In the N-terminal haemagglutinin (HA)-tagged mutant 
of Akt1 (PKBα) for the dominant-negative form of Akt, the two major regulatory 
phosphorylation sites (Thr308 and Ser473) were replaced by alanine residues 
rendering both endogenous and transfected Akt inactive 549. Drp1K38A has a mutation 
in the GTPase domain that results in replacement of lysine 38 with alanine 
(designated as Drp1K38A), disabling its ability to induce mitochondrial fission 205. For 
the survival assay, a ratio of 1:2 plasmid enhanced green fluorescent protein (pEGFP) 
(Clontech) expression plasmid was included in order to permit visual assessment of 
mitochondrial morphology. All plasmids were a generous gift of Dr Luca Scorrano 
(Padova, Italy). EPO (Neorecormon, Roche) was diluted in distilled water to achieve 
a working concentration of 5000 U / ml. Propidium iodide was dissolved in distilled 
water and added to the Claycomb medium such that the final concentration was 3 
µM.  
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7.6.2     Experimental protocol  
 
HL-1 cells transfected with the vector control, caAkt, Mfn2 or Drp1K38A for a total 
duration of 48 or 24 hours were subjected to 12 hours of simulated ischaemia in an 
airtight temperature-controlled hypoxic chamber followed by 1 hour reoxygenation 
in Claycomb medium at 37°C supplemented with 3 µM PI to determine cell death. 
EPO and wortmannin were used to confirm the effects of Akt and its relative 
location in the RISK pathway.  
 
 
 
7.6.3     Results 
 
HL-1 cells with an overexpression of caAkt for 48 hours have a cell death percentage 
of 33.4 ± 1.2% while cells transfected with the vector control have a cell death of 
41.8 ± 4.1% following 12 hours simulated ischaemia and 1 hour reoxygenation. 
Cells which have an overexpression of Mfn2 and Drp1K38A have a significantly 
reduced cell death of 16.2 ± 3.9% and 12.1 ± 2.9% respectively vs. 41.8 ± 4.1% for 
vector control; n = 4; *p < 0.05 compared to vector control.   
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Figure 7.5: Cell death in HL-1 cells 48 hours after transfection with plasmids 
encoding for different proteins promoting mitochondrial fusion against empty 
vector, RcCMV following 12 hours hypoxia and 1 hour reoxygenation. 
Overexpression of HL-1 cells with Mfn2 or Drp1K38A decreased cell death after a 
period of SIRI; n = 4; *p < 0.05 compared to vector control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HL-1 cell death 48 hours after transfection and following 12 hour simulated ischaemia 
and 1 hour reoxygenation 
Sang Bing, Ong 
 270
HL-1 cells with an overexpression of caAkt for 24 hours has a significantly reduced 
cell death percentage of 33.0 ± 1.2% vs. 64.0 ± 5.6% for vector control; ; n = 4; *p < 
0.05 compared to vector control. Overexpression of the kinase dead form of Akt, 
Akt-AA has a cell death percentage of 63.0 ± 3.3% (see Figure 7.6).  
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Figure 7.6: Cell death in HL-1 cells 24 hours after transfection with plasmids 
encoding for different proteins promoting mitochondrial fusion against empty 
vector, RcCMV following 12 hours hypoxia and 1 hour reoxygenation. 
Overexpression of HL-1 cells with caAkt decreased cell death after a period of SIRI, 
compared with control; n = 4; *p < 0.05 compared to vector control.   
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Treatment of the HL-1 cells with the Akt activator, EPO for 40 minutes prior to 
simulated ischaemia-reoxygenation significantly reduces cell death to 20.9 ± 3.5% 
vs.  53.6 ± 3.2% for vehicle control (N=4 experiments with 80 cells per treatment 
group. *P<0.05 compared to vehicle control) while the PI3K inhibitor, wortmannin 
maintained the percentage of cell death at 55.5 ± 5.4%. Treating the cells with both 
EPO and wortmannin together also has a cell death at 53.7 ± 8.3%. EPO treatment 
with an overexpression of the dominant negative form of the Akt, Akt-AA has a 
recorded cell death percentage of 62.4 ± 3.3% (see Figure 7.7).  
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Figure 7.7: Cell death in HL-1 cells treated with different drugs following 12 
hours hypoxia and 1 hour reoxygenation. Treatment with EPO at 10 U/ml for 40 
minutes resulted in less cell death after SIRI. N=4 experiments with 80 cells per 
treatment group. *P<0.05 compared to vehicle control. 
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7.7     Aim (5)  
 
To determine whether genetic or pharmacological upregulation of Akt 
delays opening of mPTP in HL-1 cells 
 
In this section of the study, we were also interested to know whether overexpression 
of Akt delays the opening of the mPTP in HL-1 cells using the confocal laser-
induced stress model.  
 
 
7.7.1    Materials 
 
The plasmids used for the mPTP assay is similar to the ones used in the survival 
study (see Section 7.6) to correlate cell death and mPTP opening: an empty plasmid 
expression vector (RcCMV); one expressing mitofusin 2 (pCB6-MYC-Mfn2) 165; 
one containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the dominant negative 
mutant form of the mitochondrial fission protein Drp1205;  one expressing 
constitutively activated Akt (pcDNA3-HA-myrAkt) 346 and one containing the 
dominant negative form of Akt, Akt-AA (pcDNA3-HA-Akt-AA) 549. The 
constitutively active Akt construct has the c-src myristoylation sequence fused in-
frame to the N terminus of the HA-Akt (wild-type) coding sequence. The 
myristolated sequence of Akt targets it to the plasma membrane of the cells where it 
is constitutively activated 346. In the N-terminal haemagglutinin (HA)-tagged mutant 
of Akt1 (PKBα) for the dominant-negative form of Akt, the two major regulatory 
phosphorylation sites (Thr308 and Ser473) were replaced by alanine residues 
rendering both endogenous and transfected Akt inactive 549. Drp1K38A has a mutation 
in the GTPase domain that results in replacement of lysine 38 with alanine 
(designated as Drp1K38A), disabling its ability to induce mitochondrial fission by 
sequestering endogenous Drp1 181, 205. For the survival assay, a ratio of 1:2 plasmid 
enhanced green fluorescent protein (pEGFP) (Clontech) expression plasmid: plasmid 
of interest was included in order to permit visual assessment of mitochondrial 
morphology. All plasmids were a generous gift of Dr Luca Scorrano (Padova, Italy). 
EPO (Neorecormon, Roche) was diluted in distilled water to achieve a working 
concentration of 5000 U / ml. Wortmannin (Tocris) was dissolved in DMSO to 
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achieve a working concentration of 100 µM. TMRM was dissolved in DMSO and 
added to the Krebs buffer such that the final concentration is 3 µM.  
 
 
 
7.7.2     Experimental protocol  
 
To test the hypothesis that fused mitochondria protects the cells against ischaemia-
reperfusion injury by preventing opening of mPTP in the mitochondrial membrane; 
we subjected the HL-1 cells transfected with either one of the following: 
1. RcCMV – empty vector (Vector Control) 
2. caAkt – constitutively active Akt 
3. Drp1K38A – the dominant negative form of the fission protein  
4. Mfn2 – fusion-promoting protein 
 
to confocal laser-induced reactive oxygen species release to trigger the opening of 
the mPTP. For each transfected cell as represented in green, ROI analysis was 
performed on the section of the cell containing TMRM. For each treatment group, 
approximately 60 cells were subjected to ROI analysis. The varying fluorescent 
intensities for the cells were converted to Excel format and subsequently into line 
graphs, and the half-times to achieve maximum fluorescent intensity determined to 
compare the time needed for mPTP opening upon lasers-induced release of free 
oxygen radicals from TMRM. EPO and wortmannin were used to confirm the effects 
of Akt and its relative location in the RISK pathway.  
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7.7.3     Results 
 
 
Normalised half-time until mPTP opening for cells with an overexpression of caAkt 
for 48 hours is 2.0 ± 0.4 while cells with an overexpression of Mfn2 for 48 hours 
have a normalised half time of 2.3 ± 0.7. only cells with an overexpression of 
Drp1K38A have a significant delay in the normalised half-time until mPTP opening of 
2.4 ± 0.3 compared to the vector control at 1.0 ± 0.1; N=4 experiments with 20 cells 
per treatment group; *P<0.05.  
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Figure 7.8: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells transfected with different fusion proteins for 48 hours followed 
by confocal-lasers induced oxidative stress. CsA acts as a positive control.  Over-
expressing caAkt, Mfn2, or Drp1K38A delayed the time taken to induce mPTP 
opening, with only Drp1K38A achieving significance. As expected, CsA delayed the 
time taken to induce mPTP opening. N=4 experiments with 20 cells per treatment 
group. *P<0.05. 
 
 
 
 
 
 
   Time until mPTP opening in HL-1 cells 48 hours following transfection 
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HL-1 cells with an overexpression of caAkt for 24 hours have a significantly delayed 
normalised half-time until mPTP opening by 2.4 ± 0.4 fold vs. 1.0 ± 0.1 for vector 
control; N=4 experiments with 20 cells per treatment group. *P<0.05 vs. vehicle 
control. Cells with overexpressed Akt-AA have a normalised half-time of 0.5 ± 0.1. 
Treatment with CsA significantly delayed the time until mPTP opening in cells with 
an overexpression of vector control for 24 hours by 2.1 ± 0.3 fold; N=4 experiments 
with 20 cells per treatment group; *P<0.05 vs. vehicle control.    
 
 
 
Figure 7.9: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells transfected with different plasmids for 24 hours followed by 
confocal-lasers induced oxidative stress. CsA acts as a positive control.  Over-
expressing caAkt significantly delayed the time taken to induce mPTP opening. As 
expected, CsA delayed the time taken to induce mPTP opening. N=4 experiments 
with 20 cells per treatment group. *P<0.05 vs. vehicle control, †p<0.05 compared to 
Akt-AA. 
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Treatment with EPO for 40 minutes significantly delayed the normalised half-time 
until 1.8 ± 0.2 vs. 1.0 ± 0.1 for vehicle control; N=4 experiments with 20 cells per 
treatment group; *P<0.05. Cells treated with wortmannin have a normalised time 
until mPTP opening at 1.2 ± 0.3. The beneficial effects of EPO in terms of delaying 
mPTP opening was blocked by the use of wortmannin (1.1 ± 0.2) and Akt-AA (0.5 ± 
0.1). Treatment with CsA delayed the time significantly at 2.1 ± 0.3; N=4 
experiments with 20 cells per treatment group; *P<0.05. 
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Figure 7.10: Normalised half-times to reach maximum red fluorescent intensity 
for HL-1 cells treated with different drugs under confocal-lasers induced 
oxidative stress. CsA acts as a positive control. Treatment with EPO at 10 U/ml 
for 40 minutes resulted in a significant delay in the time taken to induce mPTP 
opening. As expected, CsA delayed the time taken to induce mPTP opening. N=4 
experiments with 20 cells per treatment group. *P<0.05 
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7.8       Aim (6)  
 
To determine whether genetic or pharmacological upregulation of Akt 
modulates mitochondrial morphology in HL-1 cells 
 
After demonstrating the pro-survival and delaying of mPTP opening effects of Akt 
overexpression in previous sections, we investigated the effects of Akt 
overexpression on the modulation of mitochondrial morphology in HL-1 cells in this 
section. 
 
7.8.1     Materials 
 
To investigate the changes in mitochondrial morphology in HL-1 cells following up-
regulation of Akt, similar plasmids used in the previous sections investigating cell 
death (see Section 7.6) and mPTP (see Section 7.7) were also used in this study: an 
empty plasmid expression vector (RcCMV); one expressing mitofusin 2 (pCB6-
MYC-Mfn2) 165; one containing Drp1K38A (pcDNA3.1-HA-K38A-DRP1), the 
dominant negative mutant form of the mitochondrial fission protein Drp1205;  one 
expressing constitutively activated Akt (pcDNA3-HA-myrAkt) 346 and one 
containing the dominant negative form of Akt, Akt-AA (pcDNA3-HA-Akt-AA) 549. 
The constitutively active Akt construct has the c-src myristoylation sequence fused 
in-frame to the N terminus of the HA-Akt (wild-type) coding sequence. The 
myristolated sequence of Akt targets it to the plasma membrane of the cells where it 
is constitutively activated 346. In the N-terminal haemagglutinin (HA)-tagged mutant 
of Akt1 (PKBα) for the dominant-negative form of Akt, the two major regulatory 
phosphorylation sites (Thr308 and Ser473) were replaced by alanine residues 
rendering both endogenous and transfected Akt inactive 549. Drp1K38A has a mutation 
in the GTPase domain that results in replacement of lysine 38 with alanine 
(designated as Drp1K38A), disabling its ability to induce mitochondrial fission 205. For 
the survival assay, a ratio of 1:2 plasmid enhanced green fluorescent protein (pEGFP) 
(Clontech) expression plasmid was included in order to permit visual assessment of 
mitochondrial morphology. All plasmids were a generous gift of Dr Luca Scorrano 
(Padova, Italy). EPO (Neorecormon, Roche) was diluted in distilled water to achieve 
a working concentration of 5000 U / ml. Wortmannin (Tocris) was dissolved in 
DMSO to achieve a working concentration of 100 µM. Krebs buffer comprising (in 
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mM): NaCl 118.0, NaHCO3 25.0, d-Glucose 11.0, KCl 4.7, MgSO4.7H2O 1.2, 
KH2PO4 1.2, CaCl2.2H2O 1.8, and HEPES 10.0 (pH 7.4) was used as imaging buffer 
for confocal microscopy studies.  
 
7.8.2     Experimental protocol  
 
Upon reaching confluency of around 50 – 60% (~24 hours after seeding), the cells 
were transfected with one of the following plasmids: 
1. RcCMV – empty vector (Vector Control) 
2. caAkt – constitutively active Akt 
3. Drp1K38A – the dominant negative form of the fission protein  
4. Mfn2 – fusion-promoting protein 
 
mtRFP was always co-transfected to visualise the mitochondria as well as to indicate 
uptake and expression of the plasmids. As this was the first time that these proteins 
were overexpressed in a HL-1 cardiac cell line, we had to determine the optimum 
duration of plasmids expression to induce significant changes in mitochondrial 
morphology. EPO and wortmannin were used to elucidate the probable pathway 
linking Akt to the changes in mitochondrial morphology, if any. Images of twenty 
randomly chosen cells were taken after 24 hours for one set of experiments and 48 
hours for another set of cells and this was repeated for each group in at least four 
independent transfection experiments giving a total number of approximately 80 
cells per treatment group. Three investigators, blinded to the initial treatment, 
independently assigned the cells as displaying either predominantly (>50%) 
elongated or (>50%) fragmented mitochondria, indicating that either mitochondrial 
fusion or fission, respectively, was the predominant process in that cell at that 
particular time, a method which has been adapted from a previously published study 
165
. 
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7.8.3      Results 
 
 
HL-1 cells with an overexpression of caAkt for 48 hours have a percentage of cells 
with elongated mitochondria of 51.5 ± 4.2% vs. 43.0 ± 6.9% for vector control. 
Overexpression of Mfn2 and the mutant form of the fission protein, Drp1K38A for 48 
hours significantly increases the proportion of cells with elongated mitochondria to 
68.0 ± 4.4% and 64.8 ± 6.1% respectively; N=4 experiments with 80 cells per group; 
*p < 0.05 (see Figure 7.11).  
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Figure 7.11: Effects of overexpression of different proteins to the morphology of 
mitochondria in HL-1 cells over a period of 48 hours A significant trend of 
increasing cells with elongated mitochondria was seen for cells with an 
overexpression of Mfn2 and Drp1K38A. N=4 experiments with 80 cells per group; *p 
< 0.05 compared to Vector Control.  
 
 
 
Overexpression of the caAkt construct for 24 hours significantly increased the 
proportion of HL-1 cells with elongated mitochondria to 73.0 ± 5.0% vs. 49.0 ± 
5.8% for vector control; N=4 experiments with 80 cells per group; *p < 0.05. 
Overexpression of the dominant negative construct of Akt, Akt-AA reduces 
proportion of HL-1 cells with elongated mitochondria to 38.8 ± 16.6% (see Figure 
7.12 & 7.13).  
HL-1 mitochondrial morphology 48 hours after transfection 
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Figure 7.12: Representative confocal images of HL-1 cells transfected with 
mtRFP in addition to (A) empty vector control, (B) caAkt, (C) Akt-AA. 
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Figure 7.13: Effects of overexpression of different proteins to the morphology of 
mitochondria in HL-1 cells over a period of 24 hours A significant trend of 
increasing cells with elongated mitochondria was seen for cells with an 
overexpression of caAkt. Overexpression of the Akt-AA at 24 hours did not 
fragment the mitochondria significantly N=4 experiments with 80 cells per group; *p 
< 0.05 compared to vector control.  
 
 
 
Treatment of HL-1 cells with EPO for 40 minutes significantly increased the 
proportion of cells with elongated mitochondria to 67.0 ±v 3.4% compared to 
treating the cells with vehicle control at 29.9 ± 3.5%; N=4 experiments with 80 cells 
per group; *p < 0.05. Percentage of cells with elongated mitochondria in cells treated 
with wortmannin and EPO + wortmannin for 40 minutes was 27.8 ± 4.8% and 23.9 ± 
10.1% respectively. Percentage of cells with elongated mitochondria in cells with an 
overexpression of the Akt-AA construct with EPO treatment was 41.4 ± 7.8% (see 
Figure 7.14 & 7.15).   
 
 
 
 
 
 
HL-1 mitochondrial morphology 24 hours after transfection 
        Akt-AA 
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Figure 7.14: Representative confocal images of HL-1 cells transfected with 
mtRFP in addition to treatment with (A) EPO, (B) EPO with wortmannin, (C) 
EPO with co-transfection of Akt-AA 
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Figure 7.15: Effects of drug treatment to the morphology of mitochondria in 
HL-1 cells. A trend of increasing cells with elongated mitochondria was seen for 
cells treated with 10 U/ml EPO for 40 minutes. N=4 experiments with 80 cells per 
group; *p < 0.05 compared to Vector Control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HL-1 mitochondrial morphology following drug treatment 
EPO + Akt-AA 
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7.9     Discussion  
 
Modulation of mitochondrial morphology in HL-1 cells by a PKA 
activator, cBiMPS 
 
The results shown indicate that the use of cBiMPS increase the proportion of cells 
with elongated mitochondria after a duration of 40 minutes incubation at 37°C, albeit 
not significantly. cBiMPS is an activator of PKA 419, 550, which has been proven to 
phosphorylate and inhibit the fission protein, Drp1 182. Theoretically, using cBiMPS 
to activate PKA in the HL-1 cells should also increase proportion of cells with 
elongated mitochondria significantly. This claim is further supported by Fabio Di 
Lisa and co-workers where they showed that activation of PKA is very potent in 
reduction of infarct size (data and details not available). The question remains as to 
whether the duration of incubation of cells with cBiMPS was too long. According to 
the time-response study conducted, the increase in proportion of cells would seem to 
be within the first 15 minutes of incubation. Nevertheless, as the priority at the time 
this study was conducted was the use of the mdivi-1 drug, which also phosphorylates 
and inhibits Drp1, the idea was to incubate the PKA activator, cBiMPS and mdivi-1 
for the same duration to standardise the study. Furthermore, an incubation time of 40 
minutes seemed reasonable at that time as there was an increase of proportion of 
cells with elongated mitochondria up to ~60%. It might also be worthwhile to 
explore the alternative activators of PKA. There are a few varieties of PKA 
activators in the market, e.g. 8-CPT-cAMP, 6-MB-cAMP, 6-MBC-cAMP, 8-PIP-
cAMP, 8-HA-cAMP and 8-pCPT-2′-O-Me-cAMP. Nevertheless, Sp-5,6-DCl-
cBiMPS was considered to be the best option as a PKA activator compared to other 
activators such as dibutyryl-cAMP or 8-CTP-cAMP 419, 551. The reason cBiMPS 
from Biomol was chosen is because it was a new cAMP analogue as well as a potent 
and specific activator of cAMP-dependent protein kinase. Good cell permeability 
and resistance to hydrolysation by phosphodiesterases are other factors which make 
cBiMPS an attractive option. The dosage of cBiMPS is another factor that may be 
the cause for the failure to achieve significance in this part of the study. We chose 
the current concentration based on the study by Sandberg and co-workers in 1991 
where human platelets were used 419. It is therefore, our mistake in not realising the 
differences in cell types used and not performing a proper dose-control study. 
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Another option is to employ the use of genetic overexpression of PKA in the cells 
which will need plasmids carrying gene inserts for PKA. In summary, the role of 
PKA in inhibiting mitochondrial fragmentation and increasing proportion of cells 
with elongated mitochondria will need further re-investigation.  
 
 
 
Protecting the HL-1 cells against sIR by inhibition of mitochondrial 
fission via pharmacological activation of PKA using cBiMPS 
 
Although the previous section did not show significance in the increase in proportion 
of cells with elongated mitochondria with treatment of cBiMPS, we still followed on 
the experiments where cBiMPS was tested to determine whether PKA activation 
reduces cell death following sIR. In this section, we demonstrated that treatment with 
cBiMPS reduced cell death significantly following sIR. The cardioprotection elicited 
by activation of PKA has been shown in a study by Sanada and co-workers where 
transient activation of PKA during IPC reduces infarct size through Rho-kinase 
inhibition and actin cytoskeleton deactivation 276. In that study, PKA was activated 
using the cell-permeable cAMP analogue dibutyryl-cAMP. Similar to the effects of 
mdivi-1, the phosphorylation and inhibition of Drp1 impairs fragmentation of 
mitochondria following ischaemia and may increase the proportion of elongated 
mitochondria hence having a better survival possibility. The lack of significance in 
the increase in proportion of cells with elongated mitochondria however seems to 
allude to the possibility that PKA activation may also protect the cells via another 
mechanism other than modulating mitochondrial morphology.  
 
 
 
Delaying the opening of the mPTP in HL-1 cells by activating PKA 
using cBiMPS 
 
Pre-treatment with cBiMPS for 40 minutes prior to confocal laser-induced ROS 
release delayed the time until mPTP slightly compared to the use of EPO or CsA. 
Activation of PKA solely has never been linked to inhibition of mPTP opening in 
cardiac cells. Yet, the study of Sanada has linked the activation of PKA to 
cardioprotection from IPC 276. The inhibition of mPTP has long been known to be 
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the crucial end effect of IPC hence it would seem probable that activation of PKA 
may trigger certain mechanisms that can lead to inhibition of the mPTP as well. As 
shown in previous studies, activation of PKA is part of the framework (e.g. opening 
of the mitoKCa channel to prevent calcium overloading) leading to inhibition of 
mPTP in cardioprotection 529, 530, 552, 553. In addition, the results from previous 
sections conducted in our study showed that promotion of mitochondrial elongation 
protects by inhibiting the opening of the mPTP. In this section, PKA activation did 
not inhibit the opening of the mPTP which would not be totally unexpected judging 
from the fact that PKA activation in the previous section of our study also failed to 
induce a significant increase in fused mitochondria. These studies should be repeated 
once the timing and doses of cBiMPS have been re-optimised. Another alternative 
will be to increase the numbers of experiments for this particular mPTP assay using 
other activators of PKA as a control.  
 
 
 
 
Protecting the HL-1 cells against sIR by genetic overexpression of caAkt 
 
 
Protein Kinase B (Akt1) has long been identified as a pro-survival kinase in many 
cell types 299-301, 304, 330, 346, 554. Results from this section show that the overexpression 
of Akt1 is also cardioprotective in the HL-1 cardiac cell line. Based on our previous 
studies using the mitochondrial-shaping proteins such as Mfn1, Mfn2 and Drp1K38A, 
we initially overexpressed caAkt1 for 48 hours before subjecting the cells to sIR. 
However, we noticed that the cardioprotective effects were not so pronounced 
compared to caAkt1 that was only expressed for 24 hours prior to sIR. Therefore, we 
conclude that this may be due to an acute beneficial effect of Akt1 expression where 
chronic Akt1 expression may abrogate the beneficial effects of Akt1. This 
phenomenon is in accordance with previous studies conudcted in which they showed 
that the chronic expression of Akt1 causes hypertrophy in cardiac muscle 338, skeletal 
muscle 555 and islet beta cell mass 556. In the in vivo system though, Akt1 effects is 
counteracted by the PTEN, which prevents chronic effects that may be 
disadvantageous.  The overexpression of the dominant negative form of the Akt, 
Akt-AA also abrogates the cardioprotective effect of Akt.  
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The use of erythropoietin (EPO), a well known activator of Akt also protects the 
cells against sIR. EPO is well-known for its survival and proliferative activity and 
has been used in the cardiac research field for treating patients with arrhythmia 557 
and myocardial injury following reperfusion 255, 420, 558-562. The concentration of EPO 
(10 U/ml) was determined based on the study by Tramontano et al in which neonatal 
ventricular rat myocytes (NVRM) were used 422. Pro-survival effects of Akt are 
conferred via the RISK pathway with EPO acting as an activator of the RISK 
pathway. Upon activating the receptors, PI3K is activated hence promoting 
translocation of Akt1 from cytosol to plasma membrane where it is activated and 
translocates to different locations in the cell to perform various functions. In our 
study, we attempted to promote cardioprotection by directly over-expressing caAkt1 
and also promoting activation of Akt via the upstream activator of the RISK pathway 
using EPO. From our results, it may seem that the protective effects of EPO is more 
potent than using caAkt1 alone but there is no significance between the reduction in 
cell death caused by Akt1 and EPO. This protection conferred by EPO as an 
activator of endogenous Akt1 can be blocked by using the PI3K inhibitor, 
wortmannin, which has been shown to inhibit the PI3K by binding to its catalytic 
subunit, p110 563. Concentration of wortmannin used (100 nM) was based on 
previous studies conducted 487, 563-566. The nanomolar concentration of wortmannin 
was deemed suitable in the investigation of the effects of PKB, as it does not 
interfere with the activity of PKA, PKC or CaMKII 564. Treatment duration for 
wortmannin was similar to EPO treatment to standardise the treatment protocol. 
Overexpression of the dominant negative form of Akt1 also abrogated the protection 
conferred by EPO hence placing PI3K and Akt downstream of the EPO receptor. 
This dominant negative construct of Akt acts by inhibiting the endogenous Akt and 
has been previously used to compare against and verify the results obtained by 
constitutively active Akt 567-570. In conclusion, we verified the fact that Akt1 is 
cardioprotective in the settings of sIR. Our next step is to correlate the 
cardioprotective effects of Akt1 to inhibition of mPTP opening through which we 
will investigate the potential mechanism of this inhibition by Akt.  
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Delaying the opening of the mPTP in HL-1 cells by genetically over-
expressing caAkt 
 
Our results obtained from this section show that overexpression of caAkt1 or 
treatment of the HL-1 cells with EPO successfully delays the opening of the mPTP. 
CsA was used as a positive control to verify the involvement of the pore in this 
study. This inhibition of mPTP opening can be abrogated by use of the PI3K 
inhibitor, wortmannin or overexpression of the dominant negative/kinase dead form 
of the Akt1, Akt1K178A. The results obtained are in agreement with the previous 
survival study where both Akt1 and EPO protect the cells against sIR. Previous 
studies by Davidson et al in 2006 also showed the mPTP inhibition capability of 
Akt1 in the settings of confocal laser-induced ROS stress with HL-1 cells 259. 
Nevertheless, a study by Clarke et al in 2008 claimed that the inhibition of mPTP is 
mainly due to reduction of ROS levels rather than protein phosphorylation, though 
the role of Akt in inhibition of mPTP was still maintained under the caspase-
dependent pathway 506. The use of EPO to inhibit mPTP has been perpetuated in 
numerous studies but the mechanism of EPO in inhibiting mPTP still remains 
unresolved. Similarly, there is a lack of a consensus agreement in establishing the 
primary endpoint of mPTP inhibition by Akt. Most of the studies have implicated the 
phosphorylation of GSK3β 356, 571, 572 or upregulation of NOS in inhibition of the 
pore by Akt 573-575. In the next section, we attempt to investigate the possibility of 
Akt mediating mPTP inhibition through modulation of mitochondrial dynamics. 
EPO as an Akt activator therefore should also be able to inhibit the mPTP. Blocking 
the downstream effectors of EPO by using wortmannin as a PI3K inhibitor blocked 
the mPTP inhibiting effect. Similarly, inhibiting the Akt directly by use of the 
AktK178A also prevents the mPTP opening from being delayed. Nevertheless, the 
use of the dominant negative form of Akt, Akt
-AA and wortmannin in investigating 
the effects on opening of the mPTP has never been explored in previous literature.  
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Modulation of mitochondrial morphology in HL-1 cells by genetically 
over-expressing caAkt 
 
In this section, we show that overexpression of caAkt1 increases the proportion of 
HL-1 cells with elongated mitochondria. Treatment with EPO for 40 minutes also 
increases the proportion of cells with elongated mitochondria. Conversely, this effect 
can be blocked by use of wortmannin and overexpression of Akt1
-AA. We can 
therefore postulate that Akt plays a role in modulation of mitochondrial dynamics 
and this may explain the mPTP inhibition effects of Akt1. At this stage, we still 
cannot infer directly that Akt1 overexpression promotes mitochondrial elongation as 
the increase in proportion of cells with elongated mitochondria can be either due to 
promotion of fusion or inhibition of fission. We will therefore need to follow up this 
study in future using photo-activable green fluorescent protein (PA-GFP) to monitor 
and detect mitochondrial fusion. If there is significant mitochondrial fusion by 
overexpression of Akt1, we should expect to see a faster spread of PA-GFP among 
neighbouring mitochondria. In the case of inhibition of fission however, there should 
be less of a PA-GFP spread to neighbouring mitochondria. This concept has been 
explored by the group of Orian Shirihai in which they investigated networking of the 
mitochondrial network in beta cells 463, COS cells and INS cells 576. Yet, the 
clarification of whether Akt promotes mitochondrial fusion or inhibit fission was not 
investigated. This is the first time that EPO as an Akt activator also increases number 
of cells with elongated mitochondria, in line with previous sections of our study, 
cells with elongated mitochondria have a higher resistance towards sIR and delayed 
opening of the mPTP.  
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7.10    Conclusion 
 
In this chapter of the study, we have demonstrated that activating the PKA in HL-1 
cardiac cells protects against sIR. However, there appears to be no significant effect 
on mitochondrial morphology or delaying of mPTP opening. Hence, we believe the 
cardioprotective effects of PKA may be independent of mitochondrial morphology 
and mPTP opening, although this study has to be repeated. However, genetically 
oever-expressing the PKB in HL-1 cells protects against sIR, delays opening of the 
mPTP and increases the proportion of cells with elongated mitochondria.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sang Bing, Ong 
 293
Chapter Eight:   SUMMARY AND DISCUSSION 
 
 
The main findings of the current study are: 
 
1. Overexpression of the mitochondrial fusion proteins Mitofusin 1 and 2 (Mfn1 
and Mfn2), the dominant negative mitochondrial fission protein, Drp1K38A, or 
treatment with mdivi-1 increased the proportion of HL-1 cells with fused 
mitochondria, protects against sIR and  innibits mPTP opening . 
2. Inhibiting mitochondrial fragmentation in adult cardiomyocytes, which has a 
very different spatial arrangement of mitochondria compared to the HL-1 cell 
line by the use of mdivi-1, the small molecule inhibitor of Drp1, protects 
against sIRI and delayed the time until mPTP opening. 
3. The use of mdivi-1 in an in vivo murine infarct model successfully reduces 
infarct size following sIR.  
4. Genetically over-expressing the pro-survival kinase, Akt or upregulation of 
endogenous Akt by the use of erythropoietin (EPO) induced an increase in 
proportion of HL-1 cells with elongated mitochondria and protects the cells 
against sIR by inhibition of mPTP opening.  
 
We show for the first time that promoting mitochondrial fusion by the 
overexpression of fusion proteins is able to promote survival of HL-1 cells, a murine 
atrial-derived cell line in the context of simulated ischaemia-reperfusion injury (IRI) 
possibly through the inhibition of mPTP opening. Interestingly, the inhibition of the 
fission protein, Drp1 by the small molecule inhibitor, mdivi-1, also seems to protect 
the cells against sIRI by inhibition of the mPTP. These findings have been 
extrapolated to the settings of the adult cardiomyocytes where treatment of cells with 
mdivi-1 reduced cardiomyocytes death following IR and delays the opening of the 
mPTP while mice treated with the mdivi-1 has significantly lesser degree of 
mitochondrial fragmentation following simulated ischaemia and reduced infarct size.  
 
Fusion of both of the mitochondrial membrane has been previously shown to 
be beneficial to the cells in terms of preventing apoptotic cell death, albeit the exact 
reason was not clearly known 489, 490. Downregulation or impairment of the 
mitochondrial fusion proteins Mfn1, Mfn2 or OPA1 promote fragmentation of 
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mitochondria leading to disruption of the mitochondrial respiration system and 
depolarisation of mitochondrial membrane potential 196. sIR in renal tissue has been 
found to fragment the mitochondria through the action of Drp1 leading to cellular 
apoptosis and renal injury. In our study, we demonstrated that overexpression of 
Mfn1, Mfn2 and Drp1K38A, a mutant form of the fission protein Drp1, or the usage of 
mdivi-1 significantly increases the number of cells with elongated mitochondria, by 
either directly promoting mitochondrial fusion (Mfn1, Mfn2) or inhibition of 
mitochondrial fragmentation (Drp1K38A and mdivi-1). The mutation in the GTPase 
domain of the Drp1 protein serves to alter the original function of the Drp1 which is 
to promote mitochondrial fragmentation.  The usage of Drp1K38A in our study is 
particularly important to show that potential effects from mitochondrial fusion derive 
from fusion itself and not the proteins expressed. Examples highlighting this 
importance can be shown by the studies of Neuspiel et al (2005) 462 who 
demonstrated that the transgenic overexpression of Mfn2 promotes cell survival by 
preventing Bax activation and inhibition of mitochondrial cytochrome c release 
while Mfn2 inhibition by siRNA caused the neonatal rat cardiomyocytes to be more 
prone to ceramide-induced apoptotic cell death 412. In addition, there are 
contradicting studies in which Mfn2 has been reported to induce apoptosis in 
vascular smooth muscle cells and neonatal rat cardiomyocytes by inhibiting the anti-
apoptotic pro-survival kinase pathway, PI3K-Akt 577, 578. Compared to mitochondria 
of HL-1 cells with the empty vector RcCMV, cells with overexpression of Mfn1, 
Mfn2 and Drp1K38A have a significantly higher percentage of fused mitochondria.  
 
Another novel finding in our study lies in the fact that EPO actually promotes 
mitochondrial fusion. The activation of the PI3K pathway and Akt survival kinase by 
EPO has been well-characterised 255, 309, 420, 480, including the inhibition of mPTP 
opening by activated Akt 258, 259. Nevertheless, there exist studies which have placed 
a reduction in oxidative stress as more relevant rather than the phosphorylation of 
pro-survival kinases 506. The crux of the issue at the moment is how Akt plays a role 
in inhibiting mPTP opening. To answer this question and enhance the understanding 
of the pro-survival cascade, we postulate that EPO activates Akt which then 
promotes mitochondrial fusion to inhibit the mPTP opening.  Further studies will 
need to be carried out to elucidate the pathway, possibly by carrying out similar 
studies using wortmannin as a PI3K inhibitor.   
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Interestingly, we found that the HL-1 cells with overexpression of fusion 
proteins or treated with drugs that increase mitochondrial fusion rates such as mdivi-
1 have an increased resistance to simulated ischaemia-reperfusion compared to the 
cells which were transfected with the empty vector, RcCMV or loaded with Krebs 
containing DMSO. Overexpression of hFis1 promoted mitochondrial fission as 
expected in our study. However, the amount of live cells with overexpression of 
hFis1 was also surprisingly high following 1 hour reoxygenation compared to 24 
hour reoxygenation. This might be due to the fact that fission does not always kill as 
demonstrated by some previous studies 87, 579. Conversely, fission acts to dissipate 
the death signal conveyed by the endoplasmic reticulum or calcium overloading. 
Another important point to note is fission is a normal process in the healthy cell and 
acts to regulate certain stages in the cell cycle and may actually act as quality control 
mechanism to remove the unhealthy cells or cells that have reached senescence 172, 
196, 411, 489, 580
. Similar patterns have been observed by Parone and colleagues in 2008 
where they showed that inhibition of mitochondrial fission by small hairpin RNA 
(shRNA) targeting the Drp1 actually leads to dysfunction of the mitochondria and 
loss of mtDNA when measured after 96 hours 581. 
 
  The removal and subsequent reintroduction of oxygen through blood flow 
will cause deleterious results to cells, particularly cardiac cells in the settings of 
ischaemia-reperfusion 7, 9, 230. The deprivation of oxygen is an inducer of both 
apoptotic and necrotic cardiac cell death, all of which converge on the mitochondria 
as a powerhouse of the cell as well as an apoptotic mediator 75, 540. The survival rate 
or ability of a cardiomyocyte depends on the proper functioning of the mitochondrial 
respiratory mechanisms, which may be influenced by the elongated state of 
mitochondria. Medical studies have thus placed the mitochondria as a target for 
myocardial protection 373, 406, 582.  
 
  The role of mitochondrial morphology in determining cell fate was first 
shown by the study of Frank and colleagues in 2001 where they demonstrated that 
the mitochondria of COS cells changed from a reticulo-tubular interconnected 
network to a fragmented discrete punctiform phenotype, a process which was 
dependant on the mitochondrial fission protein, Drp1 in the presence of 
staurosporine 205. Conversely, the overexpression of the mutated form of Drp1, 
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Drp1K38A prevented cytochrome c release and ensuing apoptotic cell death. Previous 
studies have also demonstrated that the inhibition of the fusion proteins Mfn1, Mfn2 
or OPA1 promotes mitochondria fission with subsequent impairment of oxygen 
consumption, reduced mitochondrial membrane potential and decreased respiration 
490
. On the contrary, the overexpression of Mfn2 has been shown to promote 
mitochondrial elongation with enhanced capacity for mitochondrial respiration and 
hyperpolarisation of the mitochondrial membrane potential 153, 583. Nevertheless, it 
has been disputed that this particular effect of mitochondrial fusion is affected by 
Mfn2 rather than the fusion process because inhibition of Drp1 failed to mediate the 
same beneficial effects 490.  
 
Following previous studies that implicated the opening of the mPTP in 
cardiac cell death during ischaemia-reperfusion 232, 374, 377, 584, we were inspired to 
investigate the possibility that the fusion of mitochondrial inner and outer membrane 
can actually promote cell survival possibly by inhibiting the opening of the mPTP. 
The mPTP has been demonstrated by many studies to play a crucial role in mediating 
the fate of the cardiac myocytes, as opening of the mPTP during the first few 
minutes of reperfusion causes an influx of solutes less than 1500 Da from the cytosol 
into the matrix leading to membrane depolarisation, uncoupling of oxidative 
phosphorylation, organelle swelling and subsequent outer membrane rupture to 
release pro-apoptotic cytochrome c into the cell 11, 477, 509. Animal studies conducted 
in the past have shown reduction of myocardial infarct size following 
pharmacological inhibition of the mPTP opening at the onset of reperfusion, 
improved recovery in the human atrial trabeculae and reduction of infarct size in 
patients undergoing primary coronary angioplasty for an acute myocardial infarction 
17, 135, 235, 420, 496, 585
. It has also been demonstrated that mice lacking the cyclophilin-
D component of the mPTP have a smaller infarct size compared to the wild-type 
littermate controls 264, 387, 496 indicating the importance of the mPTP as a critical 
mediator of cell death in the setting of myocardial ischaemia-reperfusion injury. 
Therefore, inhibiting the opening of the mPTP should theoretically promote the 
survival of the cells. In our study, we trigger the release of ROS through 
photoactivation of TMRM loaded and ‘quenched’ in the mitochondria, which 
consists of an oxygen atom in the chemical structure, by using the high intensity-
lasers of the confocal microscope. ROS release in the mitochondria has been shown 
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to be a major inducer of mPTP opening by increasing the binding of cyclophilin D to 
the ANT structure of the mPTP as well as to sensitise the PTP to Ca2+ by inhibition 
of adenine nucleotide binding 373, 377, 477, 540. By subjecting the cells to high-power 
lasers of the confocal microscope, the pre-loaded TMRM in the mitochondria will be 
photoactivated and subsequently ‘broken-down’ into the chemical derivatives, hence 
releasing the free oxygen radical. The presence of the ROS will induce mPTP 
opening which can be visualised by the increase in red fluorescent intensity, 
signifying the ‘dequenching’ of the TMRM upon release through the pore from the 
mitochondria into the cytosol.  The duration needed for mPTP opening is a very 
significant factor in the sense that it governs the survival strength of the cardiac cells 
and successfully delaying the time for mPTP opening provides a desirable 
breakthrough in the clinical setting where reperfusion to the occluded heart can be 
extended or even deemed negligible. By measuring the values of the TMRM 
fluorescent intensities through a course of time and normalising against the cells with 
the empty vector, we were able to determine when the pores start to open in the 
mitochondria. The results clearly show that the time needed for mPTP opening in the 
cells with overexpression of fusion proteins was significantly delayed, similarly to 
the use of CsA, an immunosuppressive drug which has been previously proven to 
inhibit mPTP opening.  
 
Using the mtPA-GFP simultaneously with the photosensitive TMRM, we 
managed to detect mitochondria longer than 2 µm in the adult cardiomyocytes. 
Interestingly, previous studies have also shown that mitochondria extending up to 2 
to 3 sarcomeres (4 to 6 µm) in length can be detected using electron microscopy. 
Nevertheless, the previous studies may have overlooked the connection between 
mitochondria length and sarcomere size and the physiological relevance of this 
finding. Short episodes of hypoxia have also been found to induce elongation of 
mitochondria, probably as an endogenous defence mechanism against further stress. 
There have been reports of deformed mitochondria in certain organs of 
hyperglycaemic patients and animal models of hyperglycaemia 586. The mitochondria 
are found to be swollen with disarrayed cristae and reduced electron density of 
matrix 586. In obese or Type 2 diabetic subjects, shrinkage of the mitochondria from 
skeletal muscle with less defined internal structure were observed 587. The skeletal 
muscle from obese Zucker rats showed a reduction in levels of Mfn2 as the main 
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cause of the impairment of the mitochondrial network, leading to pronounced 
fragmentation 153, 588.  
 
Kong and colleagues reported that overexpression of the fission proteins 
Drp1 and hFis1 increased the susceptibility of COS epithelial cells to calcium-
induced mPTP opening 589. Conversely, down-regulation of Drp1 in another study 
showed that the opening of the mPTP induced by mitochondrial oxidative stress 
generated in hyperglycemia was inhibited 209. Overexpression of hFis1 in our study 
did not seem to influence sensitivity of mPTP opening. This may be due to a 
difference in the models used: e.g. a limitation of the resolution in our model to 
detect increased sensitivity of mPTP opening. Another possibility is that hFis1 
causes cell death independent of the opening of the mPTP. Brady and colleagues 
showed in 2006 that the mitochondria of HL1 fragment after a 2 hour period of 
simulated ischaemia and remained in this morphology during the reperfusion period 
488
. Interestingly, if the cells were reperfused in the presence of SB203580, a 
pharmacological inhibitor of p38 MAPK, the mitochondria reverted to a fused 
morphology 488, further confirming that changes in mitochondrial morphology are 
relevant to ischaemia-reperfusion injury but also suggesting that mitochondrial 
morphology may be controlled by protein kinases. In this regard, recent data 
suggests that protein kinase A may phosphorylate and inhibit the mitochondrial 
fission protein Drp1, thereby promoting mitochondrial fusion 182, 190. Oxidative stress 
is a critical mediator of myocardial ischaemia-reperfusion injury and studies suggest 
that it too can induce mitochondrial fission 590.  Therefore, based on our study, we 
postulate that fusion of mitochondrial membrane in HL-1 cells can increase the 
resistance of the HL-1 cells to simulated ischaemia-reperfusion possibly by delaying 
the time needed until mPTP opening. Overexpressing proteins that encode for 
mitochondrial fusion in HL-1 cells delays the time needed for mPTP opening and 
protect against simulated hypoxia-reoxygenation. This seems to validate and 
associate the beneficial effects of mitochondrial fusion to inhibition of mPTP 
opening. It is not clear at the moment how fusion of the mitochondrial membranes 
prevents the mPTP from opening. Here, we propose a few possibilities; first, the 
fusion of the inner and outer membranes by the fusion proteins prevents the opening 
of the mPTP by ‘overlapping’ the potential opening sites or preventing the protein 
components that make up the pore by joining together. Fusion of mitochondria 
Sang Bing, Ong 
 299
involves the outer and inner membrane which occurs separately. Regardless of the 
exact location of the mPTP spanning the inner and outer membrane, once the outer 
membrane is fused together, opening of the mPTP will be rendered negligible. The 
spatial movement or consistent fusion of the membranes may ‘cover’ the opening 
sites of a particular mitochondrion prone to mPTP opening as well as to prevent the 
individual protein components from docking together to form the pore. As long as 
the individual constituents do not join together, the pore will not be formed and 
hence depolarisation will not occur. However, due to the fact that the cells were 
subjected to approximately 8 minutes of high intensity laser stress during 
measurement of TMRM fluorescence, the pore will eventually open at the end of the 
time course as can be seen from the line graphs.    
 
Second, fusion of two mitochondria to become one will lead to an increase in 
the overall size including the volume of the matrix and intermembrane space. This 
increase in size and volume will enhance the capacity of the mitochondria to 
accommodate calcium loading, which is an inducer for mPTP opening. The 
reduction in ratio of individual mitochondria to individual ER may also explain the 
possible benefits of mitochondrial fusion. An abundant amount of ER relative to the 
amount of mitochondria may act as Ca2+ stores in which calcium is kept in the ER 
without the need to release into the cytosol and uptake into the mitochondria leading 
to subsequent mitochondrial calcium overload. 
 
Third, fusion of the inner and outer mitochondrial membrane facilitates the 
formation of a higher number of individual cristae and possibly the narrow tubular 
cristae junction which serves to entrap more cytochrome c molecules and preventing 
the release of these apoptotic molecules into the cytosol. It is important to remember 
that fusion of two mitochondria ensures mixing of the intracellular contents. This 
fact may also provide an explanation of the increased survival of cells with fused 
mitochondria in which there is either an increased proportion of the protease PARL 
to hydrolyse the soluble domain of OPA1 or increase of the OPA1 inner 
mitochondrial membrane protein itself and hence reducing the diameter of the cristae 
junction encapsulating the cytochrome c present 11. Compartmentalisation of the 
mitochondria which occurs with the abundant excess of mitochondrial membranes 
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following fusion may also assist in maintaining the proper concentrations of oxygen 
radicals, nitric oxide (reactive species) in the mitochondria. 
 
In line with the possible theory of compartment contents mixing with the 
fusion of mitochondria, occurrence of mitochondrial DNA (mtDNA) defects can be 
salvaged by the complementation of a healthy mtDNA, particularly in the cases of 
missense or deletion mutation. mtDNA mutations and dysfunction have been 
implicated in cardiovascular (cardiac arrhythmias and cardiomyopathy) and neuronal 
diseases 591. The mtDNA is responsible for encoding of certain enzyme complexes 
(I, III-V) of the oxidative phosphorylation mechanism and the RNAs required for the 
proper translation of the mitochondrial-encoded genes itself 592.  
 
There is also the argument that upregulation of mitochondrial fusion proteins 
may conversely reduce the amount of Drp1 protein present in the cytosol, which is 
responsible for mitochondrial fission and ensuing apoptosis. This effect of reducing 
the proportion of Drp1 reaching the mitochondria can be explained by the previous 
phenomenon of reduction in calcium overloading. Elevated levels of calcium in the 
cell are an activator of calcineurin, a serine/threonine protein phosphatase which is 
usually bound to Drp1 146. Upon activation, calcineurin will dephosphorylate Drp1 
hence promoting the translocation of Drp1 to the mitochondria to perform fission 146.   
Reduction of calcium overloading may directly translates to reduction of Drp1 to 
cause mitochondrial fission and cell death.  
 
     Fragmentation of the mitochondria falls under the categories of either 
pathological or physiological events. The classical observation by Hackenbrock 593 
that condensed mitochondria are more active with an electron-dense matrix is more 
relevant in physiological settings, such as mitosis or in the presence of increased 
substrate. Mitochondrial fragmentation under pathological conditions may alter the 
fluidity of the matricial contents as well as proper localisation and positioning of the 
respiratory chain complexes leading to perturbation of ETC activity and ATP 
production.  
 
     Fusion of mitochondria may also enhance the respiratory capacity of cells 
and enable them to withstand the metabolic and biochemical stresses associated with 
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IRI. The rate and levels of oxygen consumption, maintenance of mitochondrial 
membrane potential and respiration of mitochondria in myotubes have been 
demonstrated to be affected by varying expression levels of fusion proteins.  
 
There are however, certain limitations in our study. We need to investigate 
the direct role of fusion in the cells during ischaemia and reperfusion. Our study 
employs three separate studies in which we looked at the morphology, cell survival 
and mPTP assay of the HL-1 cells. There remains the need to build up a solid link 
between these three aspects in the field of myocardial protection. Further studies to 
be carried out include the real-time imaging of the affect of fusion proteins on the 
mitochondrial morphology before, during and after ischaemia-reperfusion followed 
by monitoring of the mPTP opening to further establish the role of membrane fusion 
in inhibiting mPTP opening and promoting cell survival. The cells can be loaded into 
a simulated ischaemia-reperfusion chamber on a confocal microscope and the 
hypoxic and normoxic buffer constantly replaced for the determined length of time 
with the confocal microscope capturing images at the pre-determined set of time. At 
the moment, our group has already installed and performed a number of experiments 
on this specialised chamber docked onto the confocal microscope. It will be a matter 
of time before we achieve the aim of performing the simultaneous studies.  
 
Besides that, a simple yet more accurate method has to be developed to study 
the morphology of the mitochondria in greater detail. There is variability in our 
technique where the images of the mitochondria were obtained and saved as TIF 
files to be read blinded by three different operators. However, it has to be noted that 
viewing the cells through the lens of the confocal microscope is different from 
viewing the cells in TIF images where the image can be sometimes blurry hence 
distorting the judgmental ability of the operators. The averaging tendency of the 
three operators serves to render a much fairer and near-optimum reading of the 
morphology of the cells.  
 
Cell death by apoptosis or necrosis can occur simultaneously to the cells in 
the hypoxic chamber depending on the individual cells susceptibility and positioning 
of the cells in the wells. The amount of oxygen present in the airtight hypoxic 
chamber has yet to be measured. However, due to the length of time the nitrogen was 
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allowed to flow into the chamber (10 minutes forceful flow followed by 10 minutes 
gentle flow), it will be quite safe to assume that only a very low level (<5%) of 
oxygen is present in the chamber. Therefore, the cells should theoretically undergo 
necrosis. The choice of PI was made based on this assumption. It is worth 
mentioning that PI stains both apoptotic and necrotic cells. A combination of PI and 
Annexin V may have to be used to differentiate between early apoptotic and necrotic 
cells. However, regardless of the death pathway, we managed to address the crux of 
the issue: the cells die following reperfusion as shown by PI staining whereas cells 
with fused mitochondria were more resistant.  
 
As for the mPTP assays, there has been some controversies as to the 
components that make up the mPTP but it is irrelevant in our study because we did 
show that the pores do indeed open following ROS stress with varying intensities 
and duration as visualised by the increase in TMRM red fluorescent intensity 
following laser stress. In addition to that, the use of CsA to inhibit mPTP opening 
prove that the model is working and CypD remains a component of the mPTP.  
 
Questions pertaining to the levels of expression and presence of different 
proteins in the cells have been raised before. It will be very appropriate to perform 
Western blots to determine the levels of proteins present in the cells following 
plasmids transfection and overexpression. Possible additive effects of Mfn1 and 
Mfn2 have been queried but a consensus agreement has yet to be reached. It has been 
shown that residual levels of inner membrane fusion exist in single mitofusin 
knockout cells, whereas double Mfn1-/- or Mfn2-/- cells completely lack mixing of 
matricial content, an indication of inner membrane fusion 162, 490. This shows that the 
presence of a single mitofusin coupled with OPA1 is adequate to promote 
mitochondrial fusion in cells. Potential deleterious effects of Mfn2 in causing 
apoptosis, including its interaction with various members of the Bcl-2 family have 
also been raised by previous studies 206, 577, 578.  
 
    The use of mdivi-1, cBiMPS and EPO to induce the proportion of cells with 
elongated mticodhonria was applied throughout the whole duration of simulated 
ischaemia and reperfusion as these drugs do not confer a ‘memory’ effect in the 
cardioprotective cascade compared to the use of IPC. The application of IPC and its 
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subsequent activation of PKG and PKC elicit a cardioprotective response by 
reduction of ROS and inhibition of mPTP which can be initiated during future 
episodes of IR. Using the drugs at the onset of reperfusion only may not allow the 
drugs to have enough time to act.  
 
    Genetically over-expressing the caAkt or upregulation of Akt by EPO 
significantly increases the proportion of cells with elongated mitochondria. 
Nevertheless, we will need to verify whether this is due to increase of mitochondrial 
fusion (overexpression of Mfn1 or Mfn2) or inhibition of mitochondrial 
fragmentation (as in the use of mdivi-1, overexpression of Drp1K38A or upregulation 
of PKA). This can be done using the mtPA-GFP to determine mitochondrial fusion 
after which the mechanism can be elucidated using different constructs such as 
monitoring of Drp1 translocation. The study concerning PKC has yet to be 
performed as planned due to time limitation.  
 
 In view of the constant search for interventions to improve clinical outcomes in 
patients with coronary heart diseases, novel therapeutic strategies are being 
investigated to protect the heart against IRI. In this present study, we report that 
modulation of mitochondrial morphology may prove to be a novel cardioprotective 
strategy against IRI. This is the first time that mitochondrial fusion has been reported 
to promote cell survival by delaying the time until mPTP opening in HL-1 cardiac 
cell line. More importantly, this is the first study documenting a proper detection and 
quantification of elongated mitochodnria (> 2 µm) in adult cardiomyocytes. In 
addition to that, pharmacological manipulation using mdivi-1 has been proven to be 
beneficial in terms of cardioprotection against IRI by inhibiting excessive 
fragmentation of the mitochondria in the adult heart. This study can be further 
projected into pharmacological studies where drugs that promote mitochondrial 
fusion can be used to promote cell survival in the face of acute ischaemia-
reperfusion injury. Various possibilities may arise where drugs can be applied at the 
onset of reperfusion or pre- and post-conditioning to increase the resistance of cells 
or whole hearts to IRI and subsequently improve clinical outcomes in patients with 
coronary heart disease.  
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Chapter Nine: CONCLUSION 
 
9.1   Summary of Findings 
 
This thesis has examined the novel role of modulation of mitochondrial morphology 
in myocardial protection. We have demonstrated that increasing the proportion of 
elongated mitochondria by genetic or pharmacological methods protects cardiac cells 
against ischaemia-reperfusion injury and this can be extrapolated to the animal 
model where a reduction in infarct size was detected following treatment of the 
animal with the mitochondrial morphology-modulating drug, mdivi-1. We postulated 
that the inhibition of the mPTP may underlie the protective effect of increased 
mitochondrial fusion. Interestingly, we also discovered that erythropoietin (EPO) as 
a known protective agent, also increased the proportion of cells with elongated 
mitochondria, further supporting our hypothesis.  
 
 
9.2   Clinical Implications 
 
Current cardioprotective strategies such as ischaemic preconditioning and ischaemic 
postconditioning converge on the mitochondria by inhibition of the mPTP. Despite 
this, there have been equivocal speculations pertaining to the mechanism leading to 
the inhibition of mPTP in these interventions. In this present study, we have 
provided proof that modulation of mitochondrial morphology can lead to the 
inhibition of mPTP opening and these findings constitute a novel cardioprotective 
strategy. Specifically, we have demonstrated that inhibition of mitochondrial fission 
by pharmacological manipulation using the mdivi-1, a small molecule inhibitor of the 
fission protein, Drp1 reduced myocardial infarct size in the in vivo murine infarct 
model as well as delayed the time until mPTP opening in adult cardiomyocytes. 
Future research can be directed at other compounds to target the other fission 
protein, Drp1 or enhancing the levels of the fusion proteins such as Mfn1, Mfn2 and 
OPA1 to reduce mitochondrial fission in the clinical settings of acute ischaemia-
reperfusion injury to improve clinical outcomes in patients with coronary heart 
disease.   
 
 
Sang Bing, Ong 
 305
9.3    Future directions 
 
 
Linking mitochondrial fusion to inhibition of mPTP and cardioprotection 
We have demonstrated in the current study that promoting mitochondrial fusion 
protects the cells against simulated ischaemia-reperfusion injury and mitochondrial 
fusion delays the time until mPTP opening. Further research needs to be undertaken 
to conduct the study in real-time to connect mitochondrial fusion, cardioprotection 
and inhibition of mPTP together. Furthermore, using the real-time heated perfusion 
chamber, it would be possible to elucidate the underlying mechanism of inhibition of 
mPTP by mitochondrial fusion. We have speculated that this may be due to 
enhanced respiratory capability or a better Ca2+ retention capacity etc.  
 
Promoting mitochondrial fusion in the adult cardiomyocytes 
In the section concerning adult cardiomyocytes, we have demonstrated that using 
mdivi-1 to inhibit mitochondrial fission protects cells against IRI, inhibits the mPTP 
opening and reduced infarct size following IR. Mdivi-1 is currently the only drug 
available to inhibit mitochondrial fission. Further studies are required to actually 
promote mitochondrial fusion in the adult cardiomyocytes. The genes encoding for 
overexpression of the fusion proteins, Mfn1, Mfn2 or OPA1 can be inserted in the 
adenoviral vector for transfection into adult cardiomyocytes. Alternatively, it would 
be interesting to formulate a small molecule activator of the endogenous fusion 
proteins to be used in the animal model. 
 
Effects of PKCε upregulation or knockdown on the mitochondria 
The cardioprotective effects of PKCε have been well-documented. It would be 
interesting to investigate the effects of PKCε overexpression or knockdown of PKCε 
on the morphology of mitochondria. Our sister laboratory, the Hatter Institute in 
Cape Town, South Africa, have sent us some images of PKCε knock-outs mice but 
due to time limitation, the electron micrographs remains yet to be studied.  
 
Mechanism of mitochondrial elongation by Akt upregulation 
We have already demonstrated that activating PKA protects, yet the effects on 
mitochondrial morphology and inhibition of mPTP remains unresolved. A more 
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thorough study need to be performed to elucidate the effects of PKA activation on 
the mitochondria. We have shown that the genetic overexpression or 
pharmacological upregulation of the Akt by the use of EPO increases the proportion 
of cells with elongated mtiochohdria, protects against sIRI and inhibits opening of 
the mPTP. Future studies need to be performed to elucidate the mechanism of the 
actions of Akt in increasing mitochondrial elongation in the cells.   
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